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 1. INTRODUCTION 
 Human Cytomegalovirus (HCMV) is the prototype member of Beta 
Herpesvirinae. As with all members of Herpesviridae, the virus has the ability to 
persist in the host in a latent state after primary infection (Emery, 2001). 
 In the immunocompetent individual, the virus and host exist in a symbiotic 
equilibrium, such that disease manifestations are rarely encountered. However, when 
the host immune system is compromised, either through immaturity (neonate); 
infection for example by Human immunodeficiency virus (HIV); or through 
iatrogenic means following organ transplantation, the virus is able to exert its full 
pathogenic potential (Emery, 2001). 
 HCMV is the etiologic agent of the most common congenital virus infection 
in humans occurring in 0.2%-2.2% of all live births (Revello et al., 1999a). 
Congenital HCMV infection is silent at birth in 90% of infants yet 5-17% of these 
neonates may develop neurological impairment (Revello et al., 1999a). In other 
immunocompromised individuals the symptoms can range from mild disease to 
disseminated disease involving organs of pulmonary, nervous, gastro intestinal 
systems including liver. The usual manifestations are severe pneumonitis, 
encephalitis, chorio retinitis, optic neuritis and mild cholangitis. The reported 
prevalence of HCMV seropositivity in general population in South India is about 
98%. Data from Christian Medical College (CMC), Vellore places the prevalence of 
clinical HCMV disease post transplant at about 30%, consistent with reinfection and 
reactivation syndromes (Rao, 2002). It has been documented that at least 25% of 
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 AIDS patients develop serious HCMV disease. Retinitis occurs in 6-15% of patients, 
gastro duodenal disease in 5-10% and 30% reveal active HCMV infection at autopsy 
(Mujtaba et al., 2003). 
 Current scenario involves use of antiviral drugs viz. ganciclovir, foscarnet, 
and cidofovir as a prophylaxis in these individuals. There has been a considerable 
reduction in both the morbidity and mortality of HCMV disease in recent years 
owing to an increase in the antiviral prophylaxis. The toxicity associated with 
currently available antiviral agents and development of resistance remains a 
significant problem (Boeckh and Boivin, 1998). 
 Highly sensitive and quantitative detection methods aid in identifying 
patients at higher risk for disease prior to the onset of disease, thereby focusing 
antiviral treatment only to patients at risk for disease without covering the entire 
immunosuppressed population (Boeckh and Boivin, 1998). Quantitation of the 
systemic HCMV load may provide a highly sensitive and specific method to predict 
the development of HCMV disease. The conventional methods of quantitation like 
the traditional plaque assay, TCID50 and other modified tissue culture-based 
methods like the rapid shell vial based assays are not preferred owing to the time-
consuming procedures, poor reproducibility, and a relatively low sensitivity. The 
major problem faced with the culture techniques includes poor ability of some 
HCMV strains to form plaques, rapid loss of viability, lack of staining by 
monoclonal antibodies and nonspecific monolayer toxicity. 
 The important characteristics required for an optimal diagnostic assay for 
HCMV monitoring are  
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 (i) A high sensitivity that allows early detection in individuals at high risk 
for disease.  
(ii) Potential to quantify the results to increase the positive predictive value 
and to measure viral load during antiviral treatment. 
(iii) Rapidity to allow early initiation or change of treatment. 
(iv) A high degree of reproducibility.  
 Quantitative pp65 antigenemia assay and quantitative PCR-based methods 
have one or more of the characteristics of an ideal diagnostic test for HCMV 
monitoring. The detection of the pp65 antigen in leukocytes is a sensitive method 
widely used for the early diagnosis of HCMV infection, but it is labor-intensive, 
requires immediate processing, and relies on a subjective interpretation of the slides 
(Boeckh and Boivin, 1998; Landry et al., 1995). Qualitative PCR detection of 
HCMV DNA in leukocytes or plasma is considered the most sensitive method, but it 
lacks specificity for the diagnosis of HCMV disease (Drouet et al., 1995; Kanj et al., 
1996; Weber et al., 1994). Quantification of HCMV DNA has been proposed to be 
more specifically associated with the disease (Boeckh and Boivin, 1998; Zipeto et 
al., 1993). Real-time PCR based on the Taqman technology provides an accurate 
means to quantify viral DNA with the major advantage of avoiding post-PCR 
handling that can be the source of DNA carryover (Heid et al., 1996; Holland et al., 
1991). Several studies report the utility of real-time PCR for the quantification of 
HCMV DNA (Machida et al., 2000; Nitsche et al., 2000; Nitsche et al., 1999; 
Tanaka et al., 2000; Yun et al., 2000; Piiparinen et al., 2004; Allice et al., 2006). In 
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 these studies, the primers used for PCR were located in the major immediate-early 
gene (Nitsche et al., 1999; Tanaka et al., 2000 ; Yun et al., 2000) the US17 gene 
(Machida et al., 2000), or the glycoprotein B gene (Yun et al., 2000). The sensitivity 
of quantitative PCR may be dependent on the viral target gene (Yun et al., 2000); 
however, the most appropriate region for amplification has not been established, as 
the sequence diversity of clinical HCMV strains remains to be characterized. 
 The diversity of organs and cell types infected by HCMV in vivo has also led 
to hypothesis that HCMV disease and tissue tropism may be related to sequence 
variation among the strains (Chou and Dennison, 1991; Lurain et al., 1999). HCMV 
clinical isolates have been grouped by immunologic assays, such as neutralization 
kinetics (Rasmussen et al., 2002). The genetic basis for the biological differences 
seen among virus isolates is unknown. 
 Serologically HCMV cannot be classified into any particular subtypes, as 
significant antigenic differences do not exist (Arens, 1999). Monoclonal antibodies 
were used to differentiate between two strains of HCMV. They do not have the 
ability to distinguish individual isolates within a serotype because the major 
antigenic epitopes that define the serotype are highly resistant to change (Chou, 
1989). The need for this capability has provided the impetus for the development of 
molecular methods for subtyping HCMV. Though complete genome sequences of 
standard strain AD 169 is known, as many as 22 additional virus genes have been 
found in low passage clinical isolates and Toledo genome which were absent in 
AD169 and Towne strains (Rasmussen et al., 2002;  Cha et al., 1996). 
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  Restriction endonuclease analyses have shown genetic variation in every 
region of HCMV genome (Chandler and McDougall, 1986; Chou, 1990a). Many 
investigations have reported up to 7 subtypes by restriction analysis and up to 22 
subtypes by SSCP of the gB gene of HCMV (Chou and Dennison, 1991; Trincado et 
al., 2000; Meyer-Konig et al., 1998c). 
 Strain variations related to gB gene coding for gp55 protein and gH gene are 
well documented. These two genes code for two of the immunologically dominant 
envelope glycoproteins of HCMV involved in the induction of virus neutralizing 
antibody. Four major variants and an additional variant have been determined at the 
region coding for the cleavage site of gB. Two additional sites of variability have 
been described at restricted regions of the N and C termini of the gB gene product 
(Rasmussen et al., 2002; Zipeto et al., 1995). gH (UL-75) is one of the component 
encoding gCIII complex of HCMV which aids in the penetration of HCMV into the 
host cells. The other components include gL (UL-115) and gO (UL-74). The former 
is necessary for the transport of the gH glycoprotein to the cell surface and the latter 
plays a role in fusion of cells. Many studies have confirmed two closely related 
variants of gH gene at the N terminus (Chou, 1992a; Rasmussen et al., 2002).  Four 
variants each in gL and gO genes (Rasmussen et al., 2002) have been determined.   
Another HCMV polymorphic surface glycoprotein is gpUL73-gN, encoded by the 
ORF UL73. It is a component of the envelope gC-II complex, associated with gM 
and has the ability to induce neutralizing antibodies. UL73 shows four main 
genomic variants, denoted gN-1, gN-2, gN-3 and gN-4. The gN3 genotype can be 
further divided into two subgroups (gN3a and gN3b) and gN-4 genotype into three 
subgroups (gN-4a, gN-4b and gN-4c) (Pignatelli et al., 2003a). 
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  Molecular characterization for the purpose of sub typing though not relevant 
to treatment, is useful for epidemiologic purposes and for investigations into 
pathogenesis and disease progression of HCMV. They may also throw light on the 
most conserved regions of the viral genome and hence aid in defining genomic 
targets suitable for primers and probes selection for nucleic acid based detections.  
1.1 HYPOTHESIS 
 Nucleic acid based molecular methods aid in rapid detection, quantitation 
and characterization of HCMV from direct clinical specimens obtained from 
immunocompromised patients with suspected HCMV infections. 
1.2 BROAD AIMS 
1.2.1  To develop nucleic acid based molecular methods for detection and 
quantitation of   HCMV genome from direct clinical specimens. 
1.2.2  To develop nucleic acid based molecular methods for characterization of 
HCMV strains in the clinical specimens. 
1.3 SPECIFIC OBJECTIVES 
1.3.1 Standardization of pp65 antigenemia assay for detection and semi-
quantitation  of HCMV antigen in  peripheral blood specimens 
1.3.1.1 To compare the Conventional dextran sedimentation (CDS) and 
Direct erythrocyte lysis method (DEL) for isolation of leucocytes and 
standardize immunofluorescence based pp65 antigenemia assay. 
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 1.3.2 Evaluation of the efficiency of primers targeting morphological 
transforming region II (mtrII), UL -83 and glycoprotein O (gO) regions 
for the detection of  HCMV  DNA in clinical specimens 
1.3.2.1  To standardize uniplex PCR for UL-83 gene of HCMV. 
1.3.2.2  To standardize nested PCRs for gO gene of HCMV using two sets of               
primers. 
1.3.2.3 To standardize duplex PCR by combining the two sets of primers 
targeting gO gene. 
1.3.2.4 To evaluate the efficiency of the PCRs for mtr II, UL 83, gO and 
duplex  PCR for gO gene against pp65 antigenemia assay as the ‘gold 
standard’. 
1.3.3   Development and application of a multiplex PCR for semi-quantitation 
of  HCMV and its evaluation against pp65 antigenemia assay and 
Taqman – probe based Real time PCR assay for HCMV 
1.3.3.1 To develop a multiplex PCR assay for detection of the HCMV 
genome viz. morphological transforming region II (mtr II), the UL-83 
gene and gO region by combining the individual primer pairs. 
1.3.3.2 To evaluate the multiplex PCR by simultaneously applying it with 
pp65 antigenemia assay on peripheral blood specimens obtained from 
post-renal transplant recipients.  
1.3.3.3 To standardize Taqman probe-based real time PCR assay for 
quantitation of HCMV. 
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 1.3.3.4 To compare the results obtained with Taqman probe- based real time 
PCR   assay and multiplex PCR on different clinical specimens 
obtained from immunocompromised patients. 
1.3.3.5 To correlate the results obtained with pp65 antigenemia assay and 
Taqman  probe-based real time PCR assay. 
1.3.4 Analysis of gB genotypes of HCMV in different clinical specimens 
obtained from immunocompromised patients 
1.3.4.1 To standardize PCR-based RFLP for genotyping of gB gene of  
HCMV. 
1.3.4.2 To standardize multiplex PCR for genotyping of gB gene of HCMV. 
1.3.4.3 To evaluate the efficiency of PCR-based RFLP and multiplex nested 
PCR by simultaneously applying them on different clinical specimens  
for gB genotyping of HCMV strains.  
1.3.4.4 To study the distribution of gB genotypes in different clinical 
specimens by multiplex PCR. 
1.3.5   A study on the distribution of gH, gO and gL genotypes of the gCIII 
complex  of  HCMV  
1.3.5.1 To standardize PCR-based RFLP for gH gene of HCMV. 
1.3.5.2 To study the distribution of gH genotypes in different clinical 
specimens from immunocompromised patients. 
1.3.5.3 To standardize PCR-based RFLP for gO gene of HCMV. 
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 1.3.5.4 To study the distribution of gO genotypes in different clinical   
specimens from immunocompromised patients. 
1.3.5.5  To standardize PCR-based RFLP for gL gene of HCMV. 
1.3.5.6 To study the distribution of gL genotypes in different clinical 
specimens from immunocompromised patients. 
1.3.5.7 To study the distribution of gCIII complex and genetic linkages 
between the genes of gCIII complex. 
1.3.6   A study on the distribution of gN genotypes of HCMV in different   
clinical  specimens 
1.3.6.1 To standardize PCR-based RFLP for gN gene of HCMV. 
1.3.6.2 To study the distribution of gN genotypes in clinical specimens by 
PCR- based RFLP. 
1.3.7  A study on the distribution of gB, gCIII complex and gN variants in             
immunocompromised patients and a study on linkage of the gene            
components 
1.3.7.1 To study the distribution of HCMV variants with respect to gB, gCIII 
and   gN genes. 
1.3.7.2 To study the possible genetic linkages with respect to gB, gCIII and 
gN variants.         
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 1.3.8  A study on relationship of HCMV genotypes with viral load 
          1.3.8.1  To study the possible relationship of HCMV genotypes with the viral 
load.   
          1.3.8.2 To analyze the distribution of genotypes with respect to the five 
glycoprotein genes of HCMV in paired clinical specimens obtained 
from different patient groups. 
1.3.9.   Isolation and characterization of HCMV 
1.3.9.1 To isolate HCMV from clinical specimens and to characterize the 
isolates. 
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 2. REVIEW OF LITERATURE 
2.1 THE HUMAN HERPESVIRUSES 
 The family Herpesviridae consists of eight human herpesviruses HHV1 to 
HHV 8: herpes simplex virus 1 and 2 (HSV1 and HSV2), varicella zoster virus 
(VZV), Epstein-Barr virus (EBV), Human cytomegalovirus (HCMV) and human 
herpesvirus 6, 7 and 8 (HHV 6, HHV7 and HHV 8) (Zhou et al., 2006). The 
herpesvirus family is divided into three subfamilies, designated alpha, beta, and 
gamma. HSV-1, HSV-2, and VZV belong to the alphaherpesviruses; HCMV, HHV-
6 and HHV-7 to betaherpesviruses and Epstein-Barr (EBV) virus and HHV-8 are 
gammaherpesviruses (Zhou et al., 2006). HSV-1 and HSV-2 are neurotropic and 
cause fever blisters, genital sores and infections of the central nervous system. 
Primary varizella-zoster virus infection causes chickenpox (varicella), usually in 
children. The recurrent form of VZV is herpes zoster which occurs mostly in 
immunosuppressed and elderly subjects. In immunosuppressed individuals VZV 
may also cause infections of the central nervous system or in rare cases even visceral 
VZV disease without cutaneous involvement (Grant et al., 2002). HCMV primary 
infections of immunocompetent individuals are usually asymptomatic but might also 
cause mononucleosis-like illness. Congenital infection caused by HCMV is a major 
cause of hearing loss and mental retardation. Moreover, reactivation of the virus is 
important in immunocompromised patients, such as transplant recipients and AIDS 
patients. HHV-6 is the causative agent of exanthem subitum, an early childhood 
disease characterized by high fever and a mild skin rash, which are occasionally 
complicated by seizures or encephalitis (Yamanishi et al., 1988). HHV-6 may also 
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 reactivate during immunosuppression. The clinical manifestations of HHV-7 are less 
clear, but have been associated with some cases of exanthem subitum (Tanaka et al., 
1994; Torigoe et al., 1995; Ueda et al., 1994), pityriasis rosea (Drago et al., 1997), 
neurological symptoms (Caserta et al., 1998; Torigoe et al., 1996) and hepatitis 
(Hashida et al., 1995). EBV is the cause of the majority of mononucleosis cases. 
EBV is also associated with post-transplant lymphoproliferative disorders (PTLD) 
and other malignancies, such as nasopharyngeal carcinoma and Burkitt`s lymphoma. 
HHV-8 is etiologically linked to Kaposi's sarcoma and other malignancies.  The 
main characteristics of herpesviruses are their ability to remain in a latent or 
persistent state in their host after primary infection and reactivate under 
immunosuppression. Reactivation and infection with human herpesviruses remain 
one of the most common infectious complications after transplantation (Fishman and 
Rubin, 1998). 
2.2 HUMAN CYTOMEGALOVIRUS (HCMV) 
 In 1956, Margaret G. Smith recovered the first HCMV isolate from the 
submaxillary salivary gland tissue of a dead infant and the second isolate from the 
kidney tissue of a baby dying of cytomegalic inclusion disease (Smith, 1956). The 
same year, Rowe and coworkers, who recovered adenoviruses by observing 
cytopathic changes in uninoculated cultures of human adenoids, noted unique focal 
lesions and intranuclear inclusions primarily in the fibroblast component of cultures 
of adenoidal tissues from three asymptomatic children (Rowe et al., 1956). The 
cytopathic effect of the new virus strain (AD169) very closely resembled that of the 
Davis strain that was observed 1 year later by Weller and colleagues in human 
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 embryonic skin muscle tissue cultures inoculated with a liver biopsy taken from a 3-
month-old infant with microcephaly, jaundice, hepatosplenomegaly, chorioretinitis, 
and cerebral calcifications (Weller et al., 1957). The same group of researchers 
isolated two additional HCMV strains: the Kerr strain from the urine of a newborn 
with petechiae, hepatosplenomegaly, and jaundice, and the Esp. strain from the urine 
of an infant with hepatosplenomegaly, periventricular calcification, and 
chorioretinitis (Weller et al., 1957). 
2.3 MORPHOLOGY  
 HCMV is the largest member of the herpes virus family (Landolfo et al., 
2003). It is spherical, slightly pleomorphic and about 150 – 200 nm in diameter.   
The HCMV virion consists of an icosahedral capsid surrounded by a trilaminar 
phospholipid outer envelope about 10 nm thick. The core consists of a large double 
stranded linear DNA. Four proteins constitute the capsid: pUL 46, pUL 48.5, the 
minor capsid protein (mCP, UL85) and major capsid protein (MCP, UL86). The 
outer envelope of the virus contains multiple virally encoded glycoproteins which 
play multiple critical roles in the viral life cycle, including attachment, penetration, 
cell-to-cell spread, and envelopment and maturation of nascent viral particles (Huber 
and Compton, 1998). Three major complexes of glycoproteins can be identified: 
glycoprotein complex I (gCI), gCII and gCIII. The gCI is composed of glycoprotein 
B (gB), a glycoprotein expressed early in the replication cycle and existing as a 
heterodimer of glycoprotein (gp)115 and gp55, that remain complexed in the virion 
envelope. Up to 50 % of the protein mass of the viral envelope is represented by gB. 
Prior to infection, gB is involved in both attachment and fusion with the host cell 
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 membrane. The gCII complex includes several different highly glycosylated proteins 
in the range of 47 kD to 200 kD. One of these is glycoprotein M (gM), a 100 kD 
protein that may be responsible for the heparin-binding capacity of gCII. The third 
complex gCIII is composed of a heterotrimeric complex of gH, gL and gO. 
Although the function of the assembled gCIII complex is unknown, gL is necessary 
for the transport of gH from the nuclear membrane to the cell surface, and gO has 
been associated with fusion of CMV-infected cells. The disulfide-bonded, tripartite 
gCIII complex is displayed on the surface of infected cells and ultimately becomes 
part of the virion. Aside of gB, gCIII is most abundantly expressed in the viral 
membrane, and has a role in fusion and penetration into the host cell. The viral 
tegument (proteinaceous layer between the envelope and the inner capsid) contains 
20-25 structural virion proteins that are the major targets of host cell mediated 
immune response (Baldick and Schenk, 1996). Most of these tegument proteins are 
phosphorylated and they are also highly immunogenic. The most abundant are 
ppUL32 (pp150) and ppUL83 (pp65), of which the latter is the target antigen in 
antigenemia assays for rapid diagnosis of HCMV infections. 
2.4 GENOME  
 HCMV has a double stranded linear DNA of more than 240 kb and codes for 
more than 200 putative open reading frames (ORFs). The linear HCMV genome is 
composed of a unique long domain (UL) and a unique short (US) domain. Both ends 
of these domains are flanked by a repeat sequence, an internal and terminal long 
repeat sequence and an internal and terminal short repeat sequence, IRL, TRL and 
IRS, TRS respectively. The UL domain and US domain can be arranged head to tail 
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 or head to head and in the order UL-US or US-UL. Thus, four different isomers of 
the HCMV genome can be formed. Table 1 shows the key genes of HCMV with 
their functions. 
2.5 REPLICATION  
 The cellular receptor of CMV is unknown, but due to the ability of CMV to 
recognize and productively enter a wide range of cells suggests that the receptor is 
widely distributed (Mocarski and Courcelle, 2001). The epidermal growth factor 
receptor (EGFR) and cellular integrins have recently been suggested to function as 
entry receptors for CMV ( Feire et al, 2004; Wang et al., 2003). Viral entry is the 
result of a cascade of interactions between viral and cellular proteins and it ends in 
fusion of the virion envelope with the plasma membrane. Binding of the enveloped 
glycoproteins such as gB and gH to cellular receptors activates cellular transcription 
factors, such as NFκB and Sp1. The virus then enters the cell, releasing viral DNA, 
virion proteins and virion mRNA transcripts into the cytoplasm, where virion 
mRNA are translated. Viral DNA and certain viral proteins are transported to the 
nucleus. During productive replication the viral genes are expressed in a temporally 
co-ordinated and regulated cascade of transcriptional events that lead to synthesis of 
immediate-early (IE), early (E) and late (L) proteins (Mocarski and Courcelle, 
2001). In general, the IE proteins are activators of other genes. They have an 
important role in controlling cellular and viral gene expression, especially of early 
gene expression. Early genes encode mostly non-structural proteins, which are 
involved in the replication of viral DNA and in the induction of late gene expression. 
Late proteins are the virus structural proteins and they have a role in viral assembly 
15 
 Table 1: Key genes of HCMV and their functions 
Genes Functions 
UL 55 (gB) Envelope glycoprotein; Major target for neutralizing 
antibodies; Virus entry and cell to cell transmission 
UL 83 (pp65) Major target for CD8 restricted cytotoxic lymphocytes. 
Major virion structural protein 
US27, US28, 
UL33, UL75 
G coupled receptor family members. US 28 acts as a 
promiscuous chemokine receptor 
US2, US3, US6, 
US11 
Involved in downregulation of HLA class I display on 
infected cells 
UL 18 Class I HLA homologue; functions as NK decoy 
UL 146 CXC Chemokine homologue; chemoattractant of neutrophils 
UL 112/113 
(IE1/IE2) 
Key transactivators required for CMV replication 
UL 80A Protease; necessary for capsid assembly. 
UL 97  Protein Kinase essential for replication. Activates 
ganciclovir to its monophosphate 
UL 54  DNA polymerase. Required for CMV replication. Site of 
action of antiviral drugs ( Ganciclovir, Foscarnet, Cidofovir) 
UL 75 (gH) Viral entry, target for neutralizing antibodies 
UL 73 (gN) Induction of neutralizing antibodies 
UL 74 (gO) Viral entry and fusion of infected cells 
UL 115 (gL) Transport of gH to cell membrane 
UL 123 Target of Cytotoxic T lymphocytes 
UL 144 Truncated TNF -α- like receptor gene 
US28 Functional β chemokine receptor 
US 9 Required for replication in polarized epithelial cells of 
human retina 
 
  and morphogenesis of the virion. DNA replication, formation of the viral capsids 
and DNA packaging occur in the nucleus, whereas the maturation takes place in the 
cytoplasm before the mature virus particles leave the cell via exocytosis. The whole 
replication cycle of HCMV takes approximately 48-72 hours.  
2.6 TROPISM 
 During natural infection, it is shown that CMV replicates in many kinds of 
cells, including epithelial cells, endothelial cells, smooth muscle cells, fibroblasts, 
mesenchymal cells, hepatocytes, monocytes/ macrophages and lymphocytes ( Kahl 
et al., 2000; Plachter et al., 1996; Sinzger and Jahn, 1996; Sinzger et al., 1996). 
CMV may also infect several types of tissues, including most of the parenchymal 
organs, salivary glands, gastrointestinal and genitourinary tract ( Pass, 2001). 
2.7 EPIDEMIOLOGY AND TRANSMISSION 
 CMV shares with other herpesviruses the ability to remain latent in tissues 
after acute infection. Unlike herpes simplex virus and varicella zoster virus, which 
remain latent in highly restricted areas of the body, latent CMV can be found in 
multiple body sites, although it causes disease in only some of these that too in 
certain patient groups (Grundy, 1990). CMV infects humans of all ages, although the 
peak period of viral acquisition in the general population occurs early in life (Ho, 
1990). In the population at large, primary infection occurs by direct close personal 
contact via exposure to bodily fluids such as saliva, tears, urine, stool, semen, and 
breast milk. Infants may acquire CMV transplacentally as a result of maternal 
viremia or perinatally via breast milk.  
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  The term vertical transmission refers to the HCMV transmission from 
mother to fetus during pregnancy. Due to latency following primary infection and 
periodic reactivation of HCMV replication causing recurrent infections, in utero 
transmission of HCMV may follow either primary or recurrent infections (Ahlfors et 
al., 1984; Fisher et al., 2000; Schopfer et al., 1978). It is commonly recognized that 
primary HCMV infections are transmitted more frequently to the fetus and are more 
likely to cause fetal damage than recurrent infections (Fowler et al., 1992). In 
addition, it seems that primary infection occurring at an earlier gestational age is 
related to a worse outcome (Demmler, 1991; Stagno et al., 1986). The role of 
recurrent maternal infections in causing congenital infections is supported by reports 
and prospective studies describing congenital infections in the infants born to 
immune mothers (Schopfer et al., 1978; Embil et al., 1970; Krech et al., 1971; 
Stagno et al., 1973; Stagno et al., 1977). In a study, the incidence of symptomatic 
congenital HCMV infections in immune mothers was shown to be similar in primary 
and recurrent maternal infections (Boppanna et al., 1999). Symptomatic congenital 
infections appear to be mostly caused by reinfection of immune mothers during 
pregnancy by a new HCMV strain (Boppanna et al., 2001). 
 In later childhood, close physical contact facilitates transmission. Notably, 
infection in children is usually asymptomatic. Young children in day care centers 
transmit the virus to other children as well as to susceptible adults. (Adler, 1989; 
Adler, 1991; Gurevich and Kunha, 1981). In large day care centers, approximately 
half of all children experience active CMV infections and 10% to 15% of uninfected 
children become infected each year (Jones et al., 1996; Hutto et al., 1985). The 
highest prevalence rates of active viral transmission and excretion are found in 
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 children of 13 to 24 months of age (Dobbins et al., 1994). Depending on the 
population surveyed, the prevalence of CMV antibody seropositivity in various 
regions ranges from 40 to 100% (Bale et al., 1999; Ho, 1990; Marshall et al., 1993; 
Rubin, 1990; Tong, 1997). CMV can be heterosexually and homosexually 
transmitted; Approximately 50% of transplant patients excrete CMV in body 
secretions (e.g., saliva and urine) at some stage after organ transplantation which 
usually begins in the first month following transplant surgery. Viral shedding 
reaches peak levels during the second and third months following transplantation, at 
which time it may be associated with disease (Griffiths, 1995; Lam and Khan, 
1997). The incidence of symptoms related to CMV infection varies among different 
types of allograft recipients. In general, liver, pancreas, lung, intestinal, and heart 
transplant recipients have a greater incidence of CMV disease than do kidney 
transplant recipients. Symptomatic infections occur in approximately 39 to 41% of 
heart-lung, 9 to 35% of heart, 22 to 29% of liver and pancreas, and 8 to 32% of renal 
transplant recipients not receiving antiviral prophylaxis (Grossi et al., 1995 ; Ho, 
1994; Patel and Paya, 1997). Recipients of living-related kidney allografts 
experience less morbidity associated with CMV infection than do those receiving 
cadaveric renal allografts (Stratta, 1993). 
 In the transplant population, three patterns of CMV infection are observed, 
each with a different propensity for causing clinical disease. Primary infection 
develops in a CMV-seronegative individual who receives blood products and/or an 
organ from a CMV-seropositive donor. Most primary CMV infections in organ 
transplant recipients are due to transplantation of an organ carrying latent virus from 
a seropositive donor. Secondary or reactivation infection occurs when latent CMV 
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 reactivates posttransplantation in a CMV-seropositive recipient. CMV 
superinfection or reinfection occurs in a CMV seropositive host who receives cells 
and/or an organ from a seropositive donor, with reactivation of latent virus present 
in the allograft or reinfection by a new strain of CMV. It is difficult to distinguish 
superinfection from infection due to reactivation though, there is some indication 
that reinfection is more frequent than reactivation of endogenous CMV (Chou, 
1989).  
2.8 LATENCY AND REACTIVATION 
 Viral latency is defined as the persistence of the viral genome in the absence 
of production of infectious virions, but with the ability of the viral genome to 
reactivate under specific stimuli. Sporadic reactivation events in a latently infected 
immunocompetent host are generally well controlled by cell mediated 
immunosurveillance (Sinclair and Sissons, 2006).  Occasionally HCMV activates 
from its latent state and infectious virions appear in the saliva and/or urine. 
 One of the site of carriage of the latent HCMV is considered to be in the 
peripheral blood compartment. The proof comes from the ability of 
immunocompetent, HCMV seropositive blood donors to transmit HCMV infection 
to recipients and the fact that transmission by blood could be reduced by using 
leucocyte depleted blood products for transfusion (Yeager et al., 1981; Adler, 1983; 
Tolpin et al., 1985; Graan-Hentzen et al., 1989). It is difficult to isolate the virus 
from the blood of healthy donors ( Jordan, 1983). Highly sensitive PCRs have 
demonstrated the presence of HCMV DNA in the peripheral blood leukocytes 
(PBLs) of healthy, HCMV seropositive individuals (Taylor-Wiedeman et al., 1991; 
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 Stanier et al., 1992; Larsson et al., 1998). Study using granulocyte-macrophage 
colony stimulating factor (GM-CSF) mobilized peripheral blood cells (Slobedman 
and Mocarski, 1999), suggest that the frequency of cells that carry the HCMV 
genome is extremely low (probably <1 in 10,000 peripheral blood mononuclear 
cells), requiring very sensitive PCR conditions. By using sorted peripheral blood – 
cell populations, for the analyses it has been proved that peripheral blood monocytes 
are major site of carriage of HCMV DNA in healthy carriers (Taylor – Wiedeman et 
al., 1991; Larsson et al., 1998). HCMV DNA has also been detected in CD34+ bone-
marrow progenitors (Mendelson et al., 1996). Viral genome does not appear to be 
carried in the polymorphonuclear leucocytes (PMNL), T – cell or B – cell fractions 
of peripheral blood (Taylor- Wiedeman et al., 1991; Taylor- Wiedeman et al., 1993). 
Analysis of the conformation of HCMV DNA in peripheral blood mononuclear cells 
has shown that the viral genome migrates as a circular plasmid (Bolovan-Fritts et al., 
1999). The other sites of latency established by detection of viral DNA include early 
bone marrow haematopoietic progenitors, epithelial cells and endothelial cells 
(Hendrix et al., 1990; Kondo et al., 1994; Markovic-Lipkovski et al., 1992; Melnick 
et al., 1983; Taylor-Wiedeman et al., 1991; Taylor-Wiedeman et al., 1993; Sindre et 
al., 1996).   
 The cytomegalovirus latency – specific transcripts (CLTs) includes novel 
spliced and unspliced RNA transcripts mapping to both strands of HCMV major IE 
region (Kondo et al., 1994). No viral gene products from the CLTs have been shown 
to play a role in the latency. The roles of UL 82 (pp71), UL 111.5A encoding a 
homologue of IL-10 in latency are yet to be deciphered. The efforts to detect the 
viral transcription associated with carriage of HCMV in myeloid cells from naturally 
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 latently infected individuals has been impeded by the low frequency of cells 
carrying latent HCMV in vivo. Certain experimental models have been able to 
predict several putative latent viral RNAs to have a role in the latency but their 
definitive role awaits confirmation. 
 Reactivation of a latent virus by allogeneic stimulation of T cells has been 
demonstrated (Soderberg-Naucler et al., 1997). The bone marrow acts as a reservoir 
of latent CMV, which then seeds latent virus into the peripheral blood via 
monocytes. Differentiation of monocytes to tissue macrophages seems to lead to 
virus reactivation and productive infection (Sinclair and Sissons, 2006; Soderberg-
Naucler et al., 2001; Taylor-Wiedeman et al., 1994). The reactivation of CMV from 
latency is the critical first step in the pathogenesis of CMV infection. It is also 
observed that the load of latent viral genome is one of the factor that can influence 
reactivation.  A higher load of the latent viral genome may make it easier for the 
virus to be reactivated (Reeves et al., 2005). The key mediators for the reactivation 
of CMV from latency is Tumor necrosis factor alpha TNF α, which activate protein 
kinase C and NFκB, a promoter of the immediate early (IE) gene of CMV initiating 
replication (Prosch et al., 1995; Stein et al., 1993). This observation is important, as 
it explains why CMV infection and disease are associated with several processes 
(e.g. sepsis, other viral infections and allograft rejection) (Rubin, 2001). 
2.9 IMMUNE EVASION 
 HCMV encodes for a number of proteins which interfere with antigen 
processing. These proteins have been designated `immune evasion' molecules 
(Johnson and Hill, 1998). The US2 and US11 genes in the short unique segment of 
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 the HCMV genome code for proteins which are capable of displacing the class I 
MHC heavy chain from the endoplasmic reticulum into the cytosol, where they are 
subsequently degraded. The US6 gene codes for a protein which binds to the 
endoplasmic reticulum face of the TAP (transporter of antigenic peptides) 
heterodimer and blocks the transport of peptides produced in the proteosome into the 
endoplasmic reticulum. The US3 gene product appears to promote the retention of 
assembled class I MHC molecules in the endoplasmic reticulum. All these proteins 
thus interfere with antigen processing via the class I pathway and contribute to the 
downregulation of class I MHC molecules on the surface of HCMV infected cells 
(Wiertz et al., 1997). Normally, the cells that lack class I MHC molecules are 
usually identified and lysed by Natural killer (NK) cells. Signal peptide sequences of 
class I MHC molecules normally bind to the non-classical class I molecule HLA-E 
and allow its egress to the cell surface where it can be recognized by, and inhibit, 
NK cells. It has been shown that the UL40 gene product of HCMV contains a 
sequence homologous to the signal peptides which can facilitate HLA-E expression 
(Tomasec et al., 2000). HCMV may thus have a mechanism for simultaneously 
inhibiting Cytotoxic T lymphocyte recognition and, by still allowing HLA-E 
expression, inhibiting NK cell recognition. 
2.10 PATHOGENESIS & CLINICAL MANIFESTATIONS 
2.10.1 POST – ORGAN TRANSPLANT RECIPIENTS 
 HCMV infection and disease are important causes of morbidity and even 
mortality among transplant patients.  Three virus associated factors have been 
attributed to the pathogenesis of HCMV: the cell bound nature of the virus, ability to 
22 
 disseminate throughout the body via blood stream and monocytotropic character. 
The latent virus in the monocytes forms a circulating reservoir which on 
differentiation into macrophage is capable of active replication thus causing the 
disease (The et al., 1994). Among the host factors, failure to reconstitute CMV – 
specific cellular immunity after transplantation is considered to be a potential cause 
for progression to HCMV disease (Quinnan et al., 1982). 
 The major risk factors for the development of CMV disease in the transplant 
recipients are serological status of the donor and recipient [sero-positive donor / 
CMV sero-negative recipient (D+/R-)], primary infections occurring in sero-
negative transplant recipients, modification of immunity by the use of anti-
lymphocyte antibodies or other agents that has an influence on the cell-mediated 
immunity (Birkeland et al., 1998; Chou, 1986; Smith et al., 1998). Transplant 
recipient receiving the allograft from HLA B7 positive donors have also been 
attributed to have a higher risk of developing CMV disease (Boland et al., 1993). 
CMV is also known to be an active inducer of other herpes viruses such as EBV and 
HHV 6 (Aalto et al., 1998).  Simultaneous detection of HCMV and HHV 6 DNA in 
urine or serum of transplant recipient is considered to be a predictor of HCMV 
disease (Des Jardin et al., 1998; Ratnamohan et al., 1998). 
 HCMV reactivation following transplantation and other predisposing factors 
include type and intensity of immunosuppression, receipt of CMV contaminated 
blood products, cadaveric allograft transplantation and donor-receipient HLA 
mismatch (Bock et al., 1997; Glenn, 1981; Pillay et al., 1993, Sawyer et al., 1993). 
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 The load of CMV in the graft has been attributed to be one of the factors that 
determine severity of the CMV disease in transplant recipients. 
 Direct viral cytopathogenecity and CMV triggered immune reactivity have 
been described as major factors for CMV induced organ dysfunctions (The et al., 
1994; Smith et al., 1998; Grundy et al., 1987).  
 Irrespective of the pattern and type of CMV transmission, symptomatic 
disease in most of the transplant recipients occur between 1st and 4th months post 
transplant, when the immunosuppression is most intense (Paya and Razonable, 
2003). The definitions of CMV infection and disease in transplant recipients have 
recently been updated (Ljungman et al., 2002). “CMV infection” is defined as 
isolation of the CMV virus or detection of viral proteins or nucleic acid in any body 
fluid or tissue specimen (Ljungman et al., 2002). The minimum requirements for 
definition of “CMV disease” are fever (>38ºC, for at least 2 days within a 4-day-
period), neutropenia or thrombocytopenia, and the detection of CMV in blood. In an 
end-organ disease, e.g pneumonia, hepatitis, gastrointestinal disease, retinitis, 
nephritis, cystitis, myocarditis, pancreatitis or central nervous disease, CMV needs 
to be detected in the particular organ.  
 The consequences of HCMV infection in the transplant recipients include: 
Infectious disease syndrome caused by the virus itself, opportunistic superinfections 
with other infectious agents due to CMV associated immunosuppression, allograft 
dysfunctions and reduced graft survivals, and decreased survival rates among the 
transplant recipients. 
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  CMV pneumonia remains a life-threatening syndrome, which is usually 
complicated by other pathogens, such as Pneumocystis, Aspergillus and other fungal 
copathogens (Fishman and Rubin, 1998). In hematopoietic stem cell transplantation 
(HSCT) patients, the most frequent clinical manifestations of CMV are fever, 
pneumonitis and gastrointestinal disease (Boeckh and Ljungman, 2003). In solid 
organ transplant patients, CMV can infect various organs such as lung, liver, 
intestines, kidney and heart, and may also affect the transplanted organ (Paya and 
Razonable, 2003). In addition to direct effects of CMV on the host, there are also 
indirect effects of the virus (Rubin, 2001). These are an association of CMV with 
acute graft rejection (Pouteil-Noble et al., 1993; Reinke et al., 1994) and chronic 
graft rejection, including accelerated transplant vasculopathy in heart transplant 
recipients (Grattan et al., 1989; Koskinen et al., 1993; Valantine et al., 1999), 
vanishing bile duct syndrome  in liver transplant recipients (Arnold et al., 1992; 
Evans et al., 1999; Lautenschlager et al., 1997), chronic allograft nephropathy  in 
kidney transplant recipients (Helantera et al., 2003; Humar et al., 1999a; Tong et al., 
2002) and bronchiolitis obliterans in lung recipients (Kroshus et al., 1997). CMV is 
also associated with bacterial and fungal infections (Fishman and Rubin, 1998; 
George et al., 1997). CMV could interact with other viruses and may accelerate 
hepatitis C virus pathogenesis (Burak et al., 2002, Razonable et al., 2002a). 
Chorioretinitis is an uncommon manifestation of CMV disease in transplant 
recipients and usually occurs late (more than 6 months ) in the post transplantation 
period. The usual symptoms include scotomata with or without decreased visual 
acuity (Rubin, 1990). Recurrence of HCMV disease after treatment is seen in 6 to 
31% of kidney transplant recipients (Humar et al.,1999b; Jordan et al., 1992;  
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 Sawyer et al., 1993). Most cases of the recurrent disease occur within 3 months after 
treatment of the first episode and tend to involve multiple organs. A cadaveric 
source of the graft and lack of CMV specific T helper responses following infection 
have been associated with recurrent HCMV disease (Humar et al.,1999b;  Zeevi et 
al., 1998). 
2.10.2 CONGENITAL HCMV INFECTION 
 Intrauterine transmission occurs in 30 to 40% of cases following primary 
infection and in reactivated maternal infections, the risk of symptomatic congenital 
infection is markedly lower (Ahlfors et al., 1984; Griffiths and Baboonian, 1984; 
Stagno et al., 1986). Although existing immunity does not prevent transmission  
of the virus to the fetus, reactivated infections are less likely to cause damage to the 
offspring than primary infections (Fowler et al., 1992). Multiple mechanisms  
of immune evasion for HCMV relates to the pathogenic role of the virus  
(Greijer et al., 2001). 
 The mechanisms of HCMV transmission to the fetus remain largely 
unexplored. It has been reported that about 15% of women undergoing primary 
infection during the first months of pregnancy abort spontaneously, showing 
placental but not fetal infection (Griffiths and Baboonian, 1984; Hayes and Gibas, 
1971). Subsequently in the course of pregnancy, placental infection has been shown 
to be consistently associated with fetal infection (Muhlemann et al., 1992).  
 Guinea pig models have been helpful in establishing placenta as the reservoir 
in which CMV replicates prior to transmission to the fetus (Leiser and Kaufmann, 
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 1994). In experimental infection of the guinea pig with species-specific CMV, the 
virus disseminates hematogenously to the placenta, from which it is transmitted to 
the fetus in about 25% of cases. The guinea pig CMV also persists in placental 
tissues long after virus has been cleared from blood (Griffith et al., 1985).  
 Two in vitro models for the study of trophoblast populations lying at the 
maternal-fetal interface, villous explants and isolated cytotrophoblasts have been 
described (Fisher et al., 1985; Fisher et al., 1989; Fisher et al., 2000). Hypotheses on 
the routes of transmission of HCMV to the fetus in primary and reactivated maternal 
HCMV infection have been framed based on the results of the in vitro models, 
immunohistochemical studies of in vivo HCMV-infected placentas (Muhlemann et 
al., 1992, Sinzger et al., 1993) and findings on HCMV latency (Hahn et al., 1998, 
Soderberg-Naucler et al., 1997). First model: During primary infection of the 
mother, leukocytes carrying infectious virus may transmit HCMV infection to 
uterine microvascular endothelial cells. These cells are in direct contact with 
cytotrophoblasts of anchoring villi invading maternal arterioles and forming hybrids 
of maternal-fetal cells. Infected cytotrophoblasts may in turn transmit the infection 
to underlying tissues of villous cores, including fibroblasts and fetal endothelial cells 
(Sinzger et al., 1993), thus spreading to the fetus. Second model of transmission 
envisages the spreading of infection to the villous stroma by infected maternal 
leukocytes after primary maternal infection through breaches of the 
syncytiotrophoblast layer (Hemmings et al., 1998; Jacques and Qureshi, 1993). A 
further hypothesis has been raised suggesting possible transportation of the virus as 
antibody-coated HCMV virions by a process of transcytosis through intact 
syncytiotrophoblasts similar to that advocated for transport of maternal IgG to the 
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 fetus (Fisher et al., 2000). Finally, syncytiotrophoblasts may be directly infected, but 
the infection proceeds slowly and remains predominantly cell associated (Hemmings 
et al., 1998) until infected cells are eliminated during the physiological turnover 
(Smith et al., 1997). This hypothesis therefore excludes transmission through virus 
replication in syncytiotrophoblasts.  
 In the case of congenital HCMV infection following recurrent maternal 
infection, the placenta is considered as a hemiallograft inducing local 
immunosuppression in the uterus (Fisher et al., 2000; Roth et al., 1996). This may 
cause reactivation of latent virus in macrophages of the uterine wall, with HCMV 
transmission to the invading cytotrophoblasts. Then, virus could spread in a 
retrograde manner to anchoring villi and subsequently to the fetus (Muhlemann et 
al., 1992). In this regard, HCMV establishes a true latent infection in CD14+ 
monocytes, which can be reactivated upon allogeneic stimulation of monocyte-
derived macrophages from healthy blood donors (Soderberg-Naucler et al., 1997). 
Reactivation of latent HCMV is dependent on the production of gamma interferon in 
the differentiation process (Soderberg-Naucler et al., 2001). As a consequence of 
placental infection, HCMV impairs cytotrophoblast differentiation and invasiveness 
(Fisher et al., 2000). This explains the early abortion occurring in women with 
primary infection. In addition, HCMV infection impairs cytotrophoblast expression 
of HLA-G, thus activating the maternal immune response against the 
cytotrophoblast subpopulation expressing this molecule (Fisher et al., 2000). 
 Less than 5% of pregnant women with primary infection of HCMV are 
symptomatic (Pass and Boppana, 1999). The major symptoms include 
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 mononucleosis – like syndrome which includes fever, cervical adenopathy, sore 
throat, splenomegaly, hepatomegaly and rash. The primary infection acquired just 
before conception is generally assumed to represent a lower risk than primary 
infection acquired during pregnancy. Primary infection early in pregnancy implies 
greater likelihood of congenital disease. The ultrasonographic abnormalities found 
frequently during fetal HCMV infection include intrauterine growth retardation, 
hydrops or ascites and central nervous system abnormalities. 
 The most common clinical sequelae reported in infected infants are jaundice, 
thrombocytopenia, hepatomegaly, petechiae, purpura, pneumonitis, splenomegaly 
and seizures. Permanent outcome of HCMV infection in the infants include CNS 
manifestations like microcephaly, chorioretinitis, sensorineural hearing loss, 
intracranial calcifications, mental retardation, developmental delay or seizures and 
death (Munro et al., 2005).  
2.10.3 HIV INFECTED INDIVIDUALS  
 Prior to the introduction of highly active anti retroviral therapy (HAART), 
Cytomegalovirus (CMV) infection was one of the most important opportunistic 
infections in HIV-infected patients. Approximately 40% of HIV-infected patients 
with advanced disease suffer from one of several different manifestations of CMV 
disease during life-time (Bowen et al., 1996; Jabs et al., 1989; Pertel et al., 1992; 
Drew, 1992). The median survival period after diagnosis of CMV disease in these 
patients was 4–9 months (Harb et al., 1991; Gerard et al., 1997). After the 
introduction of HAART therapy in 1995–1996, life expectancy and quality of life 
had dramatically improved with the persistent suppression of HIV viremia. 
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 Persistent immune reconstitution, decreased CMV replication and incidence of 
CMV disease particularly CMV retinitis in HIV-infected patients were observed in 
few studies (O’Sullivan et al., 1999; Palella et al., 1998;  Ledergerber et al., 1999; 
Mocroft et al., 2000).  
 But, recent studies have documented rapid progression (2.5 times) of CMV – 
seropositive individuals to AIDS than seronegative individuals even after HAART 
therapy (Sabin et al., 2000). In the case of primary CMV infection, even patients 
with relatively high CD4+ cell count (>100/mm3) were shown to be at a significantly 
increased risk for progression to AIDS (Robain et al., 2001). A CD4 cell count 
<100/mm3 was identified as the major risk factor for CMV disease in CMV-
seropositive HIVinfected patients ( Deayton et al., 2004; Deayton, 2001; Salmon-
Ceron et al., 2000). The initial months of antiretroviral treatment  where in  cellular 
immunity is not fully reconstituted is shown to be the phase at which the HIV 
patients  develop CMV disease (Ledergerber et al., 1999; Salmon-Ceron et al., 
2000).  
 CMV retinitis is the single most common manifestation of CMV disease, 
accounting for 85% of all cases (Gallant et al., 1992; Yust et al., 2004). It is 
characterized by haemorrhagic retinal necrosis, including white areas with or 
without hemorrhages and gray-white areas of retinal necrosis. Lesions have an 
irregular, dry-appearing, granular border, with little or no overlying vitreous 
inflammation (Ljungman et al., 2002). Ophthalmologic findings are pathognomonic, 
so that the diagnosis may be established by an experienced opthalmologist within 
the context of advanced HIV-infection (Ljungman et al., 2002). The prevalence of 
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 immune recovery vitritis varies in patients with previous CMV retinitis from 18% to 
63% (Nguyen et al., 2000; Karavellas et al., 1999).  
 Gastrointestinal disease is the second most common manifestation of CMV 
infection accounting for 15% of all cases of CMV disease (Gallant et al., 1992; Yust 
et al., 2004).  CMV infection may involve all parts of the gastrointestinal tract. The 
major symptoms include odynophagia or persistent diarrhea and in severe cases 
obstruction or perforation of the gastrointestinal tract may occur. Bleeding of the 
tract rarely occurs. 
 Clinical CMV disease of the nervous system accounts for less than 1% of all 
CMV diseases in HIV-infected patients (McCutchan, 1995; Gallant et al., 1992), but 
mortality rate approximated 100% in untreated patients (McCutchan, 1995) and 
median survival from the onset of neurological symptoms was less than 2 months 
(Salazar et al., 1995; Arribas et al., 1996). Signs and symptoms of CMV encephalitis 
are unspecific, such as drowsiness, fever, disorientation, confusion, apathy, a 
relatively abrupt onset of mental status changes or focal neurological signs and may 
be similar to infections with other viruses such as herpesviruses other than HCMV, 
polyomaviruses; parasite such as Toxoplasma gondii and  fungus such as 
Cryptococcus neoformans  (Morgello et al., 1987).  
 CMV pneumonia is a very rare cause of lung disease in HIV-infected 
patients (Gallant et al., 1992). Only very few well documented studies on HIV-
infected patients with CMV pneumonia have been described (Rodriguez-Barradas et 
al., 1996; Salomon et al., 1997; Vasudevan et al., 1990). The clinical presentation of 
CMV pneumonia is indistinguishable from pneumonia caused by other infectious 
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 agents such as Pneumocystis jiroveci and manifests as fever, cough, hypoxemia and 
diffuse radiographic opacities. 
2.11 DIAGNOSIS OF HCMV INFECTIONS 
 The clinical manifestations of CMV disease may be relatively nonspecific. 
The signs and symptoms of CMV disease cannot be easily differentiated from 
illnesses caused by a variety of other opportunistic microbes or drug toxicity. It is 
also difficult to establish the cause for acute graft rejections in transplant recipients 
on clinical grounds since, HCMV plays a role in organ dysfunction. Hence, clinical 
diagnosis of HCMV is unreliable which necessitates the use of rapid and sensitive 
laboratory diagnostic tests for its diagnosis.  Laboratory methods are useful not only 
in establishing CMV disease in the patients but also to predict the risk of 
development of HCMV in the patients. Both qualitative and quantitative methods 
are currently employed in the diagnosis of HCMV disease in various patient 
populations. Quantitative methods are employed more as prognostic markers in the 
development of HCMV disease in post organ transplant recipients and HIV infected 
individuals. Since, bone marrow transplant recipients as well as neonates develop 
disease even with a low viral load, qualitative methods itself may be beneficial in 
these groups. Quantitative methods irrespective of the patient groups are useful in 
determining the response to treatment and as a surrogate marker in development of 
antiviral resistance. The diagnostic methods include serology, viral culture, antigen 
detection and detection of nucleic acids. Several specific definitions for CMV in 
blood are recommended: viremia is defined as the isolation of CMV by culture from 
blood, antigenemia as the detection of CMV pp65 in blood leukocytes, and 
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 DNAemia as the detection of DNA in samples of plasma, whole blood, isolated 
peripheral blood leukocytes or buffy-coat specimens (Ljungman et al., 2002). 
2.11.1 CONVENTIONAL LABORATORY METHODS OF DIAGNOSIS 
2.11.1.1 Serology 
 Serology is an insensitive marker of active CMV infection in the organ 
transplant recipients and HIV infected individuals and is therefore of limited 
diagnostic usefulness (Marsano et al., 1990; van Son and The, 1989; Robain et al., 
2001). The main utility of serologic studies in organ transplantation is as an accurate 
and sensitive means of determining a past history of CMV infection in potential 
organ/blood donors and allograft recipients. In patient with AIDS, seroconversion 
may be significantly delayed, and the maturation of humoral and cellular immunity 
may be clearly prolonged (Robain et al., 2001). Similarly, reactivation from latency 
may not be detected by serology due to a less effective recall immune response in 
AIDS patients (Robain et al., 2001). However, serological techniques have been 
useful in establishing primary infections in pregnant women. Seroconversion i.e. 
appearance of CMV specific IgG antibodies in a previously seronegative pregnant 
women is considered to be a definitive diagnosis of primary HCMV infection. In 
cases where seroconversion cannot be proved, detection of IgM by one of the 
numerous diagnostic tests such as complement fixation, indirect hemagglutination, 
anticomplement immunofluorescence, Radio immuno assay (RIA) or Enzyme linked 
immuno sorbent assay (ELISA) can be helpful in establishing clinically significant 
primary HCMV infections (Reynolds and Stagno, 1979; Krishna et al., 1980; 
Schmitz et al., 1980). The detection of IgM antibody seldom occurs during recurrent 
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 infections in a immunocompetent individual such as pregnant women. Hence, the 
detection of IgM antibody is considered to be a reliable marker for primary infection 
in pregnant mothers. However, the presence of IgM can reveal different clinical 
situations such as, acute phase of a primary infection (peak titres of IgM antibody is 
seen between 1 and 3 months), convalenscent or late phase of primary infection (the 
titre drops down after 3 months) mere persistence of IgM antibodies (stable levels of 
IgM for longer than 3 months) which can occur in around 28.5% of pregnant women 
(Revello and Gerna, 1999). In cases of persistent IgM levels, test like IgG avidity 
may be useful in establishing the clinical significance of the presence of IgM 
antibodies. IgG avidity tests can be helpful in distinguishing primary from non 
primary HCMV infections (Bodeus et al., 1998; Bodeus and Goubau, 1999; Revello 
and Gerna, 1999). The test principle is based on the difference in the avidity of the 
IgG antibody produced during the initial and later phase of infection. During the first 
few months of infection (primary infections) IgG of lower avidity is produced while 
in subsequent period (recurrent or remote infections) a maturation process occurs 
giving rise to IgG antibodies of a higher avidity. The result of the test is expressed as 
avidity index which is the percentage of IgG antibody bound to the antigen 
following the treatment with denaturing agents such as 6M urea. The avidity index 
within 3 months of a primary infection is usually 21 % + 13% whereas mean avidity 
index values for serum samples from subjects with remote HCMV infection were 
78% + 10% (Revello and Gerna, 1999). Thus, the presence of high IgM levels and a 
low avidity index are highly suggestive of a recent (less than 3 months) primary 
HCMV infection. In a study, the ability of three different IgG avidity assays to 
detect a primary HCMV infection was found to be approximately 100%, whereas the 
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 ability to exclude a recent infection was shown to range from 96% to 32%. These 
data indicate a need for more standardized assay (Bodeus et al., 2001). Also, the gap 
between the low and higher avidity index is immense and any value between the two 
may be inconclusive of the phase of primary infection. The determination of 
neutralizing antibodies in the immunocompetent host may aid in establishing the 
period of primary infection. The neutralizing antibodies in majority of the cases tend 
to appear after 15 weeks (range 14- 17 weeks) of primary infection. Hence, an 
absence of neutralizing antibody during convalescence is indicative of a recent 
primary infection and presence of the same rules out infection within 15 weeks 
(Eggers et al., 1998).  
2.11.1.2 Histopathology & Immunohistochemistry 
 Traditionally, the diagnosis of CMV infection was based on the histologic 
recognition of cytomegalic inclusion bodies that have the characteristic intranuclear 
owl-eye appearance in haematoxylin and eosin-stained tissue specimens. 
Histopathological studies have been considered useful in differentiating allograft 
dysfunction caused by inflammatory response provoked by CMV from cellular 
rejection (Barkholt et al., 1994; Colina et al., 1995; Ulrich et al., 1986) in liver and 
renal transplant recipients. The presence of viral inclusion bodies in liver tissue, for 
instance, correlates with active disease in most cases (Colina et al., 1995). 
Conversely, CMV may be detected in cultures of biopsy specimens that are negative 
on histopathology (Paya et al., 1989). Histopathological studies have also been used 
in establishing or ruling out CMV associated manifestations in AIDS patient 
(Rovery et al., 2006).  The use of immunohistochemistry has increased the 
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 sensitivity for the histologic diagnosis of CMV disease compared to standard 
hematoxylin and eosin staining (Barkholt et al., 1994; Colina et al., 1995; Paya et 
al., 1990). Immunostaining techniques use either a monoclonal or a polyclonal 
antibody against an early CMV antigen. The sensitivity and specificity of the 
immunohistochemistry was close to 84 and 97% in one study (Paya et al., 1990). A 
high rate of false-negativity has been shown in a study, owing to the focal 
distribution of CMV-positive cells (Colina et al., 1995).  Histopathological studies 
or immunohistochemistry are considered to be important for the identification of 
localized CMV disease, but their usefulness is limited because of the need to use 
invasive procedures to obtain samples. 
2.11.1.3 Detection of Cytomegalic endothelial cells (CEC) in circulation 
 The term endotheliemia was introduced to indicate HCMV-infected CEC in 
the peripheral blood of immunocompromised patients. CEC were first described in 
1993 by two independent groups (Grefte et al., 1993; Percivalle et al., 1993) and 
were shown to be endothelial in origin and fully permissive for HCMV replication. 
The presence of these cells is considered to indicate extensive endothelial damage. 
These cells are derived from infected endothelial cells of small blood vessels, which 
progressively enlarge until they detach from the vessel wall and enter the 
bloodstream. These cells can be identified by cytocentrifugation of the mononuclear 
fraction of leukocytes onto glass slides followed by endothelial cell-specific 
staining. A method for quantification of CEC in peripheral blood has also been 
described (Kasdeelen et al., 1998). In patients with AIDS, the detection of CEC is 
associated with lack of anti- CMV treatment, emergence of drug-resistant CMV, 
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 insufficient treatment, or transient response to antiviral therapy (Gerna et al., 1998c). 
CEC have also been studied in hematopoietic stem cell transplant recipients 
(Salzberger et al., 1997). In recent years, the introduction of HAART for AIDS 
patients and the adoption of prophylactic and preemptive therapy approaches for 
transplant recipients have nearly eliminated CEC from blood of these patient groups. 
However, CEC is shown to occur in the blood of fetuses and newborns with 
symptomatic congenital HCMV infection.   
2.11.1.4 Virus isolation 
 Conventional detection of CMV in clinical specimens is achieved by direct 
viral culture. The detection of CMV in tissue cultures from peripheral sites such as 
urine or saliva is often uninformative because the virus may be present in these sites 
for prolonged periods after the acute phase of infection and during viral reactivation. 
Nevertheless, viral isolation from these sites indicates a relative risk of about 
twofold for future CMV disease (Pillay et al., 1992; Pillay et al., 1993). 
Furthermore, viral isolation from any site in a CMV-seronegative patient is 
indicative of primary CMV infection. 
2.11.1.4.1 Conventional tube cell culture 
 For conventional cell culture, clinical specimens are inoculated onto human 
diploid fibroblast cells and incubated at 37°C. CMV exhibits a typical cytopathic 
effect (CPE) characterized by foci of flat, swollen cells. The time required for the 
development of CPE is directly related to the titer of the virus in the sample. 
Typically, the mean time for CPE to be visible is 8 days, but it can range from 2 to 
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 21 days. The long time required for diagnostic confirmation by this method limits its 
clinical usefulness. There are two methods of quantitating CMV in conventional 
tube cultures: the plaque assay and determination of TCID50. 
(i) Traditional Plaque assay 
 In a plaque assay, serial dilutions of the specimen are inoculated onto 
fibroblast monolayers and after infection the cells are overlaid with a semisolid 
medium. The virus spreads from cell to cell, resulting in a localized plaque. After an 
incubation period, the infectious plaques are enumerated under microscopic 
examination. The plaque assay and modifications of it have been used frequently for 
CMV quantitation in a wide variety of clinical specimens (Chou and Scott, 1988; 
Churchill et al., 1987). Results are obtained by calculating a logarithmic viral titer 
from the plaque counts in the dilution giving about 200 plaques.  
(ii)  TCID 50 assay 
 A less precise assay for the quantitation of CMV in tissue culture is 
determination of the TCID50. In this method, the virus titer is ascertained by 
determining the highest dilution of the specimen which produces a cytopathic effect 
in 50% of the cell cultures or wells inoculated (Schmidt, 1989). The TCID50 has 
been used to quantify CMV in lung tissue and urine. Serial log or half-log dilutions 
of the specimen are inoculated onto human foreskin fibroblasts and observed for 6 
weeks. 
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 2.11.1.4.2  Rapid shell vial assay 
 Traditional tissue culture methods have been replaced by the more rapid shell 
vial centrifugation culture assay system. Detection of CMV-specific early-antigen 
fluorescent foci by using the shell vial assay permits the detection of CMV prior to 
the development of CPE in conventional tube cell culture. Shell vial assays are 
performed in vials containing coverslips containing a fibroblast monolayer. 
Centrifugation of specimen onto the cell monolayers greatly assists absorption of 
virus, increasing apparent infectivity of the viral inoculum.  The shell vial assay 
utilizes a monoclonal antibody directed at the immediate-early (IE) or early viral 
antigen to detect CMV by indirect immunofluorescence after 16 – 48 hours of 
incubation. CMV is quantified in shell vial-based assays either by keeping the viral 
inoculum constant and counting the number of infectious foci per shell vial (Gerna 
et al., 1990) or by inoculating serial dilutions of the sample and determining the titer, 
which is defined as the reciprocal of the final dilution in which CMV can be 
detected (Slavin et al., 1992). Shell vial centrifugation culture-based assays have 
been used for the quantitation of viremia and of CMV in bronchoalveolar lavage 
(BAL) fluid (Gerna et al., 1990; Slavin et al., 1992).  
 Due to a high rate of false-negative results, virus isolation procedures are 
useful only in the setting of a positive result and is considered a parameter of risk for 
the development of CMV disease. The number of positives identified by the shell 
vial assay is greater than that detected by conventional culture.  Development of 
viremia detected by shell vial culture more than 2 months after liver transplantation 
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 is a strong predictor of CMV disease (Manez et al., 1996). Viral isolation has been 
shown to be highly useful for antiviral susceptibility testing. 
2.11.1.4.3  Limitations of viral isolation procedures 
 A delay in specimen processing of longer than 24 hours severely 
compromises the sensitivity of the assay. The other limitations include: 
 Cytotoxic effects of clinical specimens  on the fibroblasts ; Overgrowth of 
rapidly growing microorganisms (such as herpes simplex virus or bacteria); Lack of 
staining by monoclonals in case of shell vial assays; and poor ability of certain CMV 
strains to form plaques.  
2.11.1.5 pp65 antigenemia assay 
 The antigenemia assay detects and quantifies peripheral blood leukocytes, 
mostly polymorphonuclear leukocytes (PMNL) and, to a much lesser extent, 
monocytes/macrophages, which are positive for the HCMV lower matrix 
phosphoprotein pp65 (Grefte et al., 1992; Revello et al., 1992). The HCMV protein 
is transferred to PMNL from infected permissive cells via transitory microfusion 
events between two adhering cells. It has been shown that antigenemia becomes 
positive earlier than viremia but later than DNAemia at the onset of infection, and it 
becomes negative later than viremia but earlier than DNAemia in the advanced stage 
of a systemic infection in immunocompromised patients (Gerna et al., 2001). A high 
antigenemia level is often associated with HCMV disease. The assay is widely used 
as a prognostic marker for institution of antiviral therapy and monitoring of HCMV 
load during therapy. (Boeckh et al., 1992; Gerna et al., 1991). Breakpoints of 10 
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 positive cells per slide in kidney transplant recipients and HIV infected individuals 
and 100 positive cells per slide in liver and heart transplant recipients in the 
antigenemia assay have been advocated to institute early antiviral treatment (Boeckh 
and Boivin, 1998). During ganciclovir treatment of primary HCMV infections, 
antigenemia levels may increase for up to 2 to 3 weeks despite the efficacy of 
treatment as shown by the disappearance of viremia. (Boeckh et al., 1996; Gerna et 
al., 1998b). The antigenemia testing consists of a number of steps, including 
isolation of blood leukocytes preparation of cytospin slides containing a given cell 
number by centrifugation of leukocyte-rich supernatant, slide fixation and staining 
with monoclonal antibody directed against the CMV lower matrix phosphoprotein 
pp65 antigen. Immunodetection of CMV antigen is possible with either indirect 
immunoperoxidase, indirect immunofluorescence methods or phosphatase/ anti-
alkaline phosphatase (APAAP) staining . The results may be reported as the number 
of positively stained cells relative to the number of cells used to prepare the slide. 
2.11.1.5.1 Advantages and limitations of pp65 antigenemia assay 
 Advantages include a short processing time (less than 6 hours) and the lack 
of requirement of a highly specialized laboratory.  Disadvantages include the need 
for immediate processing, the relatively time-consuming nature of the different 
assay steps with large specimen numbers, and the subjective component of slide 
interpretation.  
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 2.11.1.6 Short comings of Conventional methods of detection 
 Most of the conventional methods of diagnosis of HCMV suffer from one or 
more of the following disadvantages: time-consuming, poor reproducibility, low 
sensitivity, cannot be applied on wide variety of clinical specimens, cannot be 
automated and cannot be adapted for high throughput. 
2.11.2  MOLECULAR METHODS OF DIAGNOSIS 
 Detection and quantification of HCMV DNA in blood has become a major 
diagnostic tool for HCMV diseases in immunocompromised patients. The molecular 
methods of diagnosis have one of the several characters of an ideal diagnostic tool. 
This includes rapidity, high sensitivity of detection, better reproducibility, ability to 
be applied on a wide variety of clinical specimens, scope for automation and high 
throughput.  
2.11.2.1 In situ Hybridization 
 In situ hybridization (ISH) with CMV-specific complementary DNA probes 
applied to cellular material has facilitated the histopathological identification of 
infected cells in tissues (Paya et al., 1990; Mauch et al., 1995). Hybridization has 
conventionally been performed with probes labeled with radioactive isotopes, which 
then allows the detection of sequence specific nucleic acid following 
autoradiographic analysis (Fox and Emery, 1992). The routine use of radioactive 
isotopes has largely been replaced by biotinylated DNA and 
electrochemiluminescent labels (Einsele et al., 1989; Musiani et al., 1996). 
Biotinylated probes may be used for the direct detection of CMV inclusions in 
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 formaldehyde-fixed, paraffin-embedded tissue sections in cases where active 
infection is present. Estimation and quantification of nucleic acid present in tissue 
samples or cellular smears may also be possible with ISH. The comparative 
sensitivity of ISH for diagnosing CMV disease varies in different studies. Most 
reports do not favor the use of ISH over conventional histopathologic examination 
for the diagnosis of CMV organ disease (Barkholt et al., 1994; Colina et al., 1995; 
Paya et al., 1990). Nonetheless, the test specificity for allograft biopsy specimens is 
as high as 100% and allows rapid detection of HCMV in tissues (Masih et al., 1988; 
Paya et al., 1990). Applications for this test include the diagnosis of CMV 
pneumonitis (Einsele et al., 1989), hepatitis (Masih et al., 1988; Paya et al., 1990) 
and gastroenteritis (Chou, 1990b). PCR-driven in situ hybridization (PCR-ISH), and 
Reverse transcription PCR –based in situ hybridization for detection of HCMV 
during experimental latent infection of cultured granulocyte-macrophage progenitors 
and natural infection have been described (Slobedman and Mocarski, 1999). 
However, the techniques involved are cumbersome. Specimen preparation consists 
of securing the sample to a glass slide and denaturing the DNA without detaching or 
destroying the morphologic identity of the cells.  
2.11.2.2 In vitro nucleic acid based amplification techniques 
 In 1983, Kary Mullis envisioned a process of in vitro amplification which is 
eventually known as polymerase chain reaction (PCR) (Mullis, 1990).  This is the 
hallmark of nucleic acid amplification method.  PCR became a reality within a short 
period by its first practical application. (Saiki et al., 1985). 
43 
  The primary objective of the in vitro amplification methods is to improve the 
sensitivity of tests based on nucleic acids and to eventually simplify them through 
the use of automation and the incorporation of non-isotopic detection methods.   
The in vitro amplification techniques have been classified into three categories 
(Persing and Landry, 1989).  They are— 
(1) Target amplification systems, which use PCR, self-sustaining sequence 
replication, or strand displacement amplification. 
(2) Probe amplification systems, which include those involving thermostable DNA 
ligase chain reaction (LCR). 
(3) Signal amplification, in which the signal generated from each probe molecule, is 
increased by using compound probes or branched-probe technology. 
2.11.2.2.1   Target amplification methods 
(i)  Polymerase chain reaction 
 The PCR technique is based on the reiteration of a three-step process: 
denaturing dsDNA into single strands, annealing of primers (specific synthetic 
oligonucleotides) to the ssDNA, and enzymatically extending the primers 
complementary to the ssDNA templates. After the primers are annealed to the 
denatured DNA, the ssDNA segment becomes the template for the extension 
reaction. Nucleotides, present in the solution in excess, are enzymatically joined to 
form the complementary DNA sequences. During the second and subsequent cycles, 
the original DNA segment and the newly generated complementary DNA strands 
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 become templates. Each cycle of PCR therefore doubles the amount of specific 
DNA present. A typical amplification is 20 to 40 cycles and results in a 106-fold 
amplification of the original DNA (Parsons, 1988 ; van Brunt, 1990). The 
improvement of PCR by the use of a thermostable enzyme, Taq DNA polymerase, 
has allowed semi-automation and simplification of the process to the point that it has 
become widely adopted in research laboratories.  
Confirmation of PCR product authencity: 
PCR product authencity can be determined by a number of simple methods. 
♦ Agreement between observed and expected size of the PCR product 
♦ Confirmation of the position of a single restriction site within the amplified 
DNA. 
♦ Dot-blot or Southern blot hybridization or sequencing in rare cases. 
Short comings of PCR: 
 The system is susceptible to contamination with extraneous DNA fragments 
that could be amplified along with the sample. This is important in that extraneous 
DNA can be carried over from previous amplifications (amplicons) or introduced 
from other sources. To eliminate this problem, adherence to careful laboratory 
procedures, such as rigid quality control of enzyme preparations and the use of 
dedicated pipettes and prealiquoted reagents, is necessary. Various other techniques 
for reducing extraneous DNA contamination of PCR products have been described 
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 such as treatment with psoralen and exposure to UV or use of dUTP – UNG system 
for amplification.  The system is also susceptible to various kinds of inhibition that 
may occur due to problems in the cell lysis (extraction step), nucleic acid 
degradation (during storage) or polymerase related inhibition (Wilson, 1997). 
(ii) Modifications of PCR 
(a) Nested PCR 
 In a typical nested amplification protocol, a first round amplification is 
performed with a single pair of primers for 15 to 30 cycles.  This step produces an 
amplified product, which is transferred to a new reaction tube for a second round of 
amplification by using a second pair of primers that is specific for the internal 
sequence amplified by the first pair of primers.  The second amplification usually 
proceeds for an additional 15 to 30 cycles. 
 Nested amplification offers both advantages and disadvantages.  The 
sensitivity of most nested amplification procedures is extremely high.  A single copy 
of target can be detected without the need for hybridization with labeled probes 
(Persing, 1993).  Re-amplification with the second set of internal primers also serves 
to verify the specificity of the first round product.  In addition, the transfer of 
reaction products from the first reaction effectively serves to dilute out inhibitors 
that might be present in the sample initially. 
 The incipient risk with the nested PCR is contamination due to the 
aerosolized amplified DNA during the transfer of the reaction product from the first 
reaction into a new tube for re-amplification. Several methods have been described 
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 for performing nested reactions without open transfer of amplification products 
between reaction tubes. These single tube nested protocol involve various 
approaches.  A thick layer of oil above the reaction mixture containing the first 
primer pair has been used (Feray et al., 1992).  After the first amplification, the 
reaction tubes are removed and spun in a microcentrifuge to mix the reaction 
components and dilute the first round components, and then the contents are 
reamplified.  This single tube protocol has much less risk of contamination and is 
reported to be as sensitive as the two-tube nested protocol (Yourno, 1992).  Other 
methods of single tube nested amplification are based on differential annealing of 
outer and inner primer pairs and differential melting temperatures of the large and 
small amplification products (Erlich et al., 1991). 
(b) Semi-nested PCR 
 In case of the semi-nested PCR, nested PCR reaction is carried out using two 
rounds of primers.  Of the primer sets used, one is common to both the external and 
the internal amplification. Thus, the internal target amplified includes one end of the 
initially amplified target.  The sensitivity and the specificity is the same as that of 
the nested PCR. 
(c) Multiplex PCR 
 Multiplex PCR is a variant of PCR in which two or more loci are 
simultaneously amplified in the same reaction.  This was first described by 
Chamberlain et al in 1988 (Chamberlain et al., 1988).  Co-amplification of different 
targets serves several purposes.   
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 (1) Large regions of the DNA sequence can be scanned for alterations. 
(2) Unrelated segments of the target genome can be tested. 
(3) Internal controls for the amplifiability of the sample can be included. 
(4) Cost-effective panel of tests for multiple pathogens from a single specimen can 
be developed (Persing, 1993). 
 In viral diagnosis the utility of multiplex PCR finds its place in detection of 
multiple viruses causing a syndrome, for genotyping and quantitation.  
 Critical parameters that require optimization for a successful multiplex PCR 
assay are: 
♦ Primers – their relative concentrations, length, G+C content, 
amplification target size (which is easily resolvable on the agarose gel) 
♦ Concentration of the PCR buffer 
♦ Cycling temperatures 
♦ Number of cycles for amplification 
♦ Balance between the concentrations of MgCl2 and dNTPs (Henegariu 
et al., 1997) 
48 
  In diagnostic laboratories, cost and availability of adequate sample limit the 
use of PCR. Multiplex PCR has the potential to reduce the time and effort taken 
within the laboratory without compromising test utility. 
Bias in Multiplex PCRs 
 Preferential amplification of one target sequence over another is a known 
phenomenon in multiplex PCRs that are designed to amplify more than one target 
simultaneously. Two major classes that induce bias are: PCR drift and PCR 
selection. PCR bias is assumed due to stochastic fluctuation in the interactions of 
PCR reagents particularly in the early cycles which would arise in the presence of 
very low template concentrations. PCR selection is a mechanism which inherently 
favors the selective amplification of certain templates due to the inherent nature of 
the targets. The properties of the target include interregion differences in the GC 
content, leading to preferential denaturation, higher binding efficiency of GC rich 
primers, different accessibility of targets within genomes due to secondary 
structures, and gene copy number within a genome. Amplification bias dependant 
strongly on the choice of primers have been described (Elnifro et al., 2000). 
Points to be considered during Multiplex PCR development: 
♦ A rational approach for inclusion or exclusion of specific pathogens 
♦ Compatability among the primers 
♦ Primer design must take into account all the strains of the target 
pathogen as possible 
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 Advantages of  multiplex  PCR : 
♦ One of the major problems faced in PCR include false negatives due to 
reaction failure.   Each amplicon in a multiplex PCR act as an internal 
control for the other amplified fragments. 
♦ It is shown that the degraded templates give weaker signals for long 
bands than for short; hence the quality of the template may be determined 
more effectively in multiplex than in single locus PCR.      
♦ The cost, time and labour are much reduced in multiplex PCR.  
♦ Multiplex PCR helps in conserving the template that may be in short 
supply in instances of clinical specimens such as intraocular fluids or 
CSF. 
Application of Multiplex PCR in diagnosis of HCMV infections 
 Multiplex nested PCR for detection and typing of herpesviruses: HSV1, 
HSV 2, VZV, CMV, HHV6 and EBV has been applied to CSF from patients with 
meningitis, encephalitis and other neurological syndromes. The multiplex PCR was 
based on the DNA polymerase gene. The first round amplified universal herpes 
viruses with second round identifying the specific herpes viruses (Tenorio et al., 
1993). A multiplex short tandem amplification of multiple pathogens (STAMP) 
primers has been employed for the detection of HSV, VZV, CMV and toxoplasma in 
a single tube (Dabil et al., 2001). Stair primers was employed for the simultaneous 
50 
 detection of HSV, VZV, CMV, EBV and HHV-6 in a single multiplex reaction in 
the tear samples (Robert et al., 2002).    
 Two different genes of HCMV were detected with a single step multiplex 
PCR in clinical specimens from renal transplant recipients and other seropositive 
patients. The test was based on the IE and LA genes of HCMV and allowed 
monitoring of CMV infection by quantitation (Caballero et al., 1997). Another 
multiplex PCR was used to simultaneously amplify four different regions of HCMV 
genome. The test had a high diagnostic utility for detection of CMV variants with 
maximal sensitivity and specificity (Markoulatos et al., 1999). Multiplex PCR for 
genotyping of HCMV genome is also described (Tarrago et al., 2003). 
(d) Quantitative PCRs 
 Quantitative PCR assays have been useful in establishing relative or absolute 
amounts of target DNA. Methods developed for DNA quantitation by PCR may be 
classified into two categories: semiquantitative and competitive assays. 
Semiquantitative PCR 
 Semiquantitative PCR methods provide relative data. These procedures are 
designed to perform titer determinations of the target template or of an external 
control by end-point sample dilution prior to PCR (Drouet et al., 1993b; Kulski, 
1994) or by co-amplification of target and an endogenous cellular (e.g., β-globin) 
DNA sequence (Kellogg et al., 1990). The amount of DNA is extrapolated from a 
standard curve derived from the amplification of known amounts of the external 
standard. 
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  The relationship between the amount of initial target DNA to the final 
amplified product is given by the following formula: 
Y = X (1 +E)n 
 Where Y is the amount of final amplicon; X is the amount of initial target 
DNA; E is the efficiency of the reaction and n is the number of amplification cycle. 
In a normal PCR, the efficiency of the reaction is seldom 100%. The efficiency of 
the PCRs can be affected due to several factors such as primer-annealing kinetics; 
concentrations of DNA, deoxynucleoside triphosphates, MgCl2, and primers; 
number of cycles, incomplete DNA strand separation and PCR product strand 
reannealing. 
Competitive PCR 
 The competitive PCR method is based on co-amplification of an exogenous 
template as an internal standard that competes with the target sequence for the same 
primers so that any variable affecting amplification has the same effect on both. In 
competitive PCR, the equation of PCR amplification is as follows: 
C/T =   C’/T’ 
where C and T are the product yields of the competitor and the target templates, 
respectively, and C’ and T’ are the initial amounts of both templates.  
 In quantitative competitive PCRs, two main types of competitors have been 
used. Homologous competitors containing small deletions or insertions with respect 
to the target sequence (Boivin et al., 1995; Fox et al., 1992), and heterologous 
52 
 competitors having the target sequence for primers as the target nucleic acid but 
differing in the intervening sequence (Gerna et al., 1994; Gerna et al., 1998a). In 
case of the homologous competitors, the amplicons are differentiated by resolving 
them on agarose gels or by restriction enzyme digestion. In case of the heterologous 
competitors, the products of the competitor and the targets are differentiated by 
different capture probes.  
 The advantage of the homologous competitor is that the amplification 
efficiency of the competitor and the target is similar, but, heteroduplexes between 
the two may form during the plateau phase of reaction. However, the formation of 
heteroduplexes is avoided in case of the heterologous competitors by difference in 
the intervening sequences while the amplification efficiency may be lost due to 
differences in the G+C contents and size of the competitor and target.  
Commercial Quantitative PCR assays for HCMV 
 The Sharp Signal System (Digene Corp., Silver Spring, Md.) and 
AMPLICOR CMV test (Roche Diagnostic Systems, Branchburg, N.J.) are the 
commercial assay available for quantitation of HCMV in PMNL or plasma. Both 
systems use non-isotopic hybridization for viral target detection in a convenient 
microplate assay. AMPLICOR CMV Test (Roche Molecular Systems, Branchburg, 
N.J.) is a fully automated system that amplifies, CMV DNA, captures the 
biotinylated amplification product with a specific oligonucleotide probe, and detects 
the bound products colorimetrically. The results are available within 6 hours 
(Didomenico et al., 1996). 
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 Limitations of the Quantitative PCRs 
♦ Almost all the quantitative PCRs are end point quantitation i.e. the 
quantitative data is obtained from the end point of the amplification. There 
may not be a strict relationship between the initial template and final 
amplicon concentration since the final amount of amplicon present may have 
been affected by inhibitors, poorly optimized reaction conditions, saturation 
of inhibitory PCR – by products and double stranded amplicons.  
♦ Most of the in house quantitative PCRs suffer from substantial intra and inter 
assay variability and narrow dynamic range which necessitates dilution of 
the amplicon prior to conventional detection or use of diluted clinical sample 
before amplification. 
(e) Real-Time PCR 
 Real- time PCR also known as “Kinetic PCR” is an in vitro amplification 
technique where in amplification of the template and detection of the amplicons 
occur simultaneously. The real – time PCR has several advantages over the 
conventional PCRs, which include: speed, high sensitivity, reduced inter and intra 
assay variability, broad dynamic range and reduced chances of cross contaminations. 
 Several factors such as reduced amplicon size, reduced cycling profiles, 
avoidance of post-PCR handling steps, use of fluorogenic labels and sensitive 
methods for detecting the emissions contribute to the beneficial characteristics of the 
Real time PCR. 
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 Different chemistries in  Real- time PCR 
 There are five different chemistries available for detection of genome by 
Real –time PCR. These are broadly classified as amplicon sequence specific and non 
– specific methods of Real time PCR detection. 
Non specific Real time PCR detection 
 This method utilizes DNA binding fluorophores. Intercalating agents such as 
ethidium bromide, YO PRO -1, SYBR green fluoresce when associated with ds 
DNA and exposed to suitable wavelength of light. The advantage of the method 
include need for less expertise, less expense and eliminates risk of detection failures 
due to sequence variations in the template. The limitations however include 
association of the fluorophore to the primer dimers or other non-specific products 
which may cause confusion in the interpretation and less power to discriminate 
variants. The limitations are overcome by use of software capable of fluorescent 
melting curve analysis. This method makes use of difference in the temperature at 
which the ds DNA amplicon is denatured (TD). The primer dimer which is shorter 
than the specific amplicon can be discriminated due to a reduced TD. 
Amplicon specific Real-time PCR chemistries 
 This method utilizes the use of amplicon specific fluorogenic probes for 
quantitation of genomes. Most of the fluorogenic probe based assays rely upon 
Fluorescence resonance energy transfer (FRET) occurring between fluorophores or a 
fluorophore and non – fluorescent quencher (NFQ). FRET is a spectroscopic process 
by which energy is passed between molecules separated by 10 – 100 Ao that have 
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 overlapping emission and absorption spectra (Clegg, 1992). The mechanism is a non 
– radiative induced – dipole interaction as determined by Forster. The efficiency of 
the energy transfer is proportional to the inverse sixth power of the distance (R) 
between the donor and acceptor (1/R 6) fluorophores (Selvin, 1995). 
Linear oligoprobes based assays 
 The method uses a pair of adjacent, fluorogenic hybridization oligoprobes. 
This chemistry is used in the LightCycler equipment (Roche Molecular 
Biochemicals, Mannheim, Germany) (Wittwer et al.,1997). In this method, the 
upstream oligoprobe is labeled with a 3’ donor fluorophore (fluorescein 
isothiocyanate, FITC), and the downstream probe is commonly labeled with either a 
LightCycler Red 640 or Red 705 acceptor fluorophore at the 5’-terminus, so that 
when both oligoprobes are hybridised, the two fluorophores are located within 10 
nucleotides of each other. 
 Different linear class of oligoprobes are available now. They include: 
Displacement probes, Light up probes and HyBeacons. 
Displacement probes: 
 These are double-stranded oligoprobes that function by displacement 
hybridization (Li et al., 2002).  In this process, a 5’ fluorophore labeled 
oligonucleotide, in its resting state, is hybridised with a complementary, but shorter, 
quenching DNA strand that is 3’ end-labeled with an NFQ. When the full-length 
complementary sequence in the form of an amplicon is present, the reporter strand 
will preferentially hybridise to the longer amplicon, disrupting the quenched 
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 oligoprobe duplex and permitting the fluorophore to emit its excitation energy 
directly. 
Light up probes: 
 The light-up probe is a peptide nucleic acid (PNA) to which the asymmetric 
cyanine fluorophore thiazole orange is attached ( Svanvik et al., 2001). PNA is a 
DNA analogue that is formed of neutral repeated N-(2-aminoethyl) glycine units 
instead of negatively charged sugar phosphates (Egholm et al., 1993).  PNA retains 
the same sequence recognition properties as DNA. When hybridised with a nucleic 
acid target, as either a duplex or triplex, the fluorophore becomes strongly 
fluorescent. These oligoprobes do not interfere with the PCR or require 
conformational change, they are sensitive to single nucleotide mismatches and, 
because a single reporter is used, they allow the direct measurement of fluorescence 
instead of the measurement of a change in fluorescence between two fluorophores 
(Svanik et al., 2001). Non specific fluorescence with extended cycling has been 
observed (Svanvik et al., 2000) 
HyBeacon probes: 
 The HyBeacon is a single linear oligonucleotide internally labelled with a 
fluorophore that emits an increased signal upon formation of a duplex with the target 
DNA strand (French et al., 2001). This chemistry does not require destruction, 
interaction with a second oligoprobe or secondary structure changes to produce a 
signal, and it is relatively cheap and simple to design. 
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  The other chemistries utilizing the linear oligoprobe include Q-PNA and 
DzyNA primers.  
Dual Labelled oligoprobes based assays 
5’Nuclease Oligoprobes: 
 This assay utilizes Hydrolysis or Taqman probes for quantitation of the 
targets. The Taqman probes consist of a 5’ reporter fluorophore such as  
6-carboxyfluoroscein ( FAM) and a 3’ quencher which can be a fluorophore such as 
TAMRA or an NFQ that dissipates energy as heat. When in close proximity the 
fluorescence emitted by the reporter fluorophore is quenched by the quencher. When 
the probe hybridizes to the specific target molecule, during the extension step, the 
probe gets cleaved due to the 5’ – 3’ endonuclease activity of the DNA polymerase. 
This separates the reporter from the quencher and the fluorescence of the reporter 
fluorophore is no longer quenched by the quencher molecule. The fluorescence 
emitted is monitored by the instrument. This is the chemistry used in ABI Prism 
sequence detection systems. The quantitation of the target is given based on the 
threshold cycle (CT) values. The CT is defined as the PCR cycle in which the gain in 
fluorescence generated by the accumulating amplicon exceeds ten standard 
deviations of the mean baseline fluorescence, using data taken from cycles 3–15.  
In LightCycler, the fractional cycle is called the crossing point (CP). Another major 
advance in the probe design for the Taqman assay is the minor groove binding 
(MGB) probes, in which NFQ is used with a molecule that stabilizes the probe and 
target duplex (Afonina et al., 2002). This allows the use of shorter probes and makes 
the assay more convenient for identifying single nucleotide polymorphisms (SNP). 
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 Hairpin oligoprobes - Molecular beacons: 
 Molecular beacons are the first hairpin oligoprobes used in real-time PCR. 
The molecular beacon’s fluorogenic labels are positioned at the termini of the 
oligoprobe. The labels are held in close proximity by distal stem regions of 
homologous base pairing deliberately designed to create a hairpin structure. The 
closed hairpin is quenched due to FRET. In the presence of a complementary 
sequence, the oligoprobe will hybridise, shifting into an open configuration. The 
fluorophore is now spatially removed from the quencher’s influence, allowing 
fluorescent emissions to be monitored (Tyagi and Kramer, 1996). This structural 
change occurs in each cycle, increasing in cumulative intensity as the amount of 
specific amplicon increases. The quencher is usually DABCYL  
(4-(4’-dimethylamino- phenylazo)-benzene), an NFQ. 
Self fluorescing amplicon based assays 
 In this chemistry the labels become irreversibly incorporated into the PCR 
product. The two methods described include the sunrise primers, and scorpion 
primers (Nazarenko et al., 1997; Whitcombe et al., 1999). The sunrise primer 
consists of a 5’ fluorophore and 3’ DABCYL NFQ. The labels are separated by 
complementary stretches of sequence that create a stem when the sunrise primer is 
closed. The 3’ end consists of a target specific primer sequence. This enables the 
sunrise primer to be duplicated by the nascent complementary strand, thus 
destabilizing the stem and hence the fluorophores is free to emit the excitation 
energy for monitoring. The scorpion primer is similar in design to the sunrise primer 
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 except for an adjacent hexethylene glycol molecule that blocks duplication of the 
signaling portion of the scorpion. 
 A self-quenching hairpin primer has been described which is commercially 
entitled the light upon extension (LUX) fluorogenic primer (Nazarenko et al., 2002). 
This chemistry is dark in the absence of specific amplicon, through the natural 
quenching ability of a carefully placed guanosine nucleotide. The natural quencher 
is brought into close proximity with the FAM or JOE 5’ 2,7-dimethoxy-4,5-
dichloro-6-carboxy-fluoroscein fluorophore via a stretch of 5’ and 3’complementary 
sequences. However, in the presence of specific target, the primer hybridises, 
opening the hairpin and permitting fluorescence from the fluorophore. 
Multiplex Realtime PCR assays & Real–time PCR based genotyping 
 Multiplex real-time PCR more commonly refers to the use of multiple 
fluorogenic oligoprobes for the discrimination of amplicons that may have been 
produced by one or several primer pairs. The development of multiplex realtime 
PCR has proven problematic because of the limited number of fluorophores 
available and the frequent use of monochromatic energizing light sources. Some 
real-time PCR designs have made use of conserved single or multiple nucleotide 
changes among similar templates to allow their differentiation by concurrent 
changes to the oligoprobe’s TM or the amplicon’s TD (Espy et al., 2000; Nicolas et 
al., 2002). Combining the use of multiple fluorophores with the discrimination of 
additional targets by temperature allows the identification of a significantly larger 
number of amplicon targets. 
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  The SYBR green and Linear oligoprobe chemistries are most commonly 
used to perform genotyping assays. Genotyping data are obtained as end point 
analysis after the completion of the PCR. The amplicon is denatured and rapidly 
cooled to encourage the formation of fluorophore and target strand complexes. The 
temperature is then gradually raised, and the fluorescence from each vessel is 
continuously recorded. The detection of sequence variation using fluorescent 
chemistries rely upon the destabilization incurred as a result of the changes, thus 
altering the expected TM in a manner that reflects the particular nucleotide change. 
The resulting rapid decrease in fluorescence is presented as a ‘melt peak’ using 
software capable of calculating the negative derivative of the fluorescence change 
with temperature. The other chemistries such as the Taqman probe or the hairpin 
probes need two different probes with different fluorophores to differentiate the 
genotypes. Between the above two chemistries, the hairpin probes are more suited 
for genotyping since, the occurrence of a mismatch between a hairpin 
oligonucleotide and its target has a greater destabilizing effect on the duplex than 
that with the linear probe. 
Designing of oligoprobes for Real – time PCR assay 
♦ Optimal length of the probe is usually 20 – 40 nucleotides, the MGB probes 
are usually shorter (around 14 nucleotides) 
♦ The G+ C content must be between 40 -60% 
♦ No runs of single nucleotide, particularly G is recommended 
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 ♦ Presence of G at the 5’ end is avoided  as it is a natural quencher 
♦ Complementarity with the primers or repeated sequence motifs are not 
recommended 
♦ TM of the probe is usually 5 – 10
oC higher than that of the primers, enabling 
hybridization of probe prior to primer extension 
♦ The Taqman (5’nuclease) probes are usually designed closer to the forward 
primer 
♦ The Taqman probes for identification of SNPs are designed to have the 
mismatch at the centre of the probe rather than at the 5’ end to prevent knock 
out by the polymerase enzyme. 
♦ The fluorogenic oligoprobes are labeled at the 3’ terminus with a phosphate 
or octanediol molecule to prevent Taq mediated extension. This prevents the 
oligoprobes from functioning as a primer.  
Limitations of Real – time PCR 
♦ The establishment cost of the real – time PCR may be too high for low –        
throughput laboratories. 
♦ Monitoring of amplicon size is difficult.  
♦ Only limited fluorescent chemistries may be adaptable on a given platform. 
♦ Restricted multiplexing capabilities. 
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 Application of Real time PCR in diagnosis of HCMV infections 
 Many real-time quantitative tests for CMV DNA using the chemistries listed 
are available. Several different gene targets viz. gB ( Yun et al., 2000; Schaade et al., 
2000; Kearns et al., 2001; Guiver et al., 2001;  Kearns et al., 2002; Ando et al., 2002 
; Pang et al., 2003; Li et al., 2003; Hong et al., 2004 ), IE gene(Tanaka et al., 2000; 
Limaye et al., 2001; Greenlee et al., 2002; Visconti et al., 2004; Kalpoe et al., 2004),  
US – 17 (Machida et al., 2000; Aberle and Puchhammer-Stockl, 2002; Ikewaki et 
al., 2003) , UL – 83 (Gault et al.,2001; Gouarin et al., 2004) , DNA polymerase 
(Sanchez et al., 2001; Sanchez and Storch, 2002), MIE (Nitsche et al., 1999; Nitsche 
et al., 2003; Satou et al., 2001),pp150 IL 32 gene (Hanfler et al., 2003), UL 65 (pp 
67) gene ( Persson et al., 2003) have been used for quantitation of HCMV. It has 
been shown that the gene of interest can affect the sensitivity of the assay (Yun et 
al., 2000).  The real time PCRs have been applied majorly on fractions of blood  or 
whole blood , though , certain studies have shown the utility of quantitation in 
clinical specimens such as amniotic fluid, urine, intraocular fluids, respiratory fluids 
and cerebrospinal fluid (Gouarin et al., 2002; Ando et al., 2002; Kearns et al., 2002; 
Aberle and Puchhammer-Stockl, 2002). Most studies have compared the real-time 
PCR assays with antigenemia assay (Tanaka et al., 2000; Gault et al., 2001; 
Yakushiji et al., 2002), conventional culture (Machida et al., 2000; Najioullah et al., 
2001) and conventional PCRs including COBAS AMPLICOR PCR (Schaade et al., 
2000; Satou et al., 2001; Funato et al., 2001; Pang et al., 2003; Herrmann et al., 
2004) and found good correlation with regard to the quantitative data. Machida et al 
(2000) found a better correlation of pp65 antigenemia assay with viral loads 
determined in leucocyte component than in the plasma component by real time PCR. 
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 In general, quantitative real-time PCR has several advantages to the antigenemia test 
including increased sensitivity for early detection of CMV infection or reactivation, 
utility for patients with neutropenia, stability of target DNA in blood specimens than 
the antigen, wide detection range (7 to 8 log10) of CMV DNA, ability to process 
large number of specimens, flexibility of time of transport and processing of 
specimens, and the potential for increased accuracy of results through precision 
instrumentation (Funato et al., 2001; Mengelle et al., 2003;  Nitsche et al., 2003; 
Yakushiji et al., 2002). Real-time PCRs have been shown to be more suitable for 
monitoring CMV reactivation in immunocompromised patients  and for guiding 
clinical management and monitoring of  Bone marrow transplants (BMT), Stem cell 
(SCT) and Solid organ transplant (SOT) patients (Meyer-Koenig et al., 2004; 
Piiparinen et al., 2004; Ikewaki et al., 2003). A study revealed, that for the SCT 
patients the optimal cutoff value of CMV DNA load defining relevant viral 
reactivation  was slightly higher than that for the SOT patients (Kalpoe et al., 2004). 
Recently, using a real-time PCR assay, the viral load of herpes viruses, including 
CMV, was assessed in the CSF (Aberle and Puchhammer-Stockl, 2002). Although 
unclear at this time, assessment of viral load in the CNS may have prognostic 
implications, may predict distinct CNS manifestations, and may be useful for 
differentiating between real infection and nonspecific presence of virus in the CSF, 
especially in severly immunocompromised individuals. Real time PCR has also been 
used to establish primary infections in the pregnant women by detecting the HCMV 
DNA in the amniotic fluid (Gouarin et al., 2002). Real time PCR coupled with 
automated extraction systems have been used for monitoring of immunosuppressed 
patients. Nitsche et al (1999) compared the Light cycler and Taqman probe based 
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 assay and concluded that both are equal when sensitivity and dynamic ranges were 
considered. Multiplex real time PCR assays have been developed for simultaneous 
detection of HSV, CMV and VZV using SYBR green chemistry in separate tubes.  
A multiplex PCR was also developed for simultaneous detection of HCMV and 
Human DNA (Sanchez and Storch, 2002). 
(iii) Nucleic acid sequence-based amplification (NASBA) 
 Nucleic acid sequence-based amplification (NASBA) is a commercial 
development of the isothermal Transcription based amplification system (TAS) 
method and alternative of Transcription mediated amplification (TMA). Unlike, RT- 
PCR NASBA allows specific amplification of unspliced RNA in a genomic DNA 
background. Amplification by NASBA is isothermal and involves the coordinated 
activities of three enzymes, AMV Reverse Transcriptase, RNase H, and T7 RNA 
Polymerase. Quantitative detection is achieved by way of internal calibrators, added 
at isolation, which are co-amplified and subsequently identified along with the wild 
type of RNA using electrochemiluminescence. In this procedure, a strand of RNA is 
the target for an oligonucleotide primer that contains a polymerase-binding site. 
After hybridization of the primer to the target, a reverse transcriptase elongates the 
primer complementary to the target sequence. This is followed by selective 
degradation of the template RNA by RNAse H followed by annealing of another 
oligonucleotide primer to the first strand and extension by Reverse transcriptase. 
This is followed by the activity of T7 RNA polymerase which produces multiple 
copies of RNA that are detected by electrochemiluminescence. A 105-copy 
amplification occurs within 15 minutes. NASBA based on pp67 mRNA, a late viral 
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 transcript of HCMV appeared to be a promising tool for initiation and termination of 
preemptive therapy for solid organ transplant recipients with reactivated HCMV 
infection (Gerna et al., 1999), whereas monitoring of immediate early mRNA 
expression appeared to be a useful parameter for initiation of preemptive therapy in 
HSCT recipients (Gerna et al., 2000). 
(iv) Strand displacement amplification (SDA) 
 SDA is an isothermal amplification method based on the displacement of one 
probe when DNA polymerase is used to extend a second probe. In the original 
method (Walker et al., 1992b), the target DNA underwent initial cleavage into 47-bp 
fragments and heat denaturation. A probe containing a HincII recognition site on the 
5' end was hybridized to the target fragments. When it is bound to the target site, the 
probe possessing the HincII recognition site (6 nucleotides) and several more bases 
that do not hybridize to the target nucleic acid is extended past the end of the target 
fragments. DNA polymerase then generates a nucleic acid strand complementary to 
the target and free end of the probe, incorporating a modified dATP (dATPαS). The 
HincII enzyme then nicks the probe strand at the HincII recognition site (the 
hemiphosphorothioate HincII recognition site prevents complete cleavage of the 
dsDNA). DNA polymerase then generates a nucleic acid strand that is 
complementary to the target nucleic acid strand and that displaces the original probe 
segment from the target fragment. Because of the orientation of the HincII 
recognition site, the complementary probe sequence generated by DNA polymerase 
retains a functional HincII recognition site. This allows continual nicking of the 
probe by HincII and subsequent displacement through the action of DNA 
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 polymerase. Strand displacement amplification generates upto 107 copies of the 
template DNA in 2 hours (Walker et al., 1992 a). A loop mediated isothermal 
amplification based on the principles of SDA has been developed for rapid detection 
of HCMV genome (Suzuki et al., 2006). 
2.11.2.2.2  Probe based amplification methods 
(i) Ligase chain reaction (LCR) 
 The ligase chain reaction, also called the ligase amplification reaction or the 
oligonucleotide ligation assay is a probe amplification technique for detecting the 
target sequence. Unlike PCR, which creates new DNA molecules from individual 
nucleotides, the ligase reaction uses a thermostable ligase enzyme to join two 
oligonucleotides that are immediately adjacent to each other. Like PCR, this reaction 
is cyclic; denaturation, annealing, and ligation are the basis for the amplification 
reaction. As in PCR, the ligated oligonucleotide pairs, along with the original 
sequence, become templates for the next cycle (Wu and Wallace, 1989). Twenty to 
30 cycles of this reaction yield a 106-fold increase in the original target. The method 
has an ability to detect as few as 10 nucleic acid targets (Backman, 1992). In the 
ligase reaction, the entire target sequence must be known, because a 1-bp mismatch 
at the point of ligation can prevent ligation of the oligonucleotides. Although this 
could be detrimental in many situations, failure to ligate can be used to detect point 
mutations in the target sequence. The end-products are visualized by agarose gel 
electrophoresis or by hybridization using chemiluminescent probes. Another variety 
of ligase reaction, the gapped -LCR involves the use of both a polymerase and a 
ligase (Birkenmeyer and Mushahwar, 1991). Two oligonucleotide primers are 
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 annealed to the target but are spaced so that polymerase fills a gap between the two 
primers; the ligase then connects the filled gap and the second primer. Ligase chain 
reaction has been used in identification of mutation related to gancicliovir resistance 
in the UL 97 gene of HCMV (Bourgeois et al., 1997). 
(ii) Cycling Probe Reaction 
 The cycling probe reaction is almost the exact opposite of LCR. In this 
procedure, a nucleic acid probe that incorporates DNA-RNA-DNA sequences is 
synthesized. After the probe is allowed to hybridize to the target, RNase H, an 
enzyme that specifically degrades the middle RNA portion of the probe, is added. 
The DNA fragments thus remain dissociate from the target. The target is now free to 
hybridize with another probe molecule; therefore, the reaction is inherently cyclic 
without external manipulations. The free DNA fragments can then be detected or 
amplified by a secondary amplification system (Duck et al., 1990). 
2.11.2.2.3 Signal amplification methods 
 Amplification of the detectable signal also improves the sensitivity of nucleic 
acid probes. A properly constructed probe system that hybridizes even one target can 
be detected if the signal is amplified sufficiently. 
(i) Hybrid capture assay 
 The hybrid capture assay is a solution based hybridization assay that involves 
amplified chemiluminescent detection. Specimens containing the target DNA 
hybridize with a specific CMV RNA probe complementary to approximately 40,000 
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 bp or 17% of the CMV genome. The resultant RNA-DNA hybrids are captured onto 
the surface of a tube coated with antibodies specific for RNA-DNA hybrids. The 
immobilized hybrids are then reacted with alkaline phosphatase conjugated 
antibodies specific for the hybrids and detected with a chemiluminescent substrate. 
Because each 38-kb RNA-DNA hybrid binds approximately 1,000 antibody 
conjugate molecules, each of which is bound to about 3 alkaline phosphatase 
molecules, the resulting signal is amplified at least 3,000-fold. The amount of light 
emitted, which is measured as relative light units on a luminometer, is proportional 
to the amount of target DNA in the specimen. Upto 54 specimens along with 
controls can be tested qualitatively within 6 hours by the assay.  
(ii) Branched DNA signal amplification assay 
 The branched DNA (bDNA) assay (Bayer, Chiron Corp., Emeryville, 
California) uses bDNA amplifiers to effect signal amplification during hybridization 
(Chernoff et al., 1997). It measures viral nucleic acids directly from clinical 
specimens by boosting the reporter signal rather than amplifying target sequences as 
the means of detection. The bDNA molecule contains multiple binding sites for an 
enzyme-labeled probe. The target nucleic acid is bound to the bDNA molecule, and 
the complex is detected with a chemiluminescent substrate. The test allows the direct 
quantification of CMV DNA in blood. The lack of amplification makes the test less 
susceptible to contamination. The test is less sensitive than most antigenemia and 
PCR assays (Ehrnst, 1996). The bDNA signal amplification assay has been used 
with blood, CSF, and semen samples (Boeckh and Boivin, 1998). The assay requires 
at least 2 x 106 PBL or 1 to 1.5 ml of ultracentrifuged CSF. PMNL should be 
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 separated within 8 hours of collection, at which time they can be frozen for 
subsequent testing. The assay procedure is as follows: The PMNL pellet or CSF 
sample is incubated with proteinase K in a lysis buffer, and the target probes are 
added. After incubation for 16 to 18 hours in a microtiter plate, the bDNA is added; 
then the enzyme-labeled probe and the chemiluminescent substrate are added. 
Finally, the light emission is measured. The quantity of DNA is measured using the 
standard curve generated by known concentrations of HCMV DNA. 
2.11.3 Clinical implications of DNAemia in different patient groups 
 PCR was first used for HCMV DNA detection in the urine of congenitally 
infected babies at the end of the 1980s (Demmler et al., 1988). The advantages of 
PCR over conventional techniques are the small amount of sample required; the 
short time required for test results (24 to 48 hours versus 2 to 28 days) and the 
ability to use frozen specimens with noninfectious virus. Detection and 
quantification of CMV, by PCR is performed in different fractions of the blood (i.e. 
cellular fractions and plasma), organ fluids (cerebrospinal fluid, urine, throat 
washing or semen) and tissue samples. Although PCR for CMV DNA detection in 
peripheral blood leukocytes is most sensitive for detecting viral infection in diverse 
group of patients, when PCR is carried out in a qualitative manner, it is of little 
clinical significance since the results obtained do not correlate with clinical 
symptoms, particularly, in CMV - seropositive patients with HIV infection or those 
who have undergone solid organ transplantation. (Monte et al., 1996). However, 
qualitative detection of HCMV DNA in peripheral blood and amniotic fluid has 
been useful in establishing primary infections in sero-negative patients and 
70 
 intrauterine infections in pregnant women respectively.  There have been 
controversies on the detection of latent HCMV in the peripheral blood leucocytes by 
qualitative PCRs. However, most studies support the concept that viral DNA is not 
detected in the peripheral blood leukocytes of HCMV-seropositive 
immunocompetent individuals (Revello et al., 1998; Zanghellini et al., 1999). 
Different fractions of blood have been used for quantitation of HCMV viz: 
peripheral blood leucocytes, plasma, serum or whole blood. Most studies show that 
the quantity of viral DNA in leukocytes is generally greater than in plasma for both 
transplant recipients and subjects with AIDS (Boivin et al., 1998; Gerna et al., 
1994). The positive predictive value of PCR of plasma for the development of CMV 
disease has been evaluated in different settings with somewhat contradictory results. 
Although CMV infection has been shown to precede the development of clinical 
disease (Hansen et al., 1994; Spector et al., 1992), PCR of plasma reflected the 
kinetics of CMV infection poorly, especially during therapy compared to PCR of 
leukocytes in subjects with AIDS (Gerna et al., 1994). In liver transplant recipients, 
PCR of serum was the best method of predicting the development of symptomatic 
CMV infection (Patel et al., 1995). PCR of plasma appeared to be an earlier and 
more sensitive marker of serious CMV infection in marrow transplant recipients 
than did PCR of leukocytes in one study (Nolte et al., 1995), while others found 
either similar (Hebart et al., 1996) or lower (Boeckh et al., 1997) sensitivity than 
PCR of leukocytes. Several longitudinal studies have utilized quantitative molecular 
assays to ascertain the relationship of systemic viral load to the onset of symptoms 
in different patient groups and to predict the subsequent development of CMV 
disease or relapse of CMV disease before the onset of clinical symptoms. 
71 
 Conventional quantitative assays such as antigenemia tests and blood cultures allow 
a reliable prediction of CMV disease (Chevret et al., 1999); however, the interval 
between first positive test result and occurrence of CMV disease is clearly shorter 
than that obtained with molecular assays, especially PCR (median, 34 days and 1 
day, respectively, versus 46 days) (Dodt et al., 1997). Quantitation of CMV DNA in 
blood leukocytes have also shown practical implications for the diagnosis of visceral 
organ disease during viremia in transplant recipients and patients with AIDS. The 
median quantity of DNA in the leukocytes of patients with visceral organ disease is 
significantly greater than that in patients with viremia alone (Saltzman et al., 1992). 
Significantly higher levels of HCMV load are detected in infants with congenital 
symptomatic HCMV infection than asymptomatic infants. Quantitative molecular 
assays have also established that the virus clearance from blood occurs 
spontaneously in both symptomatic and subclinically infected newborns, even 
though the process takes longer in symptomatic  newborns (Revello et al., 1999b). A 
study with the quantitative PCR, reported that levels of viral DNA of 103 to 105/ml 
of amniotic fluid was necessary to transmit the infection, whereas levels 105 was 
required to cause HCMV disease in the fetus. Thus, levels less than or equal to 103 
genome equivalents/ml were unable to transmit the infection and were cleared by the 
fetus during fetal life (Guerra et al., 2000; Lazzarotto et al., 2000; Maine et al., 
2001). Using the viral load to limit the amount of antiviral drug treatment does not 
appear to be safe in a clinical setting of rapid progression from first detection of 
CMV to disease in allogeneic stem cell or bone marrow transplant recipients. In 
contrast, in patients without or with mild GVHD, measurement of viral load appears 
to be a good strategy to target antiviral drug treatment (Boeckh and Boivin, 1998). 
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 Drouet et al (1993a) showed in a small group of patients that CMV retinitis in AIDS 
patients was generally associated with high levels of CMV-DNA in leucocytes as 
detected by semi-quantitative PCR. The findings have been confirmed in larger 
cohorts and by evaluating different clinical specimens. Detection of CMV-DNA in 
plasma (Jabs et al., 2002) or whole blood (Bowen et al., 1997) at the time of initial 
diagnosis of retinitis was associated with a higher risk of mortality than was a high 
HIV viral load. Erice et al (2003) found an increased risk for CMV disease in 
patients with CMV-DNA levels to >100,000 copies/ml (quantification limit of the 
assay used). Still, a substantial number of patients suffer from CMV disease with 
CMV-DNA levels significantly lower than this value (Bowen et al., 1997; Spector et 
al., 1999).  The CMV load in HIV-infected individuals seems to be generally higher 
than in transplant recipients.  
 Amplification assays for viral mRNA in leucocytes have been used mainly to 
identify active viral replication (Randhawa et al., 1994). The presence of CMV IE 
mRNA has been demonstrated in monocytes and PMNL during active CMV 
infection (Lam et al., 1998; The et al., 1995). The absence of circulating mRNA is 
associated with a lack of CMV-associated symptoms, irrespective of the presence or 
absence of CMV DNA, while its presence is detected only in the setting of disease 
(Randhawa et al., 1994). However, detection of HCMV mRNA appears to be less 
sensitive than the pp65 antigen test and shell vial culture and PCR in diagnosing 
CMV disease (Meyer-Konig et al., 1995; Patel et al., 1995). 
 Despite most diagnostic usefulness as predictive markers of CMV disease, 
the molecular assays suffer from a major limitation. The identification of a universal 
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 DNA level that indicates reliably a high risk for CMV disease and consequently 
requires preemptive therapy, however, has not yet been formulated. The factors that 
attribute to this limitation include: Differences in the test method, the method of 
quantification, the units with which the viral load is expressed, definition of CMV 
disease, the kind of immunosuppression and also there are significant differences in 
the DNA levels associated with disease with regard to different patient populations.  
2.12 MOLECULAR TYPING METHODS 
 Today's molecular techniques have been instrumental in viral subtype 
analysis that has gone well beyond the realm of antigen-antibody interaction.  The 
viral genomes can vary at the nucleotide levels but maintain their essential 
characteristics at the protein or virion levels. This variability is the basis for 
molecular characterization and subtype classification of viruses. Molecular 
characterization for the purpose of subtyping is not relevant to treatment but is 
useful mainly for epidemiological purposes and for investigations into pathogenesis 
and disease progression (Arens, 1999). They may also throw light on the most 
conserved and hypervariable regions in the viral genome which may be useful in 
designing primers and probes to be used in the molecular assays described. 
Serologically HCMV cannot be distinguished and thus molecular methods are sort 
out for genotyping the virus. 
2.12.1 GENOTYPIC METHODS 
 Nucleic acid-based subtyping was first applied to study the epidemiology of 
a nosocomial outbreak of Klebsiella pneumoniae infection (Sadowski et al, 1979).  
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 Initial applications involved primarily the detection and characterization of plasmids 
in bacteria.  Developments in nucleic acid isolation, separation, and amplification 
since 1975 have led to the application of nucleic acid-based subtyping methods to 
various specific epidemiologic problems.  The different genotypic methods that are 
available for human viruses include: Nucleotide sequencing, Restriction fragment 
length polymorphism (RFLP), Blotting techniques, Oligonucleotide fingerprint 
analysis, Reverse hybridization, DNA enzyme immunoassay (DEIA), RNase 
protection analysis, Single strand conformation polymorphism (SSCP), 
Heteroduplex mobility assay (HMA), Heteroduplex tracking assay, Genome 
segment length polymorphism and Amplified fragment length Polymorphism 
(AFLP) (Arens, 1999). Other than these genotypic methods, Multiplex PCRs and 
Real-time PCRs have also been used for genotyping of the viruses. The genotyping 
methods that are available for HCMV include DNA sequencing, RFLP/ PCR-RFLP, 
SSCP, Southern blotting, DEIA and AFLP. 
2.12.1.1 Nucleotide sequencing or DNA sequencing 
 DNA sequencing refers to the biochemical methods for determining the 
order of the nucleotide bases viz. adenine, guanine, cytosine and thymine in a DNA 
oligonucleotide. 
(i) Early methods of DNA sequencing 
 In 1973, Gilbert and Maxam reported the sequence of 24 base pairs using a 
method called wandering spot analysis. Maxam and Gilbert (1980) developed a 
DNA sequencing method based on chemical modification of DNA and subsequent 
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 cleavage at specific bases. The advantage of the procedure included the use of 
purified DNA without the need for cloning which was necessary for plus-minus 
sequencing. The limitations of the method included complex techniques, use of 
hazardous chemicals and difficulties with scale up. The chain terminator method 
introduced by Sanger became the method of choice owing to its efficiency and 
rapidity. The key principle of this method was the use of dideoxynucleotide 
triphosphates (ddNTPs) as DNA chain terminators. The classical chain termination 
or Sanger method requires a single stranded DNA template, a DNA primer, a DNA 
polymerase, radioactively or fluorescently labeled nucleotides and modified 
nucleotides that terminate DNA strand elongation. The method also required the 
sample to be divided into four, each containing all the required reaction mixture 
along with one of the four ddNTPs. The ddNTPs acted as chain –terminators. After 
the reaction, the newly synthesized and labeled DNA fragments were heat 
denatured, and separated on a denaturing polyacrylamide – urea gel with resolution 
of just one nucleotide. This was either followed by reading of bands in the X ray 
films after autoradiography or on the gel under UV transilluminator (Sanger et al., 
1977). 
(ii) Variations in chain termination sequencing 
 The technical variations of chain termination sequencing included labeling of 
the primers at 5’ end with biotin, radioactive labels or fluorescent dye; or the 
nucleotides with the dyes. Both the methods required four separate reactions for 
sequencing. Later, development occurred by means of fluorescently labled ddNTPs 
and primers that set the stage for automated, high – throughput DNA sequencing. 
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 (iii) Dye terminator sequencing and Automated sequencing 
 This method involves the use of labeling the chain terminators. The major 
advantage of the method is that the sequencing can be performed in a single 
reaction. In this method, each of the ddNTPs is labeled with a different fluorescent 
dye, each fluorescing at a different wavelength. The advantages include greater 
expediency and speed and is now the mainstay in automated sequencing with DNA 
sequencers. The limitations of the method however include dye effects due to 
differences in the incorporation of the dye-labelled chain terminators into the DNA 
fragment, resulting in unequal peaks and shapes in the trace chromatogram after 
capillary electrophoresis. This problem has been overcome by introduction of DNA 
polymerase and dyes that minimize the incorporation variability.  Modern automated 
DNA sequencers can sequence upto 384 fluorescently labeled samples in a single 
run and perform as many as 24 runs a day.  
 Current methods of DNA sequencing involves PCR amplification of the part 
of the genome to be sequenced followed by cycle sequencing, clean up of the 
products and re- suspension in a buffer solution before loading onto the sequencer. 
Most of these methods can directly sequence short DNA fragments (300 – 1000 
nucleotides) in a single reaction. 
(iv) Large – scale sequencing strategies 
 Large scale sequencing aims at sequencing very long DNA fragments which 
may involve the whole genome of the pathogen. The brief steps involved are: 
Fragmenting of the DNA using restriction enzymes or shearing with mechanical 
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 forces, cloning of the different fragments into DNA vector usually a bacterial 
plasmid followed by its amplification in the E. coli. The fragments are purified from 
individual bacterial colonies, completely sequenced and assembled electronically 
into one long contiguous sequence by identifying 100% identical overlapping 
sequences between them. This method is called “shotgun sequencing”. The 
limitation of such a method includes a complex and error prone assembly process in 
genomic regions with sequence repeats. 
(v) Newer high throughput methods of sequencing 
 The newer method of sequencing involves in vitro clonal amplification of the 
region of interest to generate many copies of the individual molecule followed by 
parallelized sequencing. The in vitro clonal amplification methods produce many 
physically isolated locations containing many copies of single fragments. The 
known methods of in vitro clonal amplification include emulsion PCR and bridge 
PCR (Margulies et al., 2005). In the former the individual DNA molecule is isolated 
along with primer – coated beads in aqueous bubbles within an oil phase. This is 
followed by a PCR that coats the beads with clonal copies of the isolated library 
molecule and the beads are subsequently immobilized for later sequencing. In the 
latter method, the fragments are amplified upon primers attached to a solid surface. 
 In parallelized sequencing, the physically localized clonal DNA sequences 
are sequenced by the dye-termination electrophoretic sequencing or reversible 
terminator methods. This method, use dye terminators, adding one nucleotide at a 
time, detecting fluorescence corresponding to that position, then removing the 
blocking group to allow the polymerization of another nucleotide. Pyrosequencing 
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 also uses DNA polymerization to add nucleotides, adding one type of nucleotide at a 
time, then detecting and quantifying the number of nucleotides added to a given 
location through the light emitted by the release of attached pyrophosphates 
(Ronaghi et al., 1996). 
 Another recent method of sequencing called “Sequencing by ligation” 
utilizes DNA ligase to identify the target sequence (Shendure et al.,2005). This 
method uses a pool of random oligonucleotides labeled according to the sequenced 
position. Oligonucleotides are annealed and ligated. Preferrential ligation by DNA 
ligase for matching sequences results in a signal corresponding to complementary 
sequence at that position. 
(vi) Advantages and limitations of DNA sequencing 
 The advantages of DNA sequencing as a genotypic method include its wide 
applicability, and ability to identify single nucleotide variation. The limitations 
however, include technical complexity, high cost of the equipment and large amount 
of the data which may be complex to analyze. 
2.12.1.2 Restriction Fragment length polymorphism (RFLP) 
 This method utilizes the ability of restriction enzymes to recognize and 
cleave specific genomic sequences. A particular restriction enzyme generates a 
unique family of fragments from a particular DNA molecule. The genomic variants 
are differentiated based on the presence or absence of restriction sites and the pattern 
of fragments generated by the enzyme. The technique requires fairly large amounts 
of purified or partially purified DNA. Currently, the method involves amplification 
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 of specific regions of the genome by PCR followed by treatment with one or more 
restriction enzymes. After the restriction enzyme reaction, the fragments are 
resolved by electrophoresis on agarose gel or polyacrylamide gel depending on the 
resolution required. Significant advantage of PCR-RFLP over genomic DNA 
restriction is that problems of poor restriction of genomic DNA as a result of DNA 
base modifications (methylation) are not encountered (Swaminathan and Matar, 
1993).  The advantage of the RFLP as a method for genotyping includes simplicity 
and wide applicability. The major limitation of the method is that any mutation 
occurring outside the recognition site of the restricition enzyme cannot be detected. 
2.12.1.3 Southern Blotting 
 Southern blotting analysis is a modification of RFLP analysis wherein the 
family of restriction fragments is transferred onto a nitrocellulose or nylon 
membrane following restriction enzyme treatment and electrophoretic separation of 
DNA. The DNA fragments are then probed using specific oligonucleotides. The 
advantages of the method include wide applicability, ability to analyze complex 
genomes. The limitations of the method however, include technical complexity, 
requirement of radioisotopes for analysis and restricted analysis of the sequences 
that are cleaved by the enzyme or the probe sites. 
2.12.1.4 Single strand conformation polymorphism (SSCP) 
 Single-strand conformation polymorphism (SSCP) analysis is the term 
applied to the method developed (Orita et al., 1989) with which it was demonstrated 
that a single nucleotide substitution was sufficient to cause a mobility shift of a 
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 fragment of single-stranded DNA in a neutral polyacrylamide gel.  Initially, the 
general procedure was to use RFLP fragments from genomic DNA (one from the 
wild-type genome and one from a possible mutant), denature the fragments by alkali 
treatment, subject them to electrophoresis in a neutral polyacrylamide gel, and 
compare their mobilities.  Modifications have been made to accommodate PCR 
amplification of a specific region of wild-type or mutant genomes prior to 
denaturation and separation on a neutral gel (Hayashi, 1991).  In either case, if 
mutations are present in the segment of the mutant genome being tested, that 
segment will likely run at a different position in the gel than the same segment from 
the wild-type genome.  The altered electrophoresis pattern is apparently due to the 
mutation-altered secondary structure of the restriction fragment or the PCR 
amplicon (Orita et al., 1989).  The separation of the wild-type and mutant fragments 
is dependent on several environmental factors, including the temperature of the gel 
during electrophoresis, the concentration and composition of the electrophoresis 
buffer, and the presence of denaturing agents in the gel.  Several sets of conditions 
should be tried empirically to optimize mutation detection.  One major advantage of 
this method is that it can "sample" the genetic makeup of several hundred base pairs 
of DNA and the major limitation is that the method can identify the presence of the 
mutation but not the precise location of the mutation. 
2.12.1.5 Amplified fragment length polymorphism (AFLP) 
 Amplified Fragment Length Polymorphism (AFLP) is a polymerase chain 
reaction (PCR) based genetic fingerprinting technique (Vos et al., 1995). AFLP uses 
restriction enzymes to cut genomic DNA, followed by ligation of complementary 
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 double stranded adaptors to the ends of the restriction fragments. A subset of the 
restriction fragments are then amplified using 2 primers complementary to the 
adaptor and restriction site fragments. The fragments are visualized on denaturing 
polyacrylamide gels either through autoradiographic or fluorescence methodologies. 
The advantages of the method include higher reproducibility, resolution and 
sensitivity. About 50 -100 fragments can be amplified at a given time. In addition, 
no prior sequence information is needed for amplification. 
2.12.1.6 DNA enzyme immuno assay (DEIA) 
 In this method, a specific region of the viral genome is amplified by PCR, 
followed by heat – denaturation of the amplicons. The denatured amplicons are then 
hybridized to probes bound to mutiwell plates. Hybrids are detected by colorimetric 
or photometric methods similar to ELISA. The advantage includes, simplicity of the 
procedure and ease of commercialization. The limitation includes high levels of 
error due to probe target mismatches. 
2.12.2 MAJOR APPLICATIONS OF GENOTYPIC METHODS FOR HCMV 
 The genotypic methods for HCMV have been used primarily to understand 
the epidemiology and transmission of the virus. CMV was the first virus to be 
subjected to RFLP analysis of viral genomic DNA pursuant to epidemiologic 
studies. In a study among infants in a nursery, RFLP analysis of CMV strains 
isolated from the urine of eight babies demonstrated that one of the babies had 
transmitted CMV to two other babies, apparently via fomites (Stagno et al., 1989).  
Southern blot analysis has been used to demonstrate that an AIDS patient can be 
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 infected with multiple strains of CMV.  In a study on transmission of CMV in 
cadaveric renal transplantation, 15 distinct strains (genotypes) of CMV were isolated 
from 19 organ recipients (i.e. four pairs [8 patients] of the 19 had paired isolates 
with the same genotype).  In all four pairs of patients who had received kidneys 
from the same cadaver, both had acquired it from the donor and that seropositive 
recipients can be reinfected by a new strain of CMV after transplantation (Arens, 
1999). Nucleotide sequencing and PCR – based RFLP methods are currently 
employed for identification of variants and or recombinants of several HCMV genes 
viz.  glycoprotein B, glycoprotein H, glycoprotein O, glycoprotein  L, glycoprotein 
N, Major immediate early gene (UL 123), UL 144, US 28,US 9 (Chou and 
Dennison, 1991; Meyer-Konig et al., 1998a; Meyer-Konig et al., 1998b; Chou, 
1992a; Rasmussen et al., 2002; Pignatelli et al., 2001, Pignatelli et al., 2003a; 
Retiere et al., 1998; Arav-Boger et al., 2002; Rasmussen et al., 2003). These 
techniques have also been useful in identifying mutations in the UL – 97 gene and 
UL -54 gene coding for phosphotransferase and DNA polymerase of HCMV 
conferring resistance to antiviral drugs (Wolf et al., 1995; Boivin et al., 1996). 
Verbraak et al (1998) used AFLP technique to study the HCMV variants based on 
the a-sequence and Immediate early genes of HCMV in the ocular specimens and 
peripheral blood of AIDS patients. 
2.12.3 HCMV STRAIN VARIATIONS AND CLINICAL SIGNIFICANCE 
 The genome of CMV is highly conserved, but diversity is sufficiently high in 
various regions of the genome to differentiate between several CMV strains or 
genotypes (Meyer-Konig et al., 1998a; Pignatelli et al., 2001; Steininger et al., 
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 2005). The relationship of strain variation in HCMV and its clinical manifestation is 
still a matter of debate. The variations in the genome of HCMV have been 
associated with the cell tropism, variations in pathogenesis, or ability of the strains 
to cause severe disease.  
 It has been shown that different gB subtypes can exhibit different cell 
tropism and that, in contrast to the gB2 and gB3 subtypes, the gB1 subtype does not 
infect lymphocytes in vivo (Meyer-Konig et al. 1998a; Meyer-Konig et al. 1998b). 
In HIV-infected individuals, the aspect of compartmentalization of different CMV 
strains has also been investigated, and differences in the distribution of various 
CMV gB subtypes between blood and eye and between blood and CSF, respectively, 
have been described (Tarrago et al., 2003; Verbraak et al., 1998). Observations on 
the predominance of a certain CMV genotype, however, were ambiguous in HIV 
infected individuals with CMV retinitis (Shepp et al., 1996; Rasmussen et al., 1997; 
Drew et al., 2002; Bongarts et al., 1996). In a clinical investigation of bone marrow 
transplant recipients it was found that certain gB subtypes are more frequently 
associated with death due to myelosuppression than others (Torok-Storb et al., 
1997). The contradictory results obtained in various investigations are attributed to 
the difference in the geographic distribution of strains (Zipeto et al., 1998), 
demographic characteristics of the infected individuals as was seen in a study 
between the distribution of HCMV strains in AIDS patients and in transplant 
recipients (Rasmussen et al., 1997) and the fact that most investigations were carried 
out to characterize the variations at only one polymorphic gene of the virus genome. 
Several investigations of CMV infections in children have shown concordantly that 
congenital and perinatal infections may occur with all CMV gB subtypes (Bale et 
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 al., 2000; Barbi et al., 2001; Trincado et al., 2000), and in overall, no particular gB 
subtype could be found to be associated with severe disease. Later, however, another 
group showed that the severity of congenital disease may be associated with viral 
polymorphisms, not in the gB gene, but in the UL144 gene, and that certain subtypes 
of this gene coding for the tumor necrosis factor (TNF)-α-like receptor may be 
associated with unfavorable outcome (Arav-Boger et al., 2002). Considering the 
large variety of virus–host interactions that are mediated by the numerous viral gene 
products, it has been difficult to predict the sets of CMV genes that would 
significantly influence a defined clinical situation. One factor that could contribute 
to variations in pathogenesis or severity of disease is that different CMV strains may 
interact differently with the host’s immune system. Investigations of renal transplant 
patients have shown that differential presentation of polymorphic gB or IE-1 
peptides by HLA molecules as well as differential recognition of these by host 
CD8+ and CD4+ T lymphocytes modulate the host’s immune response with a 
possible impact on CMV pathogenesis (Retiere et al., 2003). The action of NK cells 
has been reported to be dependent on the virus strain infecting the target cells 
(Cerboni et al., 2000). In addition, variations in CMV immune evasion genes might 
also influence the virus-host interaction (Reddehase, 2002). 
 HIV-infected patients and transplant recipients are most frequently co-
infected with different CMV strains (Lang et al., 1989, Bongarts et al., 1996). The 
compromised immune system of these patients may not be capable of limiting 
dissemination of new CMV variants. Consequently, coinfection by several CMV 
strains might provide the basis for CMV intragenic recombination and emergence of 
CMV variants with the possibility for altered biological properties. Cell culture 
85 
 experiments demonstrated that co-infection with two CMV strains may give  
rise to viable recombinant CMV-gB strains (Haberland et al., 1999). Intragenic 
recombination was demonstrated in CMV strains detected in the CSF of  
HIV-infected patients (Steininger et al., 2005). Therefore, intragenic recombination 
between different CMV strains may be common in patients with advanced  
HIV-infection and transplant recipients as they are mostly prone to mixed infections 
with multiple genotypes of HCMV, which could lead to a source of new CMV 
strains with altered biological properties. It has been recommended that knowledge 
on the strains of HCMV circulating in a given region may be essential as efforts to 
develop a CMV vaccine gain momentum (Britt, 1996; Plotkin, 2001). 
2.13 TREATMENT 
 Because CMV causes a significant disease to transplant patients, strategies 
aimed at CMV prevention have been developed. These strategies include 
“prophylaxis”, “preemptive therapy” and treatment of established CMV disease 
(Ljungman, 2002). In the prophylaxis, the patients at risk of disease based upon the 
pre-transplant CMV serological status of recipient and donor are treated after 
transplantation. In the pre-emptive therapy, antiviral agents are given in situations, 
where there is laboratory evidence of viral replication by viral culture, pp65 
antigenemia, or detection of CMV DNA. Treatment is given following established 
CMV disease in transplant recipients. The currently available antivirals for the 
treatment of CMV disease are ganciclovir, foscarnet, and cidofovir (Paya and 
Razonable, 2003). Ganciclovir is a choice for the treatment of established CMV 
disease in solid organ transplant patients, given intravenously for at least two weeks. 
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 Ganciclovir is a nucleoside analogue, which in its active triphosphorylate form 
inhibits the viral DNA polymerase and competes with deoxyguanosine triphosphate 
(dGTP) to act as a terminator of biosynthesis for the viral DNA. This 
phosphorylation in CMV infected cells is mediated by the CMV UL97 protein 
(Littler et al., 1992). This protein is a phosphotransferase that phosphorylates 
ganciclovir to ganciclovir monophosphate in infected cells (Biron, 2006). Two 
subsequent rounds of phosphorylation by cellular kinases produce ganciclovir 
triphosphate. Resistance to ganciclovir arises from mutations in the UL97 gene. 
Resistance may also arise from mutations in the viral DNA polymerase gene 
(UL54). The side-effects of ganciclovir include leukopenia and thrombocytopenia. 
Foscarnet is a pyrophosphonate analogue, which interferes with the binding of the 
pyrophosphate to its binding site of the viral DNA polymerase and it is used when 
ganciclovir is contraindicated. The major dose-limiting toxicity of foscarnet is renal 
impairment. Resistance to foscarnet arises from the point mutations in the UL54 
gene, and cross-resistance has been observed between ganciclovir and foscarnet. 
Cidofovir is a nucleoside analogue, which may also be used but reports on this 
antiviral for therapy is very limited (Biron, 2006). In addition, CMV 
immunoglobulin has been used in lung transplant recipients for the treatment of 
CMV disease together with ganciclovir (Weill et al., 2003). As a prophylaxis in 
transplant recipients, ganciclovir is administered before active CMV infection 
occurs, immediately after the transplantation, especially those D+/R- patients. 
Ganciclovir is a widely used and effective drug for CMV prophylaxis. Previously, 
ganciclovir was administered intravenously, thereafter with the availability of the 
oral ganciclovir still favored CMV prophylaxis, although the bioavailability of oral 
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 ganciclovir is lower than intravenous ganciclovir (Winston and Busuttil, 2004). 
Valganciclovir, a valine ester of ganciclovir, has been developed more recently to 
overcome the limitations of oral ganciclovir and it gives the same plasma 
ganciclovir exposures to those achieved with i.v. ganciclovir (Peskovitz et al., 2000). 
Valganciclovir prophylaxis in solid organ transplant patients has been found 
clinically as effective as oral ganciclovir with a comparable safety profile and the 
absence of ganciclovir resistance (Hodson et al., 2005; Paya et al., 2004). 
Valganciclovir has also recently been used in the treatment of CMV infection and 
CMV disease in organ transplant recipients (Babel et al., 2004; Humar et al., 2005). 
In preemptive therapy, antiviral treatment is initiated when CMV is detected in the 
blood using sensitive quantitative virological methods, such as PCR or tests for viral 
antigen. Preemptive therapy is based on frequent monitoring of the viral load in the 
peripheral blood of the recipient. It has been shown that peak viral loads correlate 
with CMV disease and that the rate of increase in viral load can identify recipients at 
risk of developing CMV disease (Emery et al., 2000). The advantages of the pre-
emptive therapy include reduction in the number of patients exposed to antivirals, 
lowering the risk of drug resistance and maximizing the cost benefit ratio. The 
effectiveness of pre-emptive ganciclovir therapy has also been shown in 
randomized, placebo-controlled trials (Strippoli et al., 2006). Recently, 
valganciclovir has also been used pre-emptively (Singh et al., 2005). Currently, 
clinical antiviral trials of the drug, Maribavir is under way. Maribavir is a potential 
inhibitor of UL – 97 kinase of HCMV. Initial research has shown a good anti 
HCMV effect of Maribavir. Maribavir had shown to antagonize the effect of 
ganciclovir though; the antiviral effects of foscarnet and cidofovir remained 
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 unaffected (Chou and Marousek, 2006).  Antiviral resistance to Maribavir has been 
shown to be conferred by mutations in a region upstream to that conferred by 
ganciclovir in the UL97 gene (Chou et al., 2007). 
2.14 MOLECULAR METHODS FOR DETECTION AND 
CHARACTERIZATION OF HCMV IN INDIA 
 In India, several studies on HCMV have been based on the use of 
conventional methods particularly employing serological techniques for the 
detection of IgG and IgM antibodies of HCMV in different patient populations (Pal 
et al., 1972; Mathur et al., 1981; Shanmugam et al., 1982; Broor et al., 1991; Kapil 
and Broor, 1992; Ray and Mahajan, 1997; Chakravarty et al., 2005; Sheevani et al., 
2005; Gandhoke et al., 2006; Kothari et al., 2006). Few reports are available on the 
use of pp65 antigenemia assays to establish CMV disease in renal transplant 
recipients (Sakhuja et al., 2002; Minz et al., 2004).There are  handful reports on the 
use molecular assays for the detection of HCMV in different patient populations. 
Sivakumar et al (2001) used Mac ELISA and a nested PCR simultaneously for 
establishing congenital CMV infection in neonates with clinically proven HCMV. 
The study suggested that Mac ELISA had parallel sensitivity and specificity to the 
nested PCR and more preferred since it was less expensive, less cumbersome and 
more user friendly. A nested PCR targeting mtr II region was used to detect HCMV 
genome in the urine specimens of congenitally infected and healthy neonates. The 
study emphasized the value of molecular detection of HCMV to establish an 
association with symptomatic disease in congenitally infected infants (Shoby et al., 
2002). A highly sensitive polymerase chain reaction (PCR) for immediate early gene 
of CMV and pp65 antigenaemia assay were applied on clinical specimens from 
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 patients with AIDS and healthy HIV seropositives to establish CMV infection. The 
study suggested that PCR is a powerful tool for detection of CMV in blood and is 
superior to the antigenaemia assay (Mujtaba et al., 2003). Nucleic acid sequence-
based amplification (NASBA) technology was used to detect pp67 mRNA of 
cytomegalovirus (CMV) in transplant recipients. The study concluded that the pp67 
mRNA assay was an accurate, rapid, and effective diagnostic tool to detect active 
CMV disease in symptomatic transplant cases (Wattal et al., 2004). Kishore et al 
(2004) employed PCR for detection of CMV disease and graft rejection in renal 
transplant recipients. The study suggested that PCR may not be sensitive enough in 
detecting CMV disease or rejection (Kishore et al., 2004). Rao et al., 2000 in a 
longitudinal study, demonstrated the importance of quantitation of HCMV genome 
to diagnose HCMV disease in seroendemic transplant population. In this study 
quantitation of the HCMV DNA was performed by limiting dilution. The study 
showed that a cutoff of 0.001 µg/ 5 µl input DNA had a good positive predictive 
value of 92.3% for symptomatic CMV disease (Rao et al., 2000). A similar study 
was performed on the bone marrow transplant recipients (Finny et al., 2001). 
Qualitative PCR have also been employed in detection of HCMV in intraocular 
specimens (Priya, 2001; Biswas et al., 2002). Studies on molecular characterization 
of HCMV however have been scarce. The only report from India on CMV 
genotypes showed that gB subtypes 2 and 3 were prevalent in immunocompromised 
patients with suspected HCMV infections in Chennai region, India.  Genotypes 1 
and 4 were not found in the study (Madhavan and Priya, 2002b). Therefore, due to 
the paucity of reports on the use of nucleic acid based molecular assays for 
detection, quantitation and characterization of HCMV such a study was undertaken. 
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 3.  STANDARDIZATION OF pp65 ANTIGENEMIA 
ASSAY TO DETECT AND QUANTITATE HCMV 
ANTIGEN IN PERIPHERAL BLOOD SPECIMENS 
3.1  BACKGROUND 
 pp65 antigenemia assay is a rapid, simple, quantitative test for the diagnosis 
of active HCMV infection. Antigenemia assay is more sensitive than serology and 
viral isolation by conventional tube culture or shell vial assays. The test has a 
prognostic value to identify immunocompromised patients at risk of developing 
HCMV disease (Boeckh and Boivin, 1998). The lead time for the test is usually 
several days to one week before the onset of symptoms in immunocompromised 
patients (The et al., 1992; Le Goff et al., 1995). The test is used for monitoring the 
development of CMV disease and /or antiviral resistance in solid organ transplant 
recipients and AIDS patients. The pp65 antigenemia assay uses monoclonal 
antibodies to detect the lower matrix protein pp65 in the leucocytes. Several 
modifications in the steps involved for the assays have evolved over period of time 
including automation of the procedure by the use of flow cytometry (Toulemonde et 
al., 2000).  
3.2 OBJECTIVE 
3.2.1 To compare conventional dextran sedimentation (CDS) and direct erythrocyte 
lysis method (DEL) for isolation of leucocytes and standardize 
immunofluorescence based pp65 antigenemia assay. 
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 3.3 MATERIALS AND METHODS 
3.3.1 Clinical specimens 
 EDTA anticoagulated peripheral blood specimens were collected from 25 
healthy blood donors (controls) and 25 post-renal transplant recipients with 
suspected HCMV infections.  
3.3.2 Total leucocyte count by manual method 
 The total leucocyte count on the peripheral blood was performed manually 
by using haemocytometer as described in Appendix I. The values obtained were 
used as a reference to calculate the recovery rates of the leucocytes obtained by CDS 
and DEL methods. 
3.3.3 pp65 antigenemia assay 
 The details of preparation of reagents are provided in Appendix I. The 
various steps involved in the pp65 antigenemia assay include: isolation of leucocytes 
followed by counting of cells, preparation and fixation of smears and detection of 
pp65 antigen by immunofluorescence staining. 
3.3.3.1 Isolation of leucocytes 
 Two different protocols were followed for isolation of leucocytes: 
i. Conventional dextran sedimentation method (CDS) 
ii. Direct erythrocyte lysis method  (DEL)  
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 3.3.3.1.1 Conventional dextran sedimentation method (CDS): 
 To 5ml of EDTA-anticoagulated blood, 1.5ml of 6% sterile dextran solution 
was added and incubated at 37oC for 30 minutes to allow aggregation and 
sedimentation of the erythrocytes. The leukocyte rich supernatant was mixed with 
10ml of sterile phosphate buffered saline (PBS) and centrifuged at 3000 rpm for 10 
minutes. The cell pellet was suspended in 1ml of 0.8% ammonium chloride for 5 
minutes to lyse the remaining erythrocytes. The mixture was centrifuged at 3000 
rpm for 5 minutes. The cells were then washed thrice with sterile PBS. The final 
leukocyte pellet was suspended in 1ml of PBS. 
3.3.3.1.2 Direct erythrocyte lysis method (DEL):  
 Twenty five ml of 0.8% ammonium chloride was added to 2ml of EDTA 
anticoagulated blood, mixed and incubated at 37o C for 5 minutes. The mixture was 
centrifuged at 3000 rpm for 5 minutes. The cell pellet was washed with sterile PBS 
thrice. The final leukocyte pellet was suspended in 1ml of PBS. 
3.3.3.2 Cell count & smear preparation 
 Cell counts were determined using a hemocytometer (Appendix I). Cytospin 
smears containing 2x 105 leucocytes/ slide were made by centrifugation at 1000 rpm 
for 5 minutes. Cytospin slides were fixed in methanol for 10 minutes; treated with 
0.5% Nonidet -P40 for 5 minutes for improving cell permeablilization; air dried for 
15 minutes.  
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 3.3.3.3 Detection of pp65 antigen by immunofluorescence staining 
 The Cytospin smear was covered with 25µl of 1/5 diluted CMV monoclonal 
antibody directed against pp65 antigen (DAKO, A/S, Denmark) and incubated in a 
moist chamber for one hour. After incubation, the smear was washed thrice with 
PBST and incubated with 25µl of 1/5 diluted FITC conjugated rabbit anti-mouse 
IgG antibody (DAKO, A/S, Denmark) for one hour in a moist chamber. The smear 
was washed thrice with PBST, counter stained with 0.5% Evans blue and mounted 
with glycerol. Number of nuclei with apple green fluorescence was scored under UV 
microscope at 400 X magnification. 
3.3.3.4 Interpretation of the results 
Positive result: 
 Presence of at least 1 positively stained leukocyte on the slide. 
Result of semi-quantitation: 
 Total no. of cells positive for pp65 antigen / 2x105 leucocytes. 
3.3.3.5 Analysis of results 
 The recovery rates (%) of the leucocytes for the CDS and DEL method were 
calculated individually. Since different volumes of blood were used for the two 
methods the total number of leucocytes were converted per milliliter of blood and 
following formula was applied:  
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 Leucocytes isolated by CDS/DEL  /ml of blood x 100 
Total no. of leucocytes/ ml (as determined by manual method) 
 
3.4   RESULTS 
3.4.1 Comparison of CDS & DEL method on recovery rates of leucocytes 
 No significant difference in the recovery rates of leucocytes was observed 
between the two methods. The mean + SD recovery rate of leucocytes by CDS 
method was 64 + 15.2% ( range 30.7% to 89%) and by DEL method was 64.8 + 
14.3% (range 33 % to 87.7%). 
3.4.2   Results of pp65 antigenemia assay on controls and clinical specimens 
 Irrespective of the method of leucocyte recovery all the 25 peripheral blood 
specimens from healthy blood donors were negative for pp65 antigenemia  
(Figure 1a). Of the 25 clinical specimens from post – renal transplant recipients,  
13 were positive by both DEL and CDS methods (Figure 1b). Discrepancy in 
determining positivity of the sample was not observed between the two methods. 
Table 2 shows the pp65 antigenemia values of the 13 positive specimens with both 
CDS and DEL method. A positive correlation was found with the semi-quantitation 
results of CDS and DEL method (rs = 0.8338, Spearman correlation coefficient test; 
p <0.001) (Figure 2a). A good agreement was found between the two methods by 
Bland – Altman plots. The bias (difference between the means) was 0.2 and the 95 
% limits of agreement were between -19.8 to 19.4 (Figure 2b). 
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 Figure 1:  Results of pp65 antigenemia assay 
 
          (a)        (b) 
 
 
 
 
 
 
 
 
 
(a) pp65 antigenemia assay performed on PBLs of healthy control negative for 
HCMV antigenemia (100x magnification). 
(b) pp65 antigenemia assay performed on PBLs of post renal transplant recipient 
positive for HCMV antigenemia (400x magnification).  
 
  Table 2: Results of pp65 antigenemia values obtained with CDS and 
DEL method on 13 peripheral blood specimens from post – renal 
transplant recipients with HCMV antigenemia 
 
 
S.No. 
pp65 antigenemia values 
CDS  
method 
DEL  
method 
1 29 37  
2 50 48  
3 35 32 
4 30 37 
5 115 92 
6 25 27 
7 125 137 
8 25 33 
9 60 65 
10 37 32 
11 9 6 
12 15 22 
13 47 32 
 Figure 2: Correlation and agreement between CDS and DEL methods 
 
 (a) 
 
 
 
 
 
 
 
 
      (b) 
 
 
 
 
 
 
 
 
 
(a) XY Scatter plot . pp65 positive cells obtained with DEL method plotted 
against that of CDS method. The correlation between the method was 
examined by spearman rank test and was found significant with a correlation 
coefficient (rs) = 0.8338 (P<0.001). 
 (b) Bland Altman plot showing good agreement between CDS and DEL methods. 
The bias was 0.2 and the 95% limits of agreement was between -19.8 to 19.4 
 3.5   DISCUSSION  
 The sensitivity, specificity and relative rapidity of pp65 antigenemia assay 
are well established. The assay is widely used as differential marker for active and 
latent HCMV infection, prognostic marker for development of HCMV disease, and 
surrogate marker for the development of antiviral resistance in transplant recipients 
and AIDS patients (Boeckh and Boivin, 1998). The maiden pp65 antigenemia assay 
protocol comprised of isolation of leucocytes by dextran sedimentation, fixation and 
detection of pp65 antigen by indirect immunoperoxidase staining (Van der Bij et al., 
1988). Isolation of leucocytes may be a critical step, since; the pp65 antigen is 
detectable more in the granulocytes particularly polymorphonuclear leucocytes 
PMNL than other fractions. Ficoll gradient may not be useful for isolation of 
leucocytes as it provides a monocyte rich fraction (Boeckh and Boivin, 1998). 
Dextran sedimentation, Polymorphprep method, direct erythrocyte lysis methods 
have all been used previously for preparation of leucocytes (Ho et al., 1998; Garcia 
et al., 1996). Significant losses of the leucocytes have been reported irrespective of 
the methods of leucocyte isolation in different studies.  Garcia et al (1996) carried 
out a prospective, parallel, and blind study comparing both qualitatively and 
quantitatively, the efficiency of Polymorphprep method and dextran sedimentation 
method. The study concluded that both methods were equally effective (Garcia et 
al., 1996). However, Ho et al (1998) compared the dextran sedimentation and direct 
erythrocyte lysis methods and found that direct erythrocyte lysis method gave higher 
yields and better results than the dextran sedimentation. Taking these into 
consideration, simple and inexpensive methods of leucocyte isolation namely the 
Conventional dextran sedimentation (CDS) and Direct erythrocyte lysis (DEL) 
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 methods were compared as a first step in optimization of pp65 antigenemia assay. 
The results showed no significant difference in terms of the recovery rates of the 
leucocytes or qualitative/ quantitative detection of antigenemia in healthy controls as 
well as the post renal transplant recipient groups. However, considering the time 
taken, expenditure and volume of specimen required, DEL method might have a 
marginal advantage over CDS method. On the other hand, in patients with severe 
leucopenia (neutrophils < 200/mm3) since a larger volume of blood (around 10 ml) 
would be required for preparing the slides the CDS may be preferred over DEL 
method. Also, in patients with lymphocytosis, it may be advisable to use the CDS 
method as it selectively provides the PMNL fraction, since lymphocytes do not 
express pp65 antigen of HCMV. No efforts were made to compare different fixation 
or staining procedures since methanol fixation and immunofluorescence staining 
techniques were well developed and routinely performed for other infectious agents 
in the laboratory. The results of the study suggest that CDS and DEL methods can 
be alternatively used for pp65 antigenemia assay. 
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 4.  EVALUATION OF THE EFFICIENCY OF PRIMERS 
TARGETING MORPHOLOGICAL TRANSFORMING 
REGION II (mtrII), UL -83 AND GLYCOPROTEIN O 
(gO) REGIONS FOR DETECTION OF HCMV IN 
CLINICAL SPECIMENS 
4.1 BACKGROUND  
 Conventional methods of laboratory diagnosis of HCMV infection include 
serology, virus culture by conventional tube method or rapid shell vial assay and 
antigen detection. Culture is the “gold standard” but is a relatively insensitive 
laboratory method. Serology results are difficult to interpret especially in 
immunocompromised patients (Madhavan and Priya, 2002a; Boeckh and Boivin, 
1998). pp65 antigenemia assay is used as a test for monitoring those at higher risk of 
developing CMV disease and to initiate pre-emptive therapy (Kusne et al., 1999; 
Amorim et al., 2001).  Detection of HCMV DNA in clinical specimens by nucleic 
acid based amplification methods such as Polymerase chain reaction (PCR) 
contributes to a rapid and early diagnosis (Yuen et al., 1995; Mansy et al., 1999; Lo 
et al., 1999). Primer pairs for the detection of the genes coding for the Immediate 
Early (IE) antigen and Late antigen (LA) were initially used for the detection of 
HCMV genome in urine and peripheral blood leucocyte specimens (Demmler et al., 
1988; Shibata et al., 1988). Since then, a variety of primer pairs are being used for 
routine diagnosis of HCMV infection in various patient populations. Different 
factors including sequence variations in the viral genome have been shown to affect 
the ability of the PCR using different primer sets to detect HCMV DNA (Brytting et 
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 al., 1992; Chou, 1992b; Distefano et al., 2004; Wirgart et al., 1998).  Little is known 
about the regions under the present study viz: morphological transforming region II 
(mtr II), UL 83 and glycoprotein O (gO) gene as targets for the detection of HCMV 
genome by PCR. In the present study, pp65 antigenemia assay was considered as 
“gold standard” to evaluate the efficacy of the Polymerase chain reaction tests to 
detect HCMV genome in the clinical specimens from immunocompromised patients 
with suspected HCMV infection. pp65 antigenemia test was considered as a “gold 
standard” since detection of antigenemia in immunocompromised patients is an 
indicator of active HCMV disease (Mazzulli et al., 1999; George and Rinaldo, 
1999).  
4.2 OBJECTIVES 
4.2.1. To standardize uniplex PCR for UL-83 gene of HCMV. 
4.2.2. To standardize nested PCRs for gO gene of HCMV using two sets of primers. 
4.2.3. To standardize duplex PCR by combining the two sets of primers targeting gO   
gene.             
4.2.4. To evaluate the efficiency of the PCRs for mtr II, UL 83, gO and duplex PCR 
for  gO gene against pp65 antigenemia assay as the ‘gold standard’. 
4.3 MATERIALS AND METHODS 
4.3.1 Standardization of Uniplex PCR for UL-83 gene of HCMV 
4.3.1.1 Standard strain of HCMV – AD169 (Christian Medical College and 
Hospital     [CMCH], Vellore, India). 
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 4.3.1.2 DNA extraction  
 DNA extraction from the standard strain of HCMV was carried out by 
QIAamp DNA mini Kit (QIAGEN, GMbH, Germany) strictly adhering to 
manufacturer’s instructions. The detailed procedure is provided in Appendix II. 
4.3.1.3 PCR amplification  
 The uniplex PCR for UL-83 gene of HCMV was performed as described 
previously (Gouarin et al., 2002) with some modifications. The original PCR in 
Taqman probe-based real time PCR format was modified to suit conventional 
uniplex PCR. The primer pairs are provided in Table 3.  For amplification, a 50µl 
reaction was set with 160 µM of each dNTPs, 10 picomoles of each primer, 1x 
buffer (10mM Tris-Cl [pH 8.3], 50mM KCl, 0.01% gelatin, 1.5mM MgCl2) and one 
unit of Taq polymerase.  Ten microlitres of extracted DNA was added as the 
template. The reactions were carried out in a thermal cycler (Perkin Elmer model no. 
2400, USA).  The thermal profile consisted of an initial denaturation at 94°C for five 
minutes for one cycle followed by 45 cycles of denaturation at 94°C for 15 seconds, 
annealing at 65°C for 20 seconds and extension at 72°C for 20 seconds and a single 
cycle of final extension at 72°C for five minutes. Negative control containing the 
reaction mixture with milli Q water in the place of extracted DNA; spiking reaction 
(to rule out inhibitors) and positive control containing HCMV AD-169 DNA were 
used to validate the PCR reaction in each run. The amplified products were then 
subjected to gel electrophoresis using two percent agarose gel containing 0.5µg/ml 
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 Table 3: Primer sequences for the detection of mtr II, UL 83 and gO genes  
   of HCMV 
 
Genes Primer sequences (5’ – 3’) Amplicon size 
 
 
 
mtr II 
I round 
 
F:     CTG TCG GTG ATG GTC TCT TC  
R:    CCC GAC ACG CGG AAA AGA AA  
 
 
 
234 bp 
II round 
 
F:     TCT CTG GTC CTG ATC GTC TT  
R:    GTG ACC TAC CAA CGT AGG TT 
 
 
 
168 bp 
 
UL 83 
 
F:     GGG ACA CAA CAC CGT AAA GC 
R:     GTC  AGC GTT CGT GTT  TCC  CA 
 
 
283 bp 
 
 
 
 
gO 
(AD169) 
I round 
 
F:     CAG CTT CGA AAA CCG GCC AAA 
TAC G 
R:    AAT ATA CTT GGG GAC GCG AAA 
TAG A 
 
 
 
375 bp 
II round 
 
F:     GCT TCG AAA ACC GGC CAA ATA CG 
R:     ATA CTT GGG GAC GCG AAA TAG A 
 
 
 
370 bp 
 
 
 
 
gO 
(Towne) 
I round 
 
F:     CAA CTC CGT AAA CCG GCC AAA T 
R:     ATA TAC TTG GGA ACG CGG 
 
 
 
375 bp 
II round 
 
F:     CTC CGT AAA CCG GCC AAA TAT G 
R:     TAC TTG GGA ACG CGG AAT 
 
 
 
370 bp 
 
F – Forward primer; R – Reverse primer 
 of ethidium bromide as described in Appendix II. The specificity and sensitivity of 
the PCR was determined as described in Appendix II. 
4.3.2  Standardization of nested PCRs for gO gene of HCMV using two sets of  
primers 
 The PCRs for gO gene of HCMV was carried out as described previously 
(Rasmussen et al., 2002) with certain modifications. In brief, two nested PCRs were 
standardized individually using two sets of primers designed for AD169 and Towne 
strains of HCMV. The primer sequences are provided in Table 3. Similar reaction 
mixtures except for the primers were used for both the PCRs.  For the first round 
amplification, a 50µl reaction was set with 160 µM of each dNTPs, 10 picomoles of 
each primer, 1x buffer (10mM Tris-Cl [pH 8.3], 50mM KCl, 0.01% gelatin, 1.5mM 
MgCl2) and one unit of Taq polymerase.  Ten microlitres of extracted DNA was 
added as the template. The reactions were carried out in a thermal cycler (Perkin 
Elmer model no. 2400, USA).  The thermal profile consisted of an initial 
denaturation at 94°C for five minutes for one cycle followed by 30 cycles of 
denaturation at 94°C for 45 seconds, annealing at 60°C for 45 seconds and extension 
at 72°C for 45 seconds and a single cycle of final extension at 72°C for five minutes. 
AD169 strain of HCMV and a clinical isolate of HCMV were used as positive 
controls for standardization of the PCRs for gO (AD169) and gO (Towne) 
respectively. The second round of amplification consisted of reaction mixture 
similar to the first round except for the primers. Two microlitres of the first round 
product was used as template for the second round and subjected to a thermal profile 
similar to the first round with 20 cycles. The amplified products were then subjected 
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 to gel electrophoresis using two percent agarose gel containing 0.5µg/ml of ethidium 
bromide as described in Appendix II. The specificity and sensitivity of the PCRs 
were determined as described in Appendix II. 
4.3.3 Standardization of duplex PCR by combining the two sets of primers 
targeting gO gene 
 Duplex nested PCR for gO gene was standardized by combining the two sets 
of primers for AD169 and Towne strains. The reaction mixture similar to that of the 
individual PCRs (section 4.3.2) was used except for the primer concentration. A 
concentration of 15 picomoles of gO (AD 169), and 10 picomoles of gO (Towne) 
primers were used. The thermal profile for the amplification was similar to the 
individual PCRs (section 4.3.2). Specificity and sensitivity of the duplex PCR was 
determined as described in Appendix II. 
4.3.4 Evaluation of the efficiency of the PCRs for mtr II, UL 83, gO (AD169) 
and duplex PCR for gO gene against pp65 antigenemia assay as the ‘gold 
standard’ 
4.3.4.1 Study design and Definition of gold standard 
 Clinical specimens received at L & T Microbiology Research Centre, Vision 
Research Foundation, in Sankara Nethralaya, Chennai, India during December 2004 
to July 2005 were investigated for the possible association of CMV infection in  
74 immunocompromised patients. Clinical specimens were investigated because of 
clinical suspicion of CMV- related disease in these patients. The patients with pp65 
antigenemia positivity were defined to have activation of HCMV disease and this 
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 test was used as the “gold standard” to evaluate the PCRs for mtrII, UL 83, gO 
(AD169) and duplex PCR for gO gene for their clinical specificity, sensitivity and 
predictive values. The nested PCR for mtrII, uniplex PCR for UL83 and nested PCR 
for gO (AD169) were applied prospectively while the duplex PCR for gO was 
applied retrospectively on the stored DNA as it was standardized at a later stage. 
4.3.4.2 Patients, Controls and Clinical specimens  
 The distribution of the clinical specimens in relation to the clinical status of 
the patients from whom they were collected is provided in Table 4.  Ninety two 
clinical specimens [74 blood, 18 urine] from 74 immunocompromised patients 
[Solid organ transplant recipients – 59, Bone marrow transplant recipients -3, HIV 
infected individuals -7 and Congenital/ neonates -5] were analyzed during the course 
of the study. Among the 74 patients, 47 were males and 27 were females. The age of 
the patients ranged from 40 hours after birth to 67 years. The patients clinically 
presented with multiple symptoms such as fever, jaundice and leucopenia. Three of 
the renal transplant recipients had clinical evidences of a moderate graft rejection. 
CMV retinitis was predominant in the HIV infected individuals. In addition blood 
samples from 45 healthy blood donors seropositive for HCMV were used as controls 
for all the tests. 
4.3.4.3 pp65 antigenemia assay, PCR for mtrII, UL-83, gO (AD169) and duplex 
PCR for gO gene of HCMV 
 pp65 antigenemia assay was performed as described in section 3.3.3. CDS or 
DEL methods were alternatively used depending on the volume of blood available.  
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 Table 4: Distribution of 92 clinical specimens in relation to the clinical 
status of the 74 patients with suspected CMV infections 
 
 
 
 
Clinical Status of 
the Patients 
 
Total number of 
patients 
 
( n = 74) 
 
Clinical Specimens collected 
 
( n= 92) 
 
Blood only 
 
(n= 56) 
 
 
Blood and urine                   
 
(n = 18 x 2 : 36) 
Solid organ   
transplantation 
59 (79.7%) 43 16 
Bone marrow 
transplantation 
3 (4.0%) 3 - 
HIV infected 
individuals 
7(9.5%) 7 - 
Congenital / 
neonates 
5(6.8%) 3 2 
  The extraction of the DNA for the PCRs was performed using two 
commercially available DNA extraction columns strictly adhering to the 
manufacturer’s instruction. The detailed procedures of the DNA extraction are 
provided in Appendix II. The PCR for detection of mtrII region was performed as 
described by Madhavan and Priya (2002a). The primer sequences are provided in 
Table 3.  For the amplification a 50µl reaction was set with 80 µM of each dNTPs, 
10 picomoles of each primer, 1x buffer (10mM Tris-Cl [pH 8.3], 50mM KCl, 0.01% 
gelatin, 1.5mM MgCl2) and one unit of Taq polymerase.  Ten µl of extracted DNA 
was added as the template. For the nested amplification, one microlitre of the first 
round product was added as the template DNA for the second round with a reaction 
mixture similar to the first round.  The reactions were carried out in a thermal cycler 
(Perkin Elmer model no. 2400, USA).  The amplification profile for CMV consisted 
of 30 cycles for the first round and 20 cycles for the second round each consisting of 
denaturation at 94°C for one minute, annealing at 55°C for one minute and extension 
at 72°C for one minute with a final extension at 72°C for ten minutes. The 
amplicons were visualized on a 2% agarose gel incorporated with ethidium bromide 
as described in Appendix II. 
 The uniplex PCR for UL83, nested PCR for gO (AD169) and duplex PCR 
for gO were performed as described in sections 4.3.1; 4.3.2; 4.3.3 respectively.  
4.3.4.4 Analysis of Results 
 Diagnostic data from clinical specimens of 74 patients with suspected 
HCMV infections were used for the determination of the clinical sensitivity, 
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 specificity, positive and negative predictive values of the different PCRs using pp65 
antigenemia results as the “gold standard”. The difference in the clinical sensitivity 
and the specificity of the PCRs were statistically analyzed by Fisher’s exact test for 
two proportions.   
4.4 RESULTS 
4.4.1 Specificity and Sensitivity of UL-83 PCR 
 The uniplex PCR for the UL-83 gene of HCMV generated amplified product 
of 283 bp. The PCR was specific for HCMV and sensitive enough to detect 50fg of 
HCMV DNA. 
4.4.2 Specificity and Sensitivity of nested PCRs for gO gene using two sets of             
primers 
 Both the nested PCRs for gO gene of HCMV generated amplified products 
of 375 bp in the first round of amplification and 370 bp in the second round. The 
PCRs were specific for HCMV and sensitive enough to detect 500fg of HCMV 
DNA. 
4.4.3 Specificity and Sensitivity of duplex PCR for gO gene  
 The duplex PCR for gO gene of HCMV generated amplified products of 375 
bp in the first round and 370 bp in the second round of amplification. The PCR was 
specific for HCMV. The duplex PCR detected 500fg of HCMV DNA. 
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 4.4.4 Results of the application of pp65 antigenemia assay, PCRs for mtr II, UL 
83, gO (AD169) and duplex PCR for gO gene on 74 immunocompromised 
patients 
 Of the 74 patients tested, the pp65 antigenemia assay became positive in 38 
patients. Hence, of the total 92 clinical specimens from 74 patients, 48 clinical 
specimens from 38 patients were considered as positive for the “gold standard”. The 
48 clinical specimens positive included blood alone from 28 patients and pairs of 
blood and urine from 10 patients. Of the 48 clinical specimens positive by the “gold 
standard”, when tested by PCR methods all were positive for mtr II region, 27 for 
UL –83 gene, 21 for gO (AD169) and 35 by duplex PCR for gO gene. The increase 
in clinical sensitivity by the PCR for mtr II over the UL 83, gO (AD169) PCR and 
duplex gO PCR were 44 %, 56 % and 27 % respectively. The increase in the clinical 
sensitivity of the PCR for mtr II was statistically significant (P < 0.0001 Fisher’s 
exact test for two proportions). However, the difference in the clinical specificity 
between the PCRs was not statistically significant. A summary of the results is 
presented in Table 5. All the 45 peripheral blood leucocytes obtained from the 
controls (seropositive healthy donors) remained negative by pp65 antigenemia assay 
and all the PCR tests for HCMV. Figures 3a, 3b, 3c and 3d shows the agarose gel 
electrophoretogram of amplicons obtained with PCR for mtr II, UL 83, gO (AD-
169) and duplex gO respectively. 
4.5 DISCUSSION 
 Human Cytomegalovirus has long been recognized as a major cause of life- 
threatening complications in immunosuppressed individuals. There is perceived 
need for the use of a  reliable technique that allows an early detection of the viral  
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 Table 5: Results of the mtrII, UL 83, gO(AD169), duplex gO PCR for the 
diagnosis of suspected HCMV infections in comparison to pp65 
antigenemia (gold standard) 
 
 
Diagnostic 
test result 
pp65  Positives  (n =  48) pp65  Negatives ( n = 44) 
No. of 
Clinical 
specimens 
SENS 
(%) 
PPV 
(%) 
FN 
(%) 
No. of 
Clinical 
specimens 
SPEC 
(%) 
NPV 
(%) 
FP 
(%) 
 
PCR for 
mtrII 
positive 
 
PCR for mtr 
II negative 
 
48 
 
0 
 
 
100 
 
 
87 
 
 
0 
 
7 
 
37 
 
 
84 
 
 
100 
 
 
16 
 
 
PCR for UL 
83 positive 
 
 
PCR for UL 
83 negative 
 
27 
 
21 
 
 
56 
 
 
87 
 
 
44 
 
4 
 
40 
 
 
91 
 
 
66 
 
 
9 
 
PCR for gO 
(AD169) 
positive 
 
PCR for 
gO(AD169) 
negative  
 
21 
 
27 
 
 
 
44 
 
 
 
 
91 
 
 
 
 
56 
 
2 
 
42 
 
 
95 
 
 
61 
 
 
5 
 
PCR for 
duplex gO 
positive 
 
 
PCR for 
duplex gO 
negative 
 
35 
 
13 
 
 
 
73 
 
 
 
 
90 
 
 
 
 
27 
 
4 
 
40 
 
 
91 
 
 
75 
 
 
9 
 Abbreviations : SENS, sensitivity; PPV, Positive predictive value; FN, False   
 negative; SPEC, specificity; NPV, Negative predictive value; FP, False positive 
   
 Increase in clinical sensitivity of the PCR for mtr II gene over other PCRs was 
statistically significant (P<0.0001, Fishers exact test) 
 Figure 3:  Agarose gel electrophoretogram showing the amplified products  
of the PCRs applied on peripheral blood and urine specimens 
 
(a)  
 
 
 
 
(a) Nested PCR for mtr II gene. Lanes: N2 – Negative control (II round) ; N1 -  
Negative control (I round); 1,2,6,8 –Blood negative for mtrII PCR; 3,4,5,7, 9 –Blood 
positive for mtrII PCR; 10, 12 – Urine negative for mtr II PCR; 11 – Urine positive 
for mtr II PCR; P- Positive control ( AD- 169 DNA);  MW – Hinf I digest of φX – 
174 DNA. 
 
(b) 
 
 
 
 
(b) Uniplex PCR for UL-83 gene. Lanes: N – Negative control; 1,2,6,8 –Blood 
negative for UL 83 PCR ;   3,4,5,7,9 –Blood positive for UL 83 PCR; 10, 12 
– Urine negative for UL 83 PCR ;    11 – Urine positive for UL 83 PCR ; P- 
Positive control ( AD- 169 DNA); MW – Hinf I digest of φX – 174 DNA. 
  168 bp 
  N2 N1  1  2   3   4   5   6   7  8   9  10 11 12  P MW 
283 bp 
 N  1   2   3   4    5   6   7   8   9 10  11 12  P MW  
  Figure 3 (continued) 
(c) 
 
 
 
 
 
 
 
 
(c) Nested PCR for  gO (AD 169). Lanes: N2 – Negative control II round ; N1 -  
Negative control I round; 1 –Urine positive for gO (AD169)PCR; 2,3–Urine 
negative for gO (AD169) PCR; 4,6 – Blood positive for gO (AD169)PCR;  
5,7,8 – Blood negative for gO (AD169)PCR; P- Positive control ( AD- 169 
DNA); U – Unloaded well; MW – Hinf I digest of φX – 174 DNA. 
 
(d) 
 
 
 
 
 
(d) Duplex PCR for gO gene.  Lanes: N2 – Negative control II round ; N1 -  
Negative control I round; 1,2 –Urine positive for duplex gO PCR; 3–Urine 
negative for duplex gO PCR; 4,5,6,7 – Blood positive for duplex gO PCR;  8 
– Blood negative for duplex gO PCR;P1 – Positive control (CMV isolate 
(control for gO (Towne)); U – Unloaded well; P2- Positive control ( AD- 
169 DNA);  MW – Hinf I digest of φX – 174 DNA. 
* denotes specimens negative by PCR for gO (AD169) 
370 bp 
N2  N1 1   2   3   4    5    6    7   8    P  U  MW 
370 bp 
N2 N1  1    2*     3     4    5*   6    7*    8    P1   U   P2 MW 
 activation to help decide on early use of pre-emptive therapy in those at greater risk 
of the disease. Technique such as virus isolation though most specific cannot be 
practiced on a regular basis due to lack of its sensitivity and non-availability of 
human diploid fibroblasts in this part of the world. Quantitative pp65 antigenemia 
assay, used to monitor and detect HCMV disease, is well established to have a 
higher positive predictive value for the disease (Boeckh and Boivin, 1998). Since, 
antigenemia is cell based and a low frequency event, a sufficient number of 
granulocytes are necessary for a reliable result (Boeckh and Boivin, 1998). This 
becomes difficult in Bone marrow transplant or other patients with severe 
leucopenia. Other difficulties include the necessity for immediate processing of the 
specimen (within 6 hrs, stored specimens may give erroneous results), difficulty in 
processing a large number of specimens at a time and subjective component in slide 
reading, which requires expertise (Boeckh and Boivin, 1998).  The drawbacks of 
pp65 antigenemia assay or virus isolation may be overcome by the use of rapid, 
sensitive and normalized method such as PCR for the detection of HCMV genome 
in the clinical specimens, which can be applied on a large scale of clinical specimens 
without any difficulty in a standard laboratory for routine diagnosis of HCMV 
infection.  
 Amplification of HCMV genome by PCR is a rapid and sensitive method for 
detection of HCMV in clinical specimens. The choice of PCR primers for HCMV 
genome detection in a clinical specimen is crucial, since the genome of HCMV is 
reported to be highly variable (Brytting et al., 1992; Chou, 1992b; Distefano et al., 
2004; Wirgart et al., 1998).  The primers targeting regions such as the Major 
immediate early gene exon 4, regions of gene coding late antigen, glycoprotein B 
(gB) and glycoprotein H (gH) which are widely used have failed to detect the 
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 HCMV genome in certain clinical specimens due to primer target mismatch owing 
to the large sequence variations in HCMV genome. Nucleotide substitutions and 
even deletions of certain ORFs have been found along the genome of HCMV (Cha 
et al., 1996).  Studies by Distefano et al (2004) suggested that PCR for gB gene was 
more reliable than the Major immediate early gene exon 4 or Late antigen gene in 
detecting HCMV genome in the clinical specimens from congenital and perinatal 
infections in Argentina. Studies by Wirgart et al (1998) suggested that the DNA 
polymerase gene and gB gene were more conserved and can be used for diagnosis of 
HCMV infections in different patient populations. PCRs for gB and gH genes of 
HCMV were compared in a Brazilian study on the renal transplant recipients by 
Aquino and Figueiredo (2001) where in a multiplex format of both the genes was 
suggested for reliable detection of HCMV genome. PCRs for Major Immediate early 
(MIE; IE1) gene, glycoprotein B (gp 58) and structural phosphoprotein (pp 150) 
were compared with pp65 antigenemia in heart and lung transplant recipients by 
Barber et al (1996) where in all the PCR showed a high sensitivity of 100% though 
gp 58 was associated more with a positive PCR signal than the other two PCRs.  
 There are only a few reports available on the primers targeting the regions of 
HCMV genome under the present study (Madhavan and Priya, 2002a; Rasmussen et 
al., 2002, Gouarin et al., 2002). Therefore, the efficacy of these three primers was 
evaluated on different clinical specimens obtained from different high risk 
immunocompromised patient populations against pp65 antigenemia assay as gold 
standard. Blood from the healthy seropositive controls did not yield any detectable 
CMV DNA by any of the three PCRs following amplification. Though PCR is 
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 considered as a highly sensitive method, they did not detect low - level latent 
HCMV infection present in the healthy immunocompetent individuals in this study.   
 pp65 antigenemia assay detected active CMV disease in 38 of 74 patients . A 
high level antigenemia (>50 cells/ 2x 105 PBLs) was seen in clinical specimens 
positive by PCR for all the three regions. We hypothesize that PCRs for all the three 
regions may become positive only with a high viral load.   
 The failure of the PCR targeting UL 83 may be due to its lower analytical 
sensitivity, as it is a uniplex PCR. The PCR for gO gene though a nested PCR, 
showed already a lower analytical sensitivity than PCR for UL 83 and this may be 
attributed to the strain variations in gO gene leading to the primer target mismatch 
and hence loss of an amplification signal. This was confirmed with the results of the 
duplex PCR for gO gene since, the duplex PCR for gO increased the sensitivity over 
the individual gO PCR for AD-169. Results of the study showed that the PCR for 
mtr II had 100% sensitivity, 100 % negative predictive value, 87% positive 
predictive value and 84% specificity. Therefore, PCR for mtrII is the most suitable 
test for qualitative detection of HCMV in clinical specimens from 
immunocompromised patients in Chennai region, India. 
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 5. DEVELOPMENT AND APPLICATION OF A 
MULTIPLEX PCR FOR SEMI- QUANTITATION  
OF HCMV AND ITS EVALUATION AGAINST  
pp65 ANTIGENEMIA ASSAY AND TAQMAN –  
PROBE BASED REAL TIME PCR ASSAY FOR HCMV 
5.1 BACKGROUND 
 Early diagnosis of HCMV infection in high-risk patients is essential in order 
to initiate antiviral therapy (Gault et al., 2001; Roberts et al., 1998). Qualitative 
detection of the HCMV by a highly sensitive PCR may be sufficient in case of 
infants infected congenitally, establishing intrauterine infections in anti-HCMV IgM 
positive pregnant women and allogeneic marrow transplant recipients with severe 
graft versus host disease where in systemic viral load is of limited value. On the 
other hand, quantitative assays may be required for monitoring HIV infected 
individuals or solid organ transplant recipients who develop HCMV disease when 
there is a high viral load (Boeckh and Boivin, 1998). Considering the limited 
resources available for health care in developing countries like India, simplicity and 
the cost of the diagnostic assay are important. The detection of pp65 antigen in 
leucocytes although a sensitive method is laborious, requires immediate processing 
and relies on subjective interpretation of the slide. In India, quantitation of HCMV 
DNA by limiting dilution was attempted successfully (Rao et al., 2000). The major 
constraint in this method includes the use of multiple reactions for each dilution of 
the specimen. Quantitative assays available commercially do not have the levels of 
sensitivity of nested PCR and are thus not appropriate where initial qualitative 
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 diagnosis is required (Caballero et al., 1997). Real-time PCR based on 5’ nuclease 
assays are expensive on a routine basis. Hence, there is a need for developing cost 
effective method that are as sensitive as qualitative PCRs with element of 
quantitation in it and would not require multiple reactions for its performance. Such 
an assay would allow the rational use of preemptive therapy for the patients at high 
risk of developing symptomatic disease.  
5.2 OBJECTIVES 
5.2.1  To develop a multiplex PCR assay for detection of the HCMV genome viz. 
morphological transforming region II (mtr II), the UL-83 gene and gO region 
by combining the individual primer pairs. 
5.2.2 To evaluate the multiplex PCR by simultaneously applying it with pp65 
antigenemia assay on peripheral blood specimens obtained from post-renal 
transplant recipients.  
5.2.3 To standardize Taqman probe-based real time PCR assay for quantitation of 
HCMV. 
5.2.4 To compare the results obtained with Taqman probe- based real time PCR 
assay and multiplex PCR on different clinical specimens obtained from 
immunocompromised patients. 
5.2.5 To correlate the results obtained with pp65 antigenemia assay and Taqman 
probe-based real time PCR assay. 
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 5.3 MATERIALS AND METHODS 
5.3.1 Standardization of multiplex PCR for HCMV 
 A multiplex nested PCR for HCMV was standardized by combining the 
individual primers for mtr II, UL 83 and gO gene (Table 3). The reaction mixture 
and thermal profiles were restandardized to achieve maximum sensitivity. The 
extraction of the DNA was carried out using commercially available DNA extraction 
columns adhering strictly to the manufacturer’s instruction (Appendix II). 
The primer sets of the individual PCRs for mtr II, UL-83  and gO gene (individual 
primer sets for AD-169 and Towne strains) (Table 3) were combined and used in a 
nested multiplex PCR reaction. For amplification a 50 µl reaction was set with 
200µM of each dNTPs, 1× PCR buffer (10mM Tris–HCl (pH 8.3), 50mMKCl, 
0.01% gelatin, 1.5mMMgCl2) and 2 units of Taq DNA polymerase. Twenty 
picomoles of each primer for gO gene, 10 picomoles of each primer for mtr II region 
and 15 picomoles of each primer for UL-83 gene were added. Ten microlitre of 
extracted DNA was added as template. The first round thermal profile consisted of 
an initial denaturation at 94◦C for 5 minutes for 1 cycle followed by 35 cycles each 
consisting of denaturation at 94◦C for 45 seconds, annealing at 60◦C for 45 seconds 
and extension at 72◦C for 45 seconds followed by a single cycle of final extension at 
72◦C for 10 minutes. Only the primers targeting mtr II and gO genes were used for 
the second round. A 50µl reaction was carried out with 200µM of each dNTPs,  
1× PCR buffer (10mM Tris–HCl (pH - 8.3), 50mM KCl, 0.01% gelatin, 1.5mM 
MgCl2) and 2 units of Taq DNA polymerase. Twenty picomoles of each primer for 
gO gene and 10 picomoles for mtr II gene were used. From the first round 2 µl of 
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 the amplified product was used as template for the nested round. The profile was 
similar to the first round of amplification with 25 cycles. For each specimen separate 
negative controls (containing water with PCR reagents), positive control (DNA 
extracted from AD 169) and spiking reaction (for validation of true negatives by 
ruling out inhibitors) were set. The amplified products were analyzed by gel 
electrophoresis using 4% agarose gel (Sisco Research Laboratories, Mumbai, India) 
containing 0.5µg/ml of ethidium bromide (Sigma, USA) (Appendix II). The 
specificity and sensitivity of the PCR was determined as described in Appendix II.  
5.3.2 Application of multiplex PCR on retrospective clinical specimens and 
controls from healthy blood donors 
 The standardized multiplex PCR was applied on 25 retrospective peripheral 
blood specimens proven to be positive for mtr II region of HCMV and 25 peripheral 
blood specimens from healthy blood donors. 
5.3.3  Evaluation of the multiplex PCR by simultaneously applying it with pp65 
antigenemia assay on peripheral blood specimens obtained from            
immunocompromised patients 
5.3. 3.1 Study design: Prospective study 
5.3.3.2 Clinical specimens 
 Seventy peripheral blood specimens from seventy post-renal transplant 
recipients were included in the study.  
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 5.3.3.3 pp65 antigenemia assay and multiplex PCR 
 pp65 antigenemia assay and multiplex PCR for HCMV were performed as 
described in sections 3.3.3 and 5.3.1  respectively. The 70 peripheral blood 
specimens were classified arbitrarily into four groups based on the results of pp65 
antigenemia assay. Group 1 consisted of the patients who had a low pp65 
antigenemia levels (0–10 cells/2×105 peripheral blood leucocytes (PBLs). Group 2 
consisted of patients with moderate pp65 antigenemia levels (11–50 cells/2×105 
PBLs). Group 3 consisted of patients with high pp65 antigenemia levels (51–100 
cells/2×105 PBLs). Group 4 consisted of patients with very high pp65 antigenemia 
levels (>100 cells/2×105 PBLs). 
5.3.3.4 Analysis of results 
 The results of the pp65 antigenemia assay and multiplex PCR applied 
simultaneously on 70 peripheral blood specimens obtained from 70 post-renal 
transplant recipients were compared. The various patterns of amplification obtained 
by application of the multiplex PCR was grouped into one of the four categories of 
pp65 antigenemia values. Mann–Whitney test was used for the statistical analysis of 
the results of multiplex PCR with pp65 antigenemia assay. P values < 0.05 were 
considered significant. 
5.3.4 Standardization of Taqman probe based Real-time PCR assay for 
quantitation of HCMV 
 The sequences of the PCR primers and that of the probe used to quantify 
HCMV were selected from the mtr II region of HCMV. The sequences of the 
forward (CMV PKSF3) and reverse primers (CMV-PKR 11) were  
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 5’ - TTACGCGACCAGATTGCAAGA - 3’ and 5’ - TACCTACGTGACCTACCAACG - 3’, 
respectively. The Taqman probe used was 5’- (6FAM) - 
CTCCGCGTCACCTTTCATCGAGTAAA - (TAMRA)- 3’. PCR was performed 
with 25µl of HCMV primer probe mixture, containing each of the primers at a 
concentration of 30 pmol, 0.006 nmol Taqman probe, and 20µl of DNA in a total 
volume of 50µl. The PCR product was detected as an increase in fluorescence with 
the Rotor-Gene 3000 (Corbett Research, Australia). A plasmid containing the target 
sequence of 74bp was used as standard. A standard graph of the cycle threshold (CT) 
values obtained from serial dilutions (10–105 copies) of the plasmid was constructed 
for HCMV. The CT values from unknown samples were plotted on the standard 
curve, and the number of HCMV genome copies/ml was calculated with Rotor-Gene 
3000 Sequence detector (Corbett Research, Australia). 
5.3.4.1 Sensitivity, Linearity and Reproducibility of Real-time PCR 
 The sensitivity and linearity of the Real-time PCR was determined using the 
plasmid standards (1 to 105 corresponding to 2.5 x 102 to 2.5 x 107 copies) in a single 
run. The intra-assay (within run) and inter-assay (between runs) reproducibility were 
evaluated using triplicates of plasmid dilutions (101, 103 and 105) corresponding to 
an input of 2.5×103, 2.5×105 and 2.5×107 copies/ml per reaction in the same and four 
independent runs, respectively. 
5.3.5 Application of Real-time PCR on 50 peripheral blood controls from 
healthy blood donors 
 The Taqman-probe based real time PCR was applied on the DNA extracted 
from 50 peripheral blood controls from healthy blood donors. The pp65 antigenemia 
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 assay, qualitative PCR for mtrII, multiplex PCR as described in sections 3.3.3. 
4.3.4.3 and 5.3.1 respectively were also applied on these clinical specimens. 
5.3.6 Comparison of the results obtained with Taqman probe-based Real time    
PCR assay and multiplex PCR on different clinical specimens obtained 
from immunocompromised patients 
5.3.6.1 Study design: Prospective study 
5.3.6.2 Clinical specimens 
 Thirty one clinical specimens (peripheral blood – 23, urine – 3, 
nasopharyngeal aspirates – 3, bronchoalveolar lavage – 1, aqueous humor – 1) from 
29 immunocompromised patients belonging to post-renal transplant recipient, 
congenitally infected infants or HIV infected individuals were included in the study. 
The specimens were received at L & T Microbiology Research centre during the 
period April 2006 to June 2006. 
5.3.6.3 Multiplex PCR and Taqman probe-based Real time PCR 
 The multiplex PCR and Taqman probe-based Real time PCR were carried 
out as described in the sections 5.3.1 and 5.3.4 respectively. 
5.3.6.4 Analysis of the results 
 The results of the multiplex PCR applied on 31 clinical specimens obtained 
from 29 immunocompromised patients were compared with those of the real-time 
PCR independently to derive the cut-off value for the different amplification patterns 
of the multiplex PCR. Mann–Whitney test was used for the statistical analysis of the 
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 results of multiplex PCR with real-time PCR. The results were expressed as 
medians, and P values <0.05 were considered significant. 
5.3.7 Correlation of the results obtained with pp65 antigenemia assay and 
Taqman       probe-based Real time PCR assay 
5.3.7.1 Study design: Prospective study 
5.3.7.2 Clinical specimens 
 Twenty three peripheral blood specimens from 22 post-renal transplant 
recipients were included in the study. The specimens were received at L & T 
Microbiology Research centre during the period April 2006 to June 2006. 
5.3.7.3 pp65 antigenemia assay and Taqman probe-based real time PCR 
 pp65 antigenemia assay and the real-time PCR were carried out as described 
in the sections 3.3.3 and  5.3.4 respectively.  
5.3.7.4 Statistical analysis 
 Spearman rank order correlation was used to correlate antigenemia levels 
and viral loads determined by Real-time PCR. P values < 0.05 were considered 
significant. 
5.4 RESULTS 
5.4.1 Sensitivity and specificity of multiplex PCR 
 The multiplex PCR was specific for HCMV genome. The multiplex PCR 
was sensitive enough to detect 20fg of HCMV DNA.  
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 5.4.2 Application of multiplex PCR on 25 retrospective clinical specimens and 
25 controls 
 The multiplex PCR generated one of the four patterns when applied on 
retrospective peripheral blood specimens positive for mtr II region of HCMV. 
Pattern I generated all the three amplicons in the first round (n = 3); Pattern II 
generated a single amplicon in the first round (n = 2); Pattern III generated two 
amplicons in the nested round (n = 14) while Pattern IV generated a single amplicon 
in the nested round (n = 6). Figure 4a and 4b shows the patterns generated by the 
multiplex PCR. All the peripheral blood leucocytes obtained from the controls 
(seropositive healthy donors) remained negative by multiplex PCR.  
5.4.3. Results of comparison of the pp65 antigenemia levels and multiplex PCR 
applied on the 70 peripheral blood samples from 70 post-renal 
transplant recipients 
 Of the 70 peripheral blood specimens obtained from 70 post-renal transplant 
recipients, 60 were positive for pp65 antigenemia assay while an additional 4 were 
positive by the multiplex PCR. The comparative data showing the patterns of 
multiplex PCR amplification observed with that of the pp65 antigenemia levels in 
the patients is shown in Table 6. The proportion of the results belonging to the 
different patterns of the multiplex PCR varied in relation to the pp65 antigenemia 
values. With the pp65 antigenemia levels 0–10, 21/28 (75%) belonged to Pattern IV, 
between 11 and 50, 11/16 (68.75 %) belonged to Pattern III, between 51 and 100, 
10/14 (71.43%) showed Pattern II and >100, 9/12 (75%) showed Pattern I. As 
shown in Figure 5 the pp65 antigenemia levels in the specimens from which all the  
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 Figure  4: Agarose gel electrophoretogram showing the patterns obtained with 
the multiplex PCR applied on four different peripheral blood 
specimens 
  (a)        
 
 
 
 
 
(a) First round amplified products. Lanes:  N – Negative control; 1 – Positive 
for all three (mtr II, UL-83, gO) regions (Pattern I); 2 – Positive for a single 
region (UL-83) (Pattern II) ; 3 and 4 – Negative for all three regions; P – 
Positive control (CMV AD-169 strain), U – Unloaded well; MW – 100 bp 
ladder. 
 
 
 
(b) 
 
 
 
 
 
(b) Second round amplified products. Lanes: N2- Negative control (II round); 
N1 – Negative control ( I round); 1 – Positive for mtr II and gO in II round; 2 
– Positive for mtr II and gO in II round  ; 3 – Positive for mtr II and gO 
regions in II round only (Pattern III); 4- Positive for mtr II region in II round 
only ( Pattern IV); P – Positive control (CMV AD-169 strain); U – Unloaded 
well; MW –Hinf I digest of φX – 174 DNA   
 370 bp 
 
 168 bp  
N2   N1  1     2     3   4     P    U  MW 
N      1   2     3    4     P    U  MW 
 Table 6: Results of the comparison of pp65 antigenemia levels with the 
amplification patterns of multiplex PCR applied on 70 peripheral 
blood specimens obtained from 70 post-renal transplant recipients 
 
pp65 
antigenemia 
range 
 
No. of 
specimens 
Characteristic pattern of amplification in 
multiplex PCR 
Pattern I Pattern II Pattern III Pattern IV 
0 to 10 cells 28* - - 01 21 
11-50 cells 16 - - 11 05 
51- 100 cells 14 02 10 02 - 
> 100 cells 12 09 01 02 - 
 
 
 * six peripheral blood specimens were negative for both pp65 antigenemia assay and   
     multiplex PCR.  
  
Figure 5: Comparison of different patterns of multiplex PCR with pp65 
antigenemia levels/2×10
5
 PBLs in the 70 peripheral blood 
specimens 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The amplification pattern I in multiplex PCR where in all three regions were 
amplified showed significantly higher pp65 antigenemia levels than patterns IV and 
III where in one or two regions were positive (P≤0.0001, Mann–Whitney test). Bars 
show the median pp65 antigenemia level for each amplification pattern. 
 three regions were amplified were significantly different from those from which one 
or two regions were amplified (P≤0.0001, Mann–Whitney test). There was a 
statistically significant difference in the median pp65 antigenemia levels observed 
with different amplification patterns of multiplex PCR.  
5.4.4  Sensitivity, Linearity and Reproducibility of Real-time PCR 
 A single copy of the plasmid corresponding to 250 copies/ml of clinical 
specimen was detected regularly per reaction. The relationship between the CT and 
log10 plasmid copy numbers was linear over the range of 10
1–105 copies 
corresponding to 2.5×103 to 2.5×107 copies/ml (Figure 6). The intra-assay 
variability and inter-assay variability was expressed as coefficient of variation (CV, 
calculated as the standard deviation divided by the mean). The percentage of CV 
obtained for 101, 103, 105 copies (corresponding to 2.5×103, 2.5×105 and 2.5×107 
copies/ml) of plasmid in intra-assay variation testing were 6.7, 7.5 and 1.3%, 
respectively, and in inter-assay variation testing, the CV (%) were 8.7, 1.1 and 2.5%, 
respectively. Table 7 shows the results of the intra-assay and inter-assay variability. 
5.4.5  Results of the application of Real-time PCR on 50 peripheral blood 
controls from healthy blood donors 
 Of the 50 peripheral blood controls, 8 (16%) samples gave positive 
amplification signal. The viral load ascertained by Taqman probe based Real-time 
PCR for the eight samples were in the range of 3 to 836 copies/ml. Median viral load 
was 26.5 copies/ml. The pp65 antigenemia assay, qualitative PCR and multiplex 
PCR were negative in all the 50 controls.  
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 Figure 6: Amplification plot and Standard curve obtained with 
application of  Taqman probe based Real time PCR  
(a) 
         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(a) Amplification plot of five standards and two specimens for CMV real-
time PCR. Specimens are marked with arrow heads (     ). Standard  DNA 
corresponding to 2.5 x 107 to 2.5x 103 were amplified for 45 cycles.  
 
(b) 
 
 
 
 
 
 
 
 
 
 
 
 
(b) Standard curve for CMV real-time PCR. CT values were plotted against 
various numbers of copies of standard DNA. The blue spots indicate the 
standards and the red spots indicate clinical specimens. The correlation 
coefficient was 0.999. 
 
 Table 7: Results of intra and inter assay variability of Taqman probe based Real time PCR 
 
(a) Intra-assay variability (within run) 
 
Plasmid 
Copies* 
Copies/ml obtained (Replicates) 
Standard 
Deviation (SD) 
Mean 
Coefficient of 
variation (CV) 
CV (%) 
I II III 
101 2550 2627 2895 181.0976 2690.667 0.0673 6.7% 
103 25570 25720 29139 2018.656 26809.67 0.0753 7.5% 
105 25073050 25203210 25692710 326733.9 25322990 0.0129 1.3% 
* plasmid dilutions 101, 103 and 105corresponds to an input of 2.5×103, 2.5×105 and 2.5×107 copies/ml per reaction  
 
 
 
(b) Inter-assay variability (between runs)     
 
Plasmid 
Copies* 
Copies/ml obtained (Runs) Standard 
Deviation 
(SD) 
Mean 
Coefficient of 
variation (CV) 
CV (%) 
I II III IV 
101 2550 2379 2920 2573 226.8252 2605.5 0.0870 8.7% 
103 25570 25555 24975 25250 283.093 25337.5 0.01117 1.1% 
105 25073050 24397650 24087943 25429967 613502 24747153 0.0247 2.5% 
 
* plasmid dilutions 101, 103 and 105corresponds to an input of 2.5×103, 2.5×105 and 2.5×107 copies/ml per reaction   
 5.4.6  Results of the quantitative measure of viral DNA in clinical specimens by 
real-time PCR and calculation of cut-off value for different patterns 
observed with the multiplex PCR 
 Table 8 shows results obtained with the different patterns of multiplex PCR 
and the median number of viral copies/ml and median log10 copies/ml as determined 
by the real time PCR applied on 31 clinical specimens obtained from 29 
immunocompromised patients. The median log10 number of viral copies/ml differed 
significantly between each pattern (P < 0.01, Mann–Whitney test) (Figure 7). 
5.4.7.  Correlation of the pp65 antigenemia assay and real-time PCR applied to 
23 peripheral blood specimens obtained from 22 immunocompromised 
patients 
 Table 9 shows the detailed results of the pp65 antigenemia assay and real-
time PCR applied on 23 peripheral blood specimens obtained from 22 post renal 
transplant recipients. Figure 8 shows a moderate positive correlation (Spearman 
rank order correlation coefficient (rs) = 0. 7778; P < 0.001) between the increase in 
the pp65 antigenemia levels with that of the viral copy numbers/ml.  
5.5 DISCUSSION  
 Quantitation of HCMV plays an important role in identifying patients at high 
risk of developing disease and also for assessing the response to antiviral treatment. 
Post-organ transplant recipients and HIV-infected individuals are monitored 
routinely for HCMV load, as increasing levels of systemic HCMV loads precede 
end-organ disease in majority of these patients. Several quantitative competitive  
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 Table 8: Results of the comparison of the amplification patterns of multiplex 
PCR and viral load obtained with Real time PCR on 31 clinical 
specimens from 29 immunocompromised patients  
 
Characteristic pattern of 
amplification in 
multiplex PCR 
No. of
specimens 
Median Copy numbers/ml  
(median log10 copy numbers/ml)  
by Real-time PCR 
Pattern I 7 1.8x 107 (7.2553) 
Pattern II 6 4.65 x 106  (6.6674) 
Pattern III 8 8.95 x 10 4 (4.9499) 
Pattern IV 10 1.9x103 (3.2559) 
 
The median viral copies/ml present in the samples positive for all three targets 
(Pattern I and II) were significantly higher than those which were positive for one or 
two regions (Pattern III and IV) 
 
 
 Figure 7: Comparison of different patterns of multiplex PCR with HCMV 
DNA copy numbers obtained by performing real-time PCR on 31 
clinical specimens  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The amplification patterns I and II in multiplex PCR where in all three 
regions were amplified showed significantly higher HCMV DNA copy numbers 
than patterns IV and III where in one or two regions were positive (P < 0.01, Mann–
Whitney test). Bars show the median HCMV DNA copy number for each 
amplification pattern. 
 Table 9:   Results of pp65 antigenemia assay, and Real-time PCR performed on 
23 peripheral blood specimens from 22 post renal transplant 
recipients 
 
Sample no. pp65 antigenemia level / 
2x 10 
5 
PBLs 
Real time PCR (log10 
copies/ml ) 
1 129 7.5563* 
2 107 7.1761 
3 92 7.2553* 
4 72 6.6628 
5 34 4.9912 
6 41 5.9912 
7 37 5.2553 
8 15 3.3979 
9 20 4.1761 
10 27 5.9138 
11 12 2.9395 
12 2 4.9085 
13 84 5.7324 
14 31 3.8976 
15 50 5.4150 
16 30 3.6335 
17 125 7.2553 
18 25 3.1139 
19 70 6.6721 
20 105 4.8751 
21 30 2.8389 
22 15 3.7559 
23 22 4.2788 
        
* Peripheral blood sample collected from same patient at an interval of one week.    
 Figure 8: Correlation of pp65 antigenemia levels in PBLs with HCMV 
DNA copy numbers on the basis of the results of 23 clinical 
specimens positive by both antigenemia assay and real-time PCR  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 The HCMV DNA log10 copies/ml was plotted against the number of pp65-
positive cells detected by the antigenemia assay. The correlation between the 
HCMV DNA copy number and the pp65 antigenemia levels was examined by 
Spearman rank test and was found to be significant, with a correlation coefficient 
(rs) = 0. 7778 (P < 0.001). 
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 methods are available for quantitation by PCR to accurately and reproducibly 
determine the systemic and site-specific HCMV load, but they are technically 
difficult to carry out routinely in clinical laboratories, time consuming and require a 
good amount of expertise. In contrast, semi-quantitative method as described in the 
study is applicable more easily to laboratories in which PCR is regularly carried out. 
 The pp65 antigenemia assay has shown false-negative results due to a low-
level expression of the pp65 antigen in white blood cells in a small number of 
patients with definite HCMV disease (Piiparinen et al., 2002; Razonable et al., 
2002b; Seropian et al., 1998). The labour-intensive nature of the procedure, the 
requirement for immediate sample processing, and the subjective interpretation of 
slides place limitations on this assay as a routine diagnostic procedure (Boeckh and 
Boivin, 1998; Razonable et al., 2002b; Landry et al., 1995). In India, it is difficult to 
procure the monoclonals as they are not indigenous and needs to be imported which 
also make the assay a little expensive. PCR-based qualitative detection of HCMV 
DNA in blood samples provides 100% sensitivity for the diagnosis of HCMV 
disease, but the specificity is generally 50% or less (Nitsche et al., 1999; Shapiro et 
al., 2000; Weber et al., 1994). The NucliSens assay, which detects the presence of 
HCMV late mRNA pp67, has a lower sensitivity compared to DNA amplification 
and antigenemia assays for detection of HCMV (Razonable et al., 2002b). The 
commercial COBAS Amplicor CMV Monitor assay has been shown to have certain 
disadvantages, such as cost, narrow dynamic range and the time-consuming nature 
of the procedure that limits its use as a surveillance tool in high-risk populations 
(Razonable et al., 2002b; Yun et al., 2000). In India, Rao et al., 2000 successfully 
quantitated HCMV genome in peripheral blood specimens of post-renal transplant 
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 recipients in a longitudinal study (Rao et al., 2000). However, the method of 
quantitation employed was limiting dilution which involved the use of several 
replicates of PCR reaction for every specimen. This makes the procedure laborious. 
 There have been many studies describing the role of real-time PCR for 
monitoring HCMV infections in solid organ transplant recipients. The innate 
advantages of the technique include reliable quantitation of HCMV DNA for 
moderate and high viral load with precise information on viral load kinetics for 
evaluation of disease progression and antiviral response, the rapidity in thermal 
cycling and simultaneous detection of amplified products during amplification 
yielding test results within 3 hours, a high inter- and intra-assay reproducibility and 
high-throughput without significant risk of cross-contaminations. (Piiparinen et al., 
2004; Allice et al., 2006). 
 In this study the linearity of the real-time PCR was maintained between 101 
and 105 copies of the plasmid corresponding to 2.5 x 10 3 to 2.5 x 107 copies / ml. 
This characteristic bestowed the technique with accurate quantitation of high HCMV 
viral load without the need for diluting the clinical specimens. The total technique 
needed not more than 2 hours to be performed including extraction of DNA. The 
high degree of reproducibility of the real-time PCR was reflected by the CVs of 
inter- and intra-assay variations. Hence, the real-time PCR was chosen to provide 
the cut-off value for the multiplex PCR. 
 Numerous studies have investigated the correlation of HCMV load and 
symptomatic HCMV disease in immunocompromised patients by the pp65 
antigenemia assay and variety of quantitative PCR assays (Kalpoe et al., 2004; 
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 Ikewaki et al., 2003; Mazulli et al., 1999). Although, there is a consensus between 
laboratories on the cut-off value for pp65 antigenemia in different patient 
populations, a comparison of quantitative PCR assay results has been elusive due to 
marked differences in PCR methods and reporting of results.  
 The sensitivity of the quantitative PCR may be dependent on the viral target 
gene. The most appropriate region for amplification has not been established, as the 
sequence diversity among the clinical isolates needs further characterization. The 
multiplex PCR was developed with three different regions of HCMV DNA, since 
detection of a single target has a greater probability of giving a false negative result 
as proven by previous studies (Distefano et al., 2004; Wirgart et al., 1998). This 
approach served as an alternative to taking up replicate assay for the same gene 
fragment. It was hypothesized that the average amount of the HCMV DNA in those 
samples from which a single gene was amplified was significantly less than in those 
from which two or more regions were amplified. The hypothesis was made on the 
basis of observation in the previous study comparing the three different PCRs for 
mtr II, UL 83 and gO with pp65 antigenemia, that all the three regions became 
positive whenever the antigenemia value was high. The quantitative element of the 
multiplex PCR lies in the combination of the three regions with different 
sensitivities. The region of UL-83 was deliberately included as uniplex PCR for 
providing an intermediate sensitivity between the first round and second round of 
the other two nested PCRs. In the present study, the results of the pp65 antigenemia 
assay and the real time PCR correlated well with the multiplex PCR confirming the 
hypothesis. In agreement with other published data the pp65 antigenemia levels 
showed moderate correlations with the real-time PCR viral loads (Gault et al., 2001; 
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 Pang et al., 2003; Piiparinen et al., 2004; Allice et al., 2006). This was an absolute 
necessity to validate the results of the multiplex PCR as it was compared with both 
the tests individually. Nevertheless, inconsistencies between the results of 
antigenemia and Real time PCR was observed in at least two samples. Sample 12 
and sample 20 in Table 9 showed a lower antigenemia with high viral DNA load 
and higher antigenemia with lower viral DNA load respectively. Findings similar to 
the former have been documented in several studies (Ikewaki et al., 2003; Gault et 
al., 2001; Piiparinen et al., 2004). The clinical significance of such a finding is not 
yet established though such condition is observed more in patients at early stage of 
CMV disease (Ikewaki et al., 2003). However, the higher antigenemia with lower 
viral load as in sample 20 (Table 9) has not been observed in many studies, but 
intermittent rise in antigenemia levels during the first three weeks of antiviral 
treatment have been suggested owing to the phagocytosis of the degrading CMV 
matrix protein pp65 from lysed, infected leukocytes or from circulating CMV-
infected endothelial cells by PMNL (Boeckh and Boivin, 1998). Concurrent measure 
of viral load in such a condition has not been reported. Hence, it is assumed in the 
absence of any solid clinical data that the phase at which the clinical specimen is 
analyzed, may account for such discrepancies. 
 There was a statistically significant difference in the quantity of the viral 
DNA between the array of specimens, which was positive for all the three targets, 
and those that were positive for either one or two regions as analyzed by the real-
time PCR. The real-time PCR was based on the mtr II region of HCMV as the 
previous study showed that this region was most conserved and provided 100% 
sensitivity for detection of HCMV DNA in immunocompromised patients.  
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  The real – time PCR detected HCMV DNA circulating in healthy controls 
while the pp65 antigenemia and multiplex PCR were negative in this population. 
The median load (26.5 copies/ml) however was comparatively less than that 
observed in immunocompromised patient group. This is in agreement with previous 
studies (Nitsche et al., 2000; Machida et al., 2000). 
 The crude way of assessing the viral load by multiplex PCR may be of very 
little significance when analyzing single samples but may be useful when serial 
samples are used in conjunction with clinical data. The quantity of HCMV DNA in 
immunocompromised individuals who develop active infection can approximately 
be predicted by cohort of samples collected at regular time intervals. Such studies 
can aid in differentiating the individuals positive for HCMV genome who are at a 
higher risk of developing an end-organ disease and those who would have a milder 
form and to know the response of an individual to antiviral therapy. The concept of 
using the multiplex PCR both for increased sensitivity and for initial assessment of 
viral load may have a significant effect on the clinical application of PCR for the 
diagnosis of HCMV. 
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 6. ANALYSIS OF gB GENOTYPES OF HCMV IN 
DIFFERENT CLINICAL SPECIMENS OBTAINED 
FROM IMMUNOCOMPROMISED PATIENTS 
6.1 BACKGROUND 
 Glycoprotein B (gB) of the human cytomegalovirus (HCMV) plays an 
important role in virus infectivity. This protein is a major component of the virion 
envelope and is transported to the plasma membrane of infected cells. It has been 
shown that monoclonal antibodies to gB inhibit virus penetration into cells and 
block transmission of infectious virus from cell to cell (Navarro et al., 1993). 
Furthermore, anti-gB antibodies constitute up to 70% of the total serum neutralizing 
activity found in persons with past HCMV infection, indicating that gB is a major 
target for neutralizing antibodies (Britt et al., 1990; Utz et al., 1989). Common and 
strain-specific epitopes have been described (Meyer et al., 1992; Basgoz et al., 
1992). In addition, it has been shown that gB protein induces cytotoxic T cell 
responses (Riddell et al., 1991; Liu et al., 1993).  
 Human Cytomegalovirus (HCMV) strains display nucleotide polymorphisms 
in the gene encoding glycoprotein B.  There are four common genotypes (types 1–4) 
determined based on the region around the proteolytic cleavage site (Chou, 1990a; 
Chou and Dennison, 1991). Additional genotypes have also been described (Shepp 
et al., 1998). In addition, variability have also been identified in regions coding for 
the amino terminal and carboxy terminal (Meyer-Konig et al., 1998c). Presence of 
mixed gB genotypes in immunocompromised patients is associated with a higher 
viral load, higher prevalence of HCMV disease and concomitant infection with other 
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 herpesviruses such as Epstein-Barr virus (EBV) ( Coaquette et al., 2004).Genotyping 
of the gB gene of HCMV is carried out usually by amplification of the proteolytic 
cleavage site (gp UL 55) of the glycoprotein B gene followed by restriction fragment 
length polymorphism of the amplified product. Most of the genotyping studies have 
been carried on isolates of HCMV, using a uniplex PCR for the amplification of the 
gB gene followed by RFLP. There are studies emerging on the genotyping of 
HCMV on direct clinical specimens (Chou, 1990a; Barbi et al., 2001; Tarrago et al., 
2003; Carraro and Granato, 2003).  In India, only one study has been carried out for 
genotyping of gB, which utilized application of the uniplex PCR on direct clinical 
specimens followed by RFLP of the amplified product (Madhavan and Priya, 
2002b). The study suggested that the uniplex PCR was less sensitive and 50% of the 
clinical specimens known to be positive for HCMV could not be genotyped. The 
other methods employed for genotyping of gB gene include single-stranded 
conformation polymorphism, heteroduplex mobility analysis, direct DNA 
sequencing, multiplex PCR and DNA Enzyme Immuno assay.  
6.2 OBJECTIVES 
6.2.1  To standardize PCR-based RFLP for genotyping of gB gene of HCMV. 
6.2.2  To standardize multiplex PCR for genotyping of gB gene of HCMV. 
6.2.3   To evaluate the efficiency of PCR-based RFLP and multiplex nested PCR by 
simultaneously applying them on different clinical specimens for gB 
genotyping of HCMV strains.  
6.2.4 To study the distribution of gB genotypes in different clinical specimens by            
multiplex PCR. 
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 6.3 MATERIALS AND METHODS 
6.3.1 Standardization of nested PCR- based RFLP for genotyping of gB gene of 
HCMV 
6.3.1.1 Nested PCR for gB gene 
 A nested PCR was performed as described by Carraro and Granato, 2003. 
DNA from HCMV-AD169 strain was used for standardization of the PCR.  
A 50µl reaction mixture was prepared with 100µM of each dNTPs,  
10 picomoles of primers (gB1246 5’CGAAACGTGTCCGTCTT3’ and gB1724 
5’GAGTAGCAGCGTCCTGGCGA3’) 1 x buffer  (10mM Tris–HCl 127(pH 8.3), 
50mMKCl, 0.01% gelatin, 2.5mMMgCl2), 1 U of Taq DNA polymerase. Ten µl of 
DNA was used as the template. The thermal profile consisted of an initial 
denaturation at 95oC for 3 min followed by 30 cycles of denaturation at 94oC for  
45 seconds, annealing at 55oC for 30 seconds, and extension at 60 sec at 72oC for  
60 seconds in a thermal cycler. The second round of amplifications was  
carried out with conditions similar to the first round, with internal  
primers (gB1319 5’TGGAACTGGAACGTTTGGC3’ and gB1604 
5’GAAACGCGCGGCAATCGG3’). Two µl of the first round amplicon was used as 
the template for the second round of amplification. Amplicons were analyzed by 
electrophoresis on a 2% agarose gel incorporated with ethidium bromide  
(Appendix II). Sensitivity and specificity of the PCR was determined as described in 
Appendix II. 
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 6.3.1.2 Restriction fragment length polymorphism (PCR-RFLP) of gB products 
 Ten µl of unpurified second round amplicons were subjected to digestion 
with HinfI and RsaI (Fermentas Inc., USA) in two separate reactions of 25 µl 
volume. The amount of enzyme, buffer composition and temperature for incubation 
are provided in Appendix II.  A control reaction containing the amplicon and buffer 
was included during each digestion. Digested fragments were analyzed after 
electrophoresis on 4% agarose gels incorporated with ethidium bromide  
(Appendix II).  
6.3.1.3 Application of nested PCR based RFLP on clinical specimens 
 The standardized nested PCR based RFLP was performed on DNA extracted 
from 46 clinical specimens from 37 patients with HCMV infections proven by 
nested PCR for mtrII region of HCMV. The 46 clinical specimens included 25 
blood, 18 urine, 1 bronchoalveolar lavage and 2 nasopharyngeal aspirate.  
6.3.2  Conversion of nested PCR-based RFLP to seminested PCR-based RFLP 
based on the results obtained with nested PCR- based RFLP of gB gene 
(section 6.4.1.3). 
6.3.2.1 Analysis of lack of amplification signal in 18 clinical specimens by 
multiple sequence alignment 
 The prototype sequences of the gB subtypes and HCMV AD169 (GenBank 
accession number: X17403) were aligned with the primer sequences used for the 
amplification to determine the reason for the failure of the amplification signals and 
total absence of gB3 genotype that existed in Chennai during 2002 ( Madhavan and 
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 Priya., 2002b) (section 6.4.1.3). The gB subtypes gB1 (GenBank accession numbers: 
M60927 and M60929); gB2 (GenBank accession numbers: M60931 and M60932); 
gB3 (GenBank accession numbers: M60933 and M60934); gB4 (GenBank 
accession numbers: M60924 and M60926) were aligned with individual primer 
sequences using the Clustal X program.  
6.3.2.2 Protocol for semi-nested PCR-based RFLP for gB gene 
 The nested PCR was converted to semi-nested PCR by excluding the outer 
forward primer (gB 1246). The first round of amplification was carried out with 10 
picomoles of the forward and reverse primers gB 1319 and gB 1724 maintaining the 
other reaction mixture components as for the nested PCR for gB gene (section 
6.3.1). The thermal profile consisted 30 cycles of 45 seconds at 94oC, 45 seconds at 
55oC and 60 seconds at 72oC. The second round of amplification was carried out 
with 10 picomoles of gB1319 and gB 1604 primers with reaction mixture similar to 
the first round. Two µl of the first round amplicon was used as the template for the 
second round. The reaction mixture was subjected to 20 cycles of amplification with 
thermal profile of first round. Sensitivity and specificity of the PCR was determined 
as described in Appendix II. The RFLP protocol was not modified (section 6.3.1.2). 
6.3.2.3 Application of seminested PCR based RFLP for genotyping of gB gene of 
HCMV on the 46 clinical specimens 
 The semi-nested PCR-based RFLP for gB gene of HCMV was applied 
retrospectively on the 46 clinical specimens from 37 patients. The details of the 
clinical specimen are provided in section 6.3.1.3. 
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 6.3.3 Standardization of multiplex nested PCR for genotyping of gB gene of 
HCMV 
 A multiplex nested PCR was standardized for genotyping of gB gene of 
HCMV using DNA from HCMV AD-169 strain. A common pair of primers was 
used to amplify consensus of all the genotypes in the first round followed by a 
genotype specific amplification in the second round (Tarrago et al., 2003).  
The primer sequences and the size of the amplicon generated by each of the 
genotypes are provided in Table 10. For amplification, a 50µl reaction mixture was 
prepared with 100µM of each dNTPs, 10 picomoles each of CMVQ1+ and 
CMVQ1- primers, 1 x buffer (10mM Tris–HCl 127(pH 8.3), 50mMKCl, 0.01% 
gelatin, 2.5mM MgCl2), 1U of Taq DNA polymerase. Five µl of DNA was used as 
the template. The thermal profile consisted of an initial denaturation of 94°C for  
2 minutes, followed by 35 cycles of 94°C for 30 seconds, 60°C for 1 minute, and 
72°C for 30 seconds and final extension step at 72°C for 5 minutes. The second 
round of amplifications was carried out with reaction mixture containing 200µM of 
each dNTPs, 10 picomoles of each inner primer (CMV GT1+, CMV GT2+, CMV 
GT3+, CMV GT4+, CMV GT5+ and CMV Q2-), 1x buffer (10mM Tris–HCl  
(pH 8.3), 50mMKCl, 0.01% gelatin, 2.5mM MgCl2), 1U of Taq DNA polymerase in 
a final volume of 50µl.  One µl of the first round amplicon was used as the template 
for the second round. The second round was carried out under conditions identical to 
those used in the first round except the annealing temperature was 58°C instead of 
60°C. Amplicons were analyzed by electrophoresis on a 3% agarose gel 
incorporated  with ethidium bromide (Appendix II). Sensitivity and specificity of the 
PCR was determined as described in Appendix II. 
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 Table 10:  Primer sequences of multiplex nested PCR for gB gene of HCMV 
 
Primers Primer sequences 
Amplicon 
size 
FIRST ROUND 
Forward CMV Q1+ 5’ TTT  GGA  GAA AAC  GCC  GAC3’                    
751 bp 
Reverse CMV Q1- 5’CGC GCG GCA ATC GGT TTG TTG TA3’ 
SECOND ROUND 
Forward primers 
CMV GT1+ (gB1) 5’ ATG ACC GCC ACT TTC TTA TC 3’                              420 bp 
CMV GT2+ (gB2) 5’ TTC CGA CTT TGGA AGA CCC AAC 3’                        613 bp 
CMV GT 3+ (gB3) 5’TAG CTC CGG TGT GAA CTC C 3’                                190 bp 
CMV GT 4+ (gB4) 5’ ACC ATT CGT TCC GAA GCC GAG GAG TCA 3’           465 bp 
CMV GT 5+ (gB5) 5’ TAC CCT ATC GCT GGA GAA C 3’                               139 bp 
Common 
reverse primer 
CMV Q2- 
 
5’ GTT GAT CCA CAC ACC AGG C 3’ 
 
 
 
The genotypes are specified within brackets ( ). 
 6.3.4 Evaluation of the efficiency of semi-nested PCR based RFLP and 
multiplex nested PCR by simultaneously applying them on different clinical 
specimens for gB genotyping of HCMV strains  
6.3.4.1 Clinical specimens 
 Seventy clinical specimens [40 blood, 23 urine, 3 nasopharyngeal aspirates, 1 
tracheal aspirate, 2 bronchoalveolar lavage and 1 gastric wash] from 51 patients 
were included in the study. Presence of HCMV was proven in these patients by 
nested PCR for mtr II region. Single samples were tested from 38 patients while two 
or more samples of either similar or different types of clinical specimens were tested 
from 13 patients. 
6.3.4.2 Semi-nested PCR-based RFLP and multiplex PCR for gB gene of HCMV  
 The semi-nested PCR-based RFLP and multiplex PCR for gB gene were 
performed as described in sections 6.3.2.2 and 6.3.3 respectively. The methods were 
compared based on the results of genotyping, time taken and expenditure incurred 
for their performance. 
6.3.5 Validation of mixed genotypes by DNA sequencing 
 Second round amplicons obtained by semi-nested PCR on three blood 
specimen that gave mixed genotypes each of gB1+gB3; gB1+gB2; gB1+gB2+gB3 
by multiplex PCR were subjected to DNA sequencing. The DNA sequencing was 
performed as described in Appendix II.  
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 6.3.6 A study on the distribution of gB genotypes in different clinical 
specimens from immunocompromised patients by multiplex PCR 
6.3.6.1 Clinical specimens and patients 
 Two hundred and eighty four clinical specimens from 239 
immunocompromised patients were included in the study. Only those clinical 
specimens which showed positivity for HCMV by nested PCR for mtrII were 
included. Two hundred single specimens (Peripheral blood – 156; Urine – 22; 
Respiratory fluids– 18; intraocular fluids - 4) were obtained from 200 patients (Post 
renal transplant (PRT) – 156; Infants – 28; HIV infected individuals (HIV) – 11 and 
Bone marrow transplant (BMT) – 5). Pairs of similar or different clinical specimens 
accounting to 72 clinical specimens were obtained from 36 patients (PRT – 23 (Pairs 
of blood and urine from 20 patients; a pair of blood samples, blood and gastric wash; 
and blood and respiratory fluid from one patient each); Infants – 3 (2 pairs of blood 
and urine and 1 pair of urine and respiratory fluid); HIV infected individuals– 9  
(9 pairs of blood and intraocular fluid) and BMT – 1 (a pair of urine and respiratory 
fluid). Four samples of clinical specimens were obtained from 3 PRTs (Two pairs of 
blood and urine from two patients, one sample of blood and three samples of urine 
from one patient). 
6.3.6.2 Application of multiplex PCR for gB gene 
 The multiplex PCR for gB gene was applied on the extracted DNA of 
clinical specimens as described in section 6.3.3. 
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 6.3.6.3 Analysis of results 
 The distribution of the genotypes was analyzed for each patient population 
irrespective of the type of specimens. The results of the patients from whom single 
specimens were obtained and those patients whose multiple specimens showed 
concordant results were analyzed together. Those patients who had a discordant 
result with multiple clinical specimens were analyzed separately. The results were 
statistically analyzed by Chi-square test and was considered significant  
when P value <0.05. 
6.4 RESULTS 
6.4.1 Results obtained with nested PCR-based RFLP of gB gene of HCMV 
6.4.1.1 Specificity and sensitivity of nested PCR for gB gene of HCMV 
 The first round yielded a product of 477 bp with HCMV AD-169. A 302 bp 
product was obtained in the second round. The nested PCR was specific for gB gene 
of HCMV and sensitive to detect 0.5 pg of HCMV DNA. 
6.4.1.2 RFLP pattern of AD-169 
 The second round amplified products of AD-169 strain gave restriction 
fragments of 202bp and 100 bp with Hinf I enzyme and 239 and 63 bp with Rsa I 
enzyme. 
6.4.1.3 Results of the application of nested PCR-based RFLP on 46 clinical 
specimens from 37 patients 
 Of the 46 clinical specimens tested by the nested PCR-based RFLP, the 
genotyping results were available for 28 clinical specimens from 24 patients. Of 
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 these 18 were genotyped as gB1 and 10 as gB2. Eighteen other clinical specimens 
from 13 patients could not be genotyped due to lack of amplification signal. Figure 
9 shows amplified products obtained by application of nested PCR for gB gene of 
HCMV on clinical specimens. 
6.4.2 Results of multiple sequence alignment of prototype sequences with gB 
primers 
 The outer forward primer showed mismatches at three sites with that of the 
gB3 prototype sequences (Figure 10). It was hypothesized that these mismatches 
were the reason for the lack of amplification signal in the 18 clinical samples. 
6.4.3 Specificity and sensitivity of the semi-nested PCR for gB gene 
 The first round yielded a product of 406bp with HCMV AD-169. A 302 bp 
product was obtained in the second round. The seminested PCR was specific for gB 
gene of HCMV and sensitive to detect 0.5 pg of HCMV DNA. 
6.4.4. Results of the application of seminested PCR-based RFLP on 46 clinical 
specimens from 37 patients 
 Of the 46 clinical specimens tested by the semi-nested PCR-based RFLP, the 
genotyping results were available for all the 46 clinical specimens from 37 patients. 
Of these 18 were genotyped as gB1 and 10 as gB2. Eighteen other clinical 
specimens from 13 patients which could not be genotyped by the nested PCR for gB 
gene was genotyped as gB3 by seminested PCR – based RFLP. gB4 genotype was 
not observed in the study. Similar genotypes were shed by patients in different 
samples. Table 11a and 11b shows the various RFLP fragments (expected pattern) 
generated by Hinf I & Rsa I in different CMV gB genotypes.  
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 Figure 9: Agarose gel electrophoretogram showing the amplified products  
of nested PCR for gB gene applied on clinical specimens 
 
 
 
 
 
 
Lanes : N2 – Negative control (II round) ; N1 - Negative control ( I round); 
1,4 - Blood positive for gB gene; 2, 3 - Blood negative for gB gene;  5, 8 - Urine 
positive for gB gene; 6,7 - Urine negative for gB gene; P - Positive control (AD 
169); MW - 100 bp ladder   
 
N2 N1    1     2      3     4      5      6     7     8     P  MW 
299 – 305 bp 
 Figure 10 : Multiple sequence alignment of eight sequences of different 
prototype HCMV strains (gB1–gB4) with the HCMV AD 169 
strain (GenBank accession number: X17403; gB2 subtype) and 
the forward outer primer (gB 1246) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Identities at nucleotide positions are shown by dashes. The region of the 
forward outer primer (gB 1246) is shown in the box. Asterisk (*) indicates 
mismatches with respect to the HCMV AD 169 strain and symbol (ˆ) indicates a 
primer–target mismatch seen in all genotypes. 
 
 
 
 Table 11:  Expected sizes of the RFLP fragments generated by (a) Hinf I 
and   (b) Rsa I on the amplicons of gB gene of HCMV by semi-
nested PCR based  RFLP 
 
 
(a) Hinf I 
gB1 gB2 gB3 gB4 
202bp 
67 bp 
36bp 
202bp 
100bp 
 
 
202bp 
97 bp 
 
 
202bp 
67 bp 
36bp 
 
 
(b) Rsa I 
gB1 gB2 gB3 gB4 
239bp 
66 bp 
 
239bp 
63bp 
 
 
195bp 
63 bp 
41 bp 
 
195bp 
66 bp 
44 bp 
 
 6.4.5 Specificity and sensitivity of multiplex PCR for genotyping of gB gene of 
HCMV 
 The multiplex nested PCR generated a 751 bp product in the first round and 
613 bp product corresponding to genotype gB2 for HCMV AD169 in the second 
round. The multiplex nested PCR for gB genotyping was specific for HCMV and 
sensitive enough to pick up 50fg of AD169 DNA. 
6.4.6 Results of comparison of seminested PCR-based RFLP and multiplex 
PCR  
6.4.6.1 Results of application of semi-nested PCR based RFLP and multiplex 
nested PCR for gB gene on 70 clinical specimens from 51 patients 
 Of the 70 clinical specimens included in the study (Table 12), all were 
genotyped by multiplex nested PCR while 5 clinical specimens could not be typed 
by PCR-based RFLP for gB gene due to lack of amplification signal. Of the 65 
clinical specimens typed by both the methods, concordant results were obtained in 
41 (15 - gB1,11- gB2 and 15 gB3). Of the 24 clinical specimens in which discordant 
results were obtained mixed infection with multiple genotypes were detected by 
multiplex nested PCR (gB 1 + gB3 - 21; gB1 + gB2 – 2 ; gB1 +gB2 + gB3 – 1)  
where as only single genotypes were identified by PCR- based RFLP ( gB1 – 10; 
gB2 – 2; gB3 - 12). The genotypes of the 5 clinical specimens, which could not be 
typed by PCR-based RFLP, showed a distribution of gB1 in 4 and gB1+gB2 in one. 
gB4, gB5 genotypes and other mixed genotypes were not found in any clinical 
specimen by both the methods. Figures 11 and 12 shows the results obtained by 
application of PCR-based RFLP and multiplex PCR for gB gene on clinical 
specimens respectively.   
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 Table 12:  Results of PCR- based RFLP and Multiplex nested PCR 
for gB       genotyping of 70 clinical specimens obtained from 51 
HCMV infected       patients 
 
 
Clinical 
Specimens 
Method Of Genotyping 
PCR - RFLP Multiplex Nested PCR 
gB1 gB2 gB3 
Single genotypes Multiple genotypes 
gB1 gB2 gB3 
gB1+ 
gB 3 
gB1+ 
gB2 
gB1+gB2
+ gB3 
Blood Leucocytes 
(40)  
14 9 16 8* 8 9 13    1 1 
Urine  (23)  9 3 8 9** 2 5 5   2 *** - 
Nasopharyngeal 
aspirate (03)  
- - 2 1**** - 1 1    - - 
Broncho alveolar 
lavage (02) 
- 1 1 - 1 - 1    - - 
Tracheal aspirate 
(01) 
1 - - 1 - - -    - - 
Gastric wash (01) 1 - - - - - 1    - - 
TOTAL  (70) ***** 25 13 27 19 11 15 21   3 1 
 
 
*         One of the blood specimen genotyped as gB1 by multiplex nested PCR could 
not be genotyped  by PCR-based RFLP. 
 
**
         Two urine specimens genotyped as gB1 by multiplex nested PCR could not 
be genotyped by PCR-based  RFLP. 
 
***          One of the urine specimen genotyped as mixed infection of gB1 and gB2 by 
multiplex nested PCR could not be genotyped by PCR-based RFLP. 
 
****     One of the Nasopharyngeal aspirate genotyped as gB1 by multiplex nested 
PCR  could not be genotyped  by PCR-based RFLP. 
 
*****    Five clinical specimens could not be genotyped by PCR-based RFLP. 
 Figure 11: Agarose gel electrophoretogram showing the restriction 
fragments obtained by semi-nested PCR based RFLP of gB gene 
of HCMV 
 
(a) 
 
 
 
 
 
 (b)   
 
 
 
 
 
(a) Rsa I enzyme (b) Hinf I enzyme.  Lanes :Un – Undigested  product ; 1 – 
Blood  CMV genotype gB1; 2 – Urine   CMV genotype  gB2; 3 – 
Nasopharyngeal aspirate  CMV genotype gB3 ; 4* - Blood CMV genotype 
gB3  (determined as gB1 + gB3 by multiplex PCR); 5#- Blood CMV 
genotype gB2  (determined as gB1 + gB2 by multiplex PCR) ; 6^- Blood 
CMV genotype gB1 (determined as gB1 + gB2 +gB3 by multiplex PCR);   
PC  –  CMV  AD-169 ( genotype gB 2);  U – Unloaded well ; MW – Hinf I 
digest of φX 174 DNA 
 
Un     1       2       3       4*      5#    6^     P     U   MW 
302 bp 
202 bp 
 
100/97bp 
67 bp 
36 bp 
 
302 bp 
239 bp 
195 bp 
 
63/66 bp 
41 bp  
Un     1     2     3       4*     5#    6^      P     U  MW 
  
 
 
Figure 12: Agarose gel electrophoretogram showing the results of 
genotyping of gB gene of HCMV by multiplex PCR 
 
 
 
 
 
 
 
Lanes: N2- Negative control (II round); N1- Negative control (I round); 1 – 
Blood CMV genotype gB1; 2 – Urine   CMV genotype gB2; 3 – Nasopharyngeal 
aspirate CMV genotype gB3; 4* - Blood CMV mixed genotype gB1 + gB3 
(determined as gB3 by PCR-RFLP); 5#- Blood CMV mixed genotype gB1 + gB2 
(determined as gB2 by PCR-RFLP); 6^- Blood CMV mixed genotype 
gB1+gB2+gB3  (determined as gB1 by PCR-RFLP) ; PC  –  CMV  AD-169 
(genotype gB 2); U – Unloaded well; MW – Hinf I digest of φX 174 DNA 
N2      N1      1        2        3       4*      5#       6^      P        U   MW 
613 bp 
420bp 
 
190bp 
 6.4.6.2 Comparison of the time taken and expenditure incurred in performing  
genotyping by multiplex PCR and PCR based RFLP for gB gene of HCMV 
 The time taken for performing multiplex PCR and semi-nested PCR-based 
RFLP were 5 hours and 10 hours respectively. The total cost of the reagents and 
other consumables incurred for performing the study of 70 samples along with 
respective controls by multiplex nested PCR was Rs.3400.00 as against Rs. 5990.00 
for PCR-based RFLP (US$=About RS 42.0). The cost calculated did not include the 
expenditure incurred on extraction of DNA from clinical specimens, labour, 
establishment and maintenance costs. There was a 43.24 % decrease in the 
expenditure incurred when multiplex nested PCR was performed instead of PCR-
based RFLP. 
6.4.7 Results of the DNA sequencing of the three amplicons that showed mixed 
genotype by multiplex PCR for gB gene 
 Figures 13 a, b, c show the results of DNA sequencing of the amplicons 
obtained by semi-nested PCR on blood specimens that gave gB 1+3, gB 1+2, 
gB1+2+3 genotypes by multiplex nested PCR. The DNA sequences revealed mixed 
bases spanning gB gene. The mixed bases at and around the Rsa I recognition site in 
the gB gene of HCMV is depicted in Figure 13a (This differentiates gB1 from gB3 
genotype). The sequence around the Hinf I recognition site lacked clarity owing to 
the frame shifts due to deletions before Hinf I recognition site in the gB sequence. 
Hence, gB1 and gB2 in case of amplicons with genotypes gB1+gB2 and gB1+2+3 
could not be differentiated by sequences at the Hinf I recognition site. The other 
regions of the gB gene carrying the variations are depicted to identify the gB1+gB2 
(Figure 13b) and gB1+2+3 (Figure 13c). The results confirm the presence of mixed  
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 (b) The bars (–) show mixed 
bases of gB1 and gB2 
genotypes. Multiple sequence 
alignment with consensus is 
also shown.  
Figure 13: Results of DNA sequencing of amplicons obtained 
by semi-nested PCR for gB gene for validation of mixed 
genotypes obtained with multiplex PCR 
(a) gB 1 + gB 3 
 
 
 
 
 
 
 
(b) gB1+gB2 
 
 
 
 
 
 
 
(c) gB1+gB2+gB3 
 
 
 
 
 
 
 
 
 
(a) The box shows the 
recognition site of Rsa I
enzyme that differentiates gB3 
from gB1. The arrow shows the 
mixed bases (C and T) at the 
recognition site of  Rsa I.  
The bars ( - ) show other 
mixed bases distributed near 
the recognition site of Rsa I
enzyme in the gB gene. 
Multiple sequence alignment 
with consensus is also shown. (c) The arrow, bars (-) and 
asterisk (*) indicate the bases 
that differentiates gB2; gB3 
and gB1 from rest two 
genotypes respectively. 
Multiple sequence alignment 
with consensus is also shown. 
 
 genotypes in the clinical specimens. Multiple sequence alignment of relevant 
genotypes is also shown (Figure 13). 
6.4.8 Results of the study on the distribution of gB genotypes in different 
clinical specimens from immunocompromised patients by multiplex PCR 
6.4.8.1 Patientwise distribution of gB genotypes 
 Genotyping results for the gB gene was available for 220 (92.1%) of 239 
patients analyzed. The 220 patients consisted of 164 PRTs, 30 infants, 20 HIV 
infected individuals and 6 BMT. Discordances between multiple clinical specimens 
were observed in 11 patients (8 PRTs and 3 HIV infected individuals). The 
distribution of gB genotypes were analyzed in 209 patients (156 PRTs, 17 HIV 
infected individuals, 30 infants and 6 BMTs). Table 13 shows the distribution of gB 
genotypes in different patient population. gB4 and gB5 genotypes were not observed 
in the study. Single genotypes were observed in 141 (67.5%) and mixed genotypes 
were observed in 68 (32.5%) of 209 patients. Among the single genotypes a 
predominance of gB1 (51.8%) was seen irrespective of the nature of patients. This 
result was statistically significant (P<0.0001, Chi- square test). When the 
distribution was studied as individual genotypes which comprised of gB1, gB2, gB3 
and gB mix, frequency of gB mix in PRT was 38.5% and in BMT was 50%. No 
mixed gB genotypes was found in the infant group (P<0.001). There was a 
predominance of males in the study population. There was no difference between the 
distribution of gB genotypes between males (n = 141) and females (n = 68) in the 
209 patients.  
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 Table 13: Distribution of gB genotypes in different patient groups 
 
Genotypes 
Patient groups 
Total 
PRT HIV Infants BMT 
gB1 51 3 16 3 73 
gB2 20 6 5 0 31 
gB3 25 3 9 0 37 
gBmix 60 5 0* 3 68 
Total 156 17 30 6 209 
 
 
* The absence of mixed genotype in the infant group was statistically significant. 
   (P<0.001, Chi square test). 
 6.4.8.2 Discordance in gB genotypes between multiple clinical specimens 
 Figure 14 summarizes the results of the discordance observed with gB 
genotypes in multiple clinical specimens. Discordances between multiple clinical 
specimens were observed in 11 patients (8 PRTs and 3 HIV infected individuals). Of 
the 8 PRTs, a pair of blood and urine was collected from 6 patients; a pair of blood 
specimens from one and three samples of urine and one blood from one patient. Of 
the six pairs of blood and urine collected, genotyping results were available in the 
urine component only for 2 (one each of gB1 and gB3) ; Out of the rest 4 PRTs, 
mixed genotypes were seen in 3 urine with single genotypes in the blood component 
and vice-versa in 1 patient. Of the two blood samples collected from the PRT, the 
second sample alone revealed the genotype gB2 and first sample was negative. The 
genotyping results on 3 urine and one blood sample collected from a single patient 
revealed mixed genotypes in first three samples (two urine and one blood specimen) 
while a single genotype in the fourth (urine)sample. Of the three blood and 
intraocular fluids from 3 HIV patients all the three revealed mixed genotype in the 
blood while a single genotype in the intraocular fluid. The strain other than gB1 
present in the blood (gB2 or gB3) was encountered in the intraocular fluid.  
6.4.8.3 Specimenwise distribution of gB genotypes 
 Results of gB genotypes irrespective of the patient group was available for 
261 specimens (Blood- 174, Urine- 52, Respiratory fluids – 21, intraocular fluids – 
13 and gastric wash -1). Table 14 shows the distribution of gB genotypes in 
different clinical specimens. Compared to other clinical specimens, a higher 
frequency of mixed genotype and gB2 were observed in blood and intraocular fluids 
respectively (P<0.05, Chi – square test).   
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 Figure 14: Flow chart showing the discordant results observed with gB 
genotypes in multiple clinical specimens from 11 patients  
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 Table 14: Distribution of gB genotypes of HCMV in different clinical specimens 
 
 
Genotypes 
Clinical specimens 
 
Total 
Blood Urine Respiratory 
fluids 
Intraocular 
fluid*** 
Gastric 
wash 
gB1 52 17 11 2 0 82 
gB2 26 6 4 6** 0 42 
gB3 25 13 3 4 0 45 
gBmix 71* 16 3 1 1 92 
 
Total 
 
174 
 
52 
 
21 
 
13 
 
1 
 
261 
 
 
*       Frequency of gB mix higher in peripheral blood  
**        Frequency of gB2 higher in intraocular fluids 
        (P<0.05, Chi – square test). 
*** All the intraocular fluids were obtained from HIV infected individuals 
 
  
6.5 DISCUSSION 
 Glycoprotein B is considered as a major viral glycoprotein playing a role in 
initiating strong immune response in humans. A correlation between gB genotype 
and CMV-associated disease in immunocompromised patients has long been sought 
for, but no convincing evidence has been found. The present study was carried out to 
analyze the distribution of gB genotypes in clinical specimens obtained from 
immunocompromised patients in Chennai region, India. There is only one study 
available on gB genotypes in India wherein, a uniplex PCR-based RFLP was 
employed on direct clinical specimens for genotyping (Madhavan and Priya, 2002b). 
Since, the sensitivity of the technique was low owing to the uniplex nature of 
amplification, initial attempt was made to perform the genotyping by an already 
existing nested PCR for gB gene (Carraro and Granato, 2003) followed by RFLP in 
the present study. The result of the nested PCR for gB gene showed no significant 
increase in the sensitivity with only 60.87% of clinical specimens being genotyped 
as opposed to 50% by uniplex PCR. A sudden absence of gB3 genotype which 
existed during the year 2002 was also observed in the results of genotyping with 
nested PCR based RFLP. To analyze the controversy, multiple sequence alignment 
of the primer sequences were performed with the prototype sequences of gB1 to gB4 
genotypes procured from Genbank database. The results indicated primer target 
mismatches in the outer forward primer with respect to gB3 genotype. It was 
hypothesized that this mismatch was responsible for the lack of amplification from 
clinical specimens. Hence, the nested PCR was converted to semi-nested PCR by 
excluding the outer forward primer. The results of application of the semi-nested 
PCR on the 46 clinical specimens proved the hypothesis since, all the clinical 
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 specimens that did not give an amplification signal with nested PCR for gB gene 
belonged to gB3 genotype. The study also indicated that the sequence variations in 
the gB genome of HCMV may complicate genotyping of HCMV. Confirmation of 
primer specificity by the BLAST program may not suffice for the genotyping 
studies. Complete alignment of the prototype sequences of all the genotypes that 
exist for the gene of interest by a multiple sequence alignment program with the 
primers used for amplification may be necessary for genotyping of HCMV. Errors in 
the published primer sequences with respect to several genes of HCMV have already 
been reported (Habbal et al., 2005).  
 The next study was undertaken to compare the efficiency of the semi-nested 
PCR based RFLP and multiplex PCR for genotyping of gB gene of HCMV. Though 
various nucleic acid based molecular methods are available for genotyping of 
HCMV, PCR-based RFLP and multiplex nested PCR were chosen in the study due 
to lower technical complexity and cost effectiveness. In this study, the multiplex 
nested PCR showed a higher efficiency in genotyping HCMV compared to the 
conventional PCR-based RFLP. There was no significant difference in the positivity 
rate of the multiplex nested PCR and semi nested PCR for gB gene. The positivity 
rates were 100 % and 92.8 % for multiplex nested PCR and semi-nested PCR 
respectively. Mixed infection with multiple genotypes was effectively picked up by 
the multiplex nested PCR compared to PCR –based RFLP. A similar pattern was 
observed in a study on serotyping of subgenus C Adenoviruses (Adhikary et al., 
2004). The presence of mixed genotype in the clinical specimens was confirmed by 
DNA sequencing. The inability of the PCR- based RFLP to identify multiple 
infections by mixed genotypes may be attributed to the selective amplification of the 
strain predominant in the clinical specimen and hence the generation of the 
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 restriction pattern respective to that strain. The PCR-based RFLP proved to be 
expensive than the multiplex nested PCR owing to the digestion step, which 
required two restriction enzymes and use of an additional agarose gel electrophoresis 
to view the digested products. The cost of the four extra primers used in the second 
round of the multiplex nested PCR was negligible as they were used in very low 
concentrations. The study showed that the multiplex nested PCR for gB gene is 
more advantageous than the commonly employed PCR based RFLP since the former 
method allowed easier detection of mixed infections with multiple gB genotypes in 
clinical specimens. It was a single step reaction devoid of the restriction digestion 
step, simple, easy to perform and less expensive than the PCR based RFLP and 
required 5 hours for completion of the test as opposed to 10 hours in case of the 
PCR based RFLP. Hence, the multiplex PCR was employed to determine the 
distribution of gB genotypes from different patient groups.  
 In the study determining the distribution of gB genotypes by multiplex PCR, 
the results of the genotype with disease outcome could not be correlated, since, the 
clinical details of the patients were not available. There was no difference in the 
distribution of gB genotypes with regard to gender in this study, though the previous 
study on gB genotypes suggested that gB3 was predominant in females and gB2 in 
males (Madhavan and Priya, 2002b). The study in 2002 on genotyping of gB gene of 
HCMV using the uniplex PCR based RFLP revealed absence of gB1 and gB4 in the 
study population. In contrary, the result of the present study saw a predominance of 
gB1 genotype followed by gB3 and gB2 in the study population irrespective of the 
patient group. The result is in agreement with reports from other countries 
(Xanthakos and Schleiss, 2003; Yu et al., 2006 ; Wu et al., 2005; Humar et al., 2003; 
Barbi et al., 2001;Bale et al., 2000).  Other findings of the present study included 
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 absence of gB4 and gB5 in the study population and gB mix in the infant group. The 
absence of gB mix genotype in the infants was in agreement to recent studies 
(Yamamoto et al., 2007; Jin et al., 2007; Xanthakos and Schleiss, 2003). Yu et al 
(2006) reported mixed genotypes in congenitally infected infants (10.13%) in China. 
However, the samples tested in the study were predominantly urine. The present 
study, however, was carried out on different clinical specimens obtained from 
infants with 44% being urine. Whether the nature of the clinical specimens could be 
attributed for the total absence of gB mix in the infant group requires to be 
established. 
 Predominance of gB2 in intraocular fluids may be attributed to the fact that 
all the intraocular fluids belonged to HIV patients and gB2 is generally known to be 
predominant in HIV patients with CMV retinitis (Drew et al., 2002) though the 
predominance of gB2 in HIV patient group was not statistically significant in this 
study group. However, reports on the predominance of a certain CMV genotype in 
patients with CMV retinitis is ambiguous (Shepp et al., 1996; Rasmussen et al., 
1997; Drew et al., 2002; Bongarts et al., 1996).  
 In the HIV patient group with discordant results between the blood and 
intraocular fluids, the genotype other than gB1 in the blood, was detected in the 
intraocular fluid. Whether different levels of neurotropism of gB subtypes as 
established by previous studies could be attributed to such an observation needs 
confirmation (Shepp et al., 1996; Tarrago et al., 2003). The frequency of mixed gB 
genotypes in PRT and HIV groups are little less than the reports available. It has 
been shown for renal transplant patients (Aquino and Figueiredo, 2000) as well as 
for lung transplant recipients (Puchhammer- Stockl et al., 2006) that up to 70 and 
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 90% of the patients, respectively, develop mixed CMV-strain infections in the 
follow-up after transplantation. The results on the mixed gB genotypes support the 
existing notion that infection with one strain does not protect against reinfection 
with another CMV strain. The significance of infections with mixed genotypes in the 
patient groups is attributed to the recombination events that might occur between the 
CMV strains leading to the generation of recombinant strains (Steininger et al., 
2005). Humar et al (2003) showed that infections with mixed CMV gB-subtype 
strains in solid organ transplantation may be associated with a delayed clearance of 
the virus from blood during therapy. This finding is of special interest because 
delayed virus clearance under antiviral therapy may also signify a higher risk for 
development of drug resistance. Coaquette et al (2004) described that mixed gB-
subtype infections were associated with increased graft rejection and disease 
progression. 
 The study on the distribution of gB genotypes in Chennai region, India 
suggests that there was no absolute segregation of gB genotypes with gender, patient 
groups or clinical specimens though certain genotypes were prevalent in different 
groups. The major limitations of the study however include, the non-availability of 
the clinical data of the patients to correlate the gB genotype distribution with respect 
to the clinical outcome; difference in sample sizes of different patient groups and 
cross-sectional design of the study. 
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 7. A STUDY ON THE DISTRIBUTION OF gH, gO AND 
gL GENOTYPES OF THE gCIII COMPLEX OF HCMV 
7.1 BACKGROUND 
 The gCIII viral-envelope complex consists of UL75 (gH), UL74 (gO), and 
UL115 (gL) (Gretch et al., 1988; Huber and Compton 1997; Huber and Compton 
1998; Huber and Compton 1999; Li et al., 1997) glycoproteins. Although the 
function of the assembled gCIII complex is unknown, the gH component is known 
to induce virus-neutralizing antibody (Rasmussen et al., 1984) and facilitates 
penetration of CMV into host cells (Keay and Baldwin 1991; Keay and Baldwin 
1996; Keay et al., 1989). gL is necessary for the transport of gH from the nuclear 
membrane to the cell surface (Kaye et al., 1992; Spaete et al., 1993) and gO has 
been associated with fusion of CMV-infected cells (Milne et al., 1998;  Paterson et 
al., 2002). A genetic homologue of CMV gO in EBV is gp42 and is indispensable 
for infecting B lymphocytes. Whether HCMV gO plays any role in cell tropism is 
yet to be determined. The disulfide-bonded, tripartite gCIII complex is displayed on 
the surface of infected cells and ultimately becomes part of the virion (Theiler and 
Compton, 2001; Theiler and Compton, 2002).  
 In view of the importance of the viral-envelope glycoprotein complexes for 
both replication and induction of a host immune response, one might predict a high 
level of genetic conservation. Several reports have confirmed the consistent 
detection of two closely related variants of the gH gene; however, very limited 
studies are available on the genetic variability of the individual gL and gO genes. A 
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 study on the distribution of the three genes of gCIII complex showed that there is 
predictable variations in the genes of the gCIII complex and the clinical strains of 
HCMV from different patient groups clustered into four groups based on the gO and 
gL sequences (Rasmussen et al., 2002). No studies have been available on the 
genotyping of the three genes of gCIII complex from India. Also, most methods 
developed for identification of the genotypes of these three genes have not been 
applied directly on the clinical specimens. This study was undertaken to elucidate 
the genetic configuration of the three genes of gCIII complex and their distribution 
by applying PCR-based RFLP methods on direct clinical specimens from different 
immunocompromised patient groups in India.  
7.2 OBJECTIVES 
7.2.1 To standardize PCR-based RFLP for gH gene of HCMV 
7.2.2  To study the distribution of gH genotypes in different clinical specimens from            
immunocompromised patients 
7.2.3  To standardize PCR-based RFLP for gO gene of HCMV 
7.2.4  To study the distribution of gO genotypes in different clinical specimens from             
immunocompromised patients 
7.2.5   To standardize PCR-based RFLP for gL gene of HCMV 
7.2.6  To study the distribution of gL genotypes in different clinical specimens from            
immunocompromised patients 
7.2.7  To study the distribution of gCIII complex and genetic linkages between the          
genes of gCIII complex. 
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 7.3 MATERIALS AND METHODS 
7.3.1 Standardization of seminested PCR-based RFLP for gH gene of HCMV 
7.3.1.1 Semi-nested PCR for gH gene 
 A semi-nested PCR was standardized for gH gene of HCMV using DNA of 
AD-169 strain by including an outer forward primer in the first round of 
amplification to an existing uniplex PCR (Chou, 1992a). A 50µl reaction mixture 
was prepared with 160µM of each dNTPs, 20 picomoles of primers gH1 and gH3 
(primer sequences are provided in Table 15), 1 x buffer  (10mM Tris–HCl 127(pH 
8.3), 50mMKCl, 0.01% gelatin, 3.0mMMgCl2), 1 U of Taq DNA polymerase. Ten µl 
of DNA was used as the template. The thermal profile followed is as shown in 
Table 15. The second round of amplification was carried out with reaction mixture 
similar to the first round with 10 picomoles each of primers gH1 and gH2. Ten µl 
from the first round amplicon was used as the template for the second round of 
amplification. The thermal profile followed for the second round is provided in 
Table 15. Amplicons were analyzed by electrophoresis on a 2% agarose gel 
incorporated with ethidium bromide (Appendix II). Sensitivity and specificity of the 
PCR was determined as described in Appendix II. 
7.3.1.2 Standardization of Poly Acrylamide Gel Electrophoresis based RFLP 
(PAGE – RFLP) of gH gene product 
 Ten µl of unpurified second round amplicon of HCMV AD 169 was 
subjected to digestion with Hha I enzyme in a 25µl reaction. The concentration of  
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 Table 15: Primer sequences, thermal profile and amplicon size for 
PCR targeting gH and gL genes of HCMV 
 
Gene Primer sequences Thermal  
Profile 
Amplicon 
Size  
 
 
 
 
 
gH  
 
 
 
 
 
 
 
 
gH1 : 5’ ccacctggatcacgccgctg 3’   
gH2: 5’ tggtgttttcacgcaggaa 3’ 
gH3: 5’ aggtattgacagatcaatgg 3’  
 
 
I round: (35 cycles) 
 
94°C -     2 minutes   
94°C  -  45 seconds 
62°C  -   30 seconds         
72°C  -   45 seconds 
72°C   -    5  minutes 
 
II round: (25 cycles) 
 
94°C -     2 minutes   
94°C  -  45 seconds 
62°C  -  30 seconds         
64°C  -  45 seconds 
64°C  -    5  minutes 
 
 
 
I round 
 
536bp 
 
 
 
 
 
II round 
 
213bp 
 
 
 
 
 
gL 
 
 
 
 
 
gL1: 5’ttgatgtgccgccgcccggatt 3’                
gL2: 5’gcaccagctcgaagcctaac 3’ 
gL3  5’atgtgccgccgcccggatt 3’  
gL4  5’ccagctcgaagcctaac 3’   
 
 
I round: (35 cycles) 
   
94°C  -    5  minutes 
94°C -   45 seconds 
65°C  -   45 seconds           
72°C  -   45 seconds 
72°C  -   10  minutes 
 
II round: (25 cycles) 
 
Profile Same as I 
round  
 
 
 
I round 
 
556bp 
 
 
 
 
II round 
 
550bp 
 
 the enzyme, buffer composition and temperature for incubation used are provided in 
Appendix II.  A control reaction containing the amplicon and buffer was included 
during each digestion. Digested fragments were analyzed after electrophoresis on 
20% polyacrylamide gels and visualized by silver staining (Appendix II).  
7.3.2 Application of PCR –based RFLP on clinical specimens 
 The standardized seminested PCR-based RFLP was applied on 34 clinical 
specimens from thirty immunocompromised patients with CMV infection proven by 
a positive PCR for mtr II gene. The 34 clinical specimens included in the study were 
as follows: Peripheral blood – 25, Urine – 6, Respiratory fluids – 3. The clinical 
specimens which gave a specific amplification signal by the PCR were genotyped by 
PAGE based RFLP. 
7.3.3 Modification of PAGE based RFLP to Agarose gel based RFLP 
 The restriction digestion was modified to visualize the restriction fragments 
on an agarose gel. The restriction enzymes were designed using a web based 
program (http://www.restrictionmapper.org) by providing consensus sequences of 
gH1 and gH2 genotypes after alignment of sequences available in the Genbank 
database (Accession numbers M94228 to M94237). Two restriction enzymes Hpa II 
and Stu I were selected for differentiation of the genotypes. Ten µl of unpurified 
second round amplicon of HCMV AD 169 was subjected to digestion with Hpa II 
and Stu I enzymes in separate 25µl reactions. The concentration of the enzyme, 
buffer composition and temperature for incubation used are provided in Appendix II.  
A control reaction containing the amplicon and buffer was included during each 
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 digestion. Digested fragments were analyzed after electrophoresis on 4% agarose 
gels incorporated with ethidium bromide (Appendix II).  
7.3.3.1 Validation of agarose gel based RFLP for gH 
 The agarose gel based RFLP for gH gene was validated against the 
conventional PAGE based RFLP. The stored amplified products of the clinical 
specimens (section 7.3.2) that was already genotyped by PAGE based RFLP were 
subjected to restriction enzyme digestion by Hpa II and Stu I enzymes.  
7.3.4 A study on the distribution of gH genotypes in different clinical specimens 
from immunocompromised patients  
7.3.4.1 Clinical specimens and patients 
 Two hundred and forty one clinical specimens from 201 
immunocompromised patients were included in the study. Only those clinical 
specimens which showed positivity for HCMV by mtr II PCR were included. One 
hundred and sixty seven single specimens (Peripheral blood –136; Urine – 12; 
Respiratory fluids– 15; intraocular fluids - 4)  obtained from 167 patients (Post renal 
transplant – 132; Infants – 20; HIV infected individuals – 11 and Bone marrow 
transplant – 4) were included. Pairs of similar or different clinical specimens 
accounting to 62 clinical specimens were obtained from 31 patients (Post renal 
transplant – 19 (Pairs of blood and urine from 18 patients; a pair of blood sample 
from one patient); Infants – 2 (pairs of blood and urine from 2 patients); HIV 
infected individuals – 9 (pairs of blood and intraocular fluids from 9 patients) and 
Bone marrow transplant – 1 (a pair of urine and respiratory fluid). Four samples of 
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 clinical specimens were obtained from 3 post renal transplant patients (Two pairs of 
blood and urine from two patients, one sample of blood and three samples of urine 
from one patient). 
7.3.4.2 PCR based RFLP for gH 
 Seminested PCR and agarose gel based RFLP for gH gene was carried out on 
the extracted DNA of the clinical specimens as described in sections 7.3.1.1 and 
7.3.3 respectively. 
7.3.4.3 Analysis of results 
 The distribution of the genotypes for gH gene was analyzed similar to gB 
gene (section 6.3.6.3). 
7.3.5 Validation of mixed genotypes of gH gene by DNA sequencing  
 Second round amplicon of gH gene from a blood specimen that gave mixed 
genotype gH1 + gH2 was subjected to DNA sequencing. The DNA sequencing was 
performed as described in Appendix II.  
7.3.6 Standardization of PCR-based RFLP for gO gene of HCMV 
 The duplex nested PCR for gO gene of HCMV was carried out as described 
in section 4.3.3. Two restriction enzymes Hpa II and Hae III were selected for 
differentiation of four genotypes of the gO gene of HCMV. Ten µl of unpurified 
second round amplicon of HCMV AD 169 was subjected to digestion with Hpa II 
and Hae III enzymes in separate 25µl reactions. The concentration of the enzyme, 
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 buffer composition and temperature for incubation used are provided in Appendix II.  
A control reaction containing the amplicon and buffer was included during each 
digestion. The products were visualized on 4% agarose gel incorporated with 
ethidium bromide (Appendix II). 
7.3.7 A study on the distribution of gO genotypes in different clinical specimens 
from immunocompromised patients  
7.3.7.1 Clinical specimens and patients 
 Two hundred and sixteen clinical specimens from 178 immunocompromised 
patients were included in the study. Only those clinical specimens which showed 
positivity for mtr II PCR were included. One hundred and forty six single specimens 
(Peripheral blood –117; Urine – 11; Respiratory fluids– 14; intraocular fluids - 4) 
were obtained from 146 patients (Post renal transplant – 111; Infants – 20; HIV 
infected individuals – 11 and Bone marrow transplant – 4). Pairs of similar or 
different clinical specimens accounting to 58 clinical specimens were obtained from 
29 patients (Post renal transplant – 17 (Pairs of blood and urine from 16 patients; a 
pair of blood sample from one patient); Infants – 2 (2 pairs of blood and urine); HIV 
infected individuals – 9 (9 pairs of blood and intraocular fluids) and Bone marrow 
transplant – 1 (a pair of urine and respiratory fluid). Four samples of clinical 
specimens were obtained from 3 Post renal transplant patients (Two pairs of blood 
and urine from two patients, one sample of blood and three samples of urine from 
one patient). 
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 7.3.7.2 PCR based RFLP for gO gene and Analysis of the results 
 PCR based-RFLP for gO gene was carried out on the extracted DNA of the 
clinical specimens as described in section 7.3.6. The distribution of the genotypes 
for gO gene was analyzed as done for gB gene (section 6.3.6.3). 
7.3.8 Validation of mixed gO genotype by DNA sequencing 
 Two blood specimens that gave mixed genotypes by duplex gO PCR-based 
RFLP were subjected to amplification by individual gO PCRs for AD169 and 
Towne strains respectively as in section 4.3.2. The second round amplicons of gO 
gene obtained by applying individual PCRs were subjected to DNA sequencing. The 
DNA sequencing was performed as described in Appendix II. 
7.3.9 Standardization of PCR-based RFLP for gL gene of HCMV 
7.3.9.1 Nested PCR for gL gene 
 A nested PCR was standardized for gL gene of HCMV using CMV-AD169 
DNA (Rasmussen et al., 2002). A 50µl reaction mixture was prepared with 200µM 
of each dNTPs, 10 picomoles of primers gL1 and gL2 (primer sequences are 
provided in Table 15), 1 x buffer  (10mM Tris–HCl 127(pH 8.3), 50mMKCl, 0.01% 
gelatin, 1.5mMMgCl2), 1 U of Taq DNA polymerase. Ten µl of DNA was used as 
the template. The second round of amplification was carried out with reaction 
mixture similar to the first round with 10 picomoles each of primers gL3 and gL4. 
Two µl from the first round amplicon was used as the template for the second round 
of amplification. The thermal profile followed for both the rounds is as shown in 
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 Table 15. Amplicons were analyzed by electrophoresis in a 2% agarose gel 
incorporated with ethidium bromide (Appendix II). Sensitivity and specificity of the 
PCR was determined as described in Appendix II. 
7.3.9.2 Standardization of RFLP of gL gene product 
 Ten µl of unpurified second round amplicon of HCMV AD 169 was 
subjected to digestion with Rsa I and Taq I enzyme in a 25µl reaction. The 
concentration of the enzyme, buffer composition and temperature for incubation 
used are provided in Appendix II.  A control reaction containing the amplicon and 
buffer was included during each digestion. Digested fragments were analyzed after 
electrophoresis on 4% agarose gel incorporated with ethidium bromide.  
(Appendix II).  
7.3.10 A study on the distribution of gL genotypes in different clinical 
specimens from immunocompromised patients  
7.3.10.1 Clinical specimens and patients 
 The same group of clinical specimens and patients included for the analysis 
of gO genotypes (section 7.3.7.1) was subjected to analysis of gL genotypes.  
7.3.10.2 PCR based RFLP for gL 
 PCR based-RFLP was carried out on the extracted DNA of the clinical 
specimens as described in section 7.3.9. The results were analyzed similar to gB 
gene (section 6.3.6.3). 
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 7.3.11 Validation of mixed genotype of gL gene by DNA sequencing 
 A blood specimen that gave mixed genotype (gL3+gL4) by nested PCR-
based RFLP for gL gene was subjected to DNA sequencing. The DNA sequencing 
was performed as described in Appendix II. 
7.3.12 A study on the distribution of gCIII complex in immunocompromised 
patients and a study on linkage of genes of gCIII complex 
7.3.12.1 Study design : Retrospective study 
7.3.12.2 Study Population 
7.3.12.2.1 Inclusion criteria for the analysis: 
 Patients who had a positive result and harbored a single genotype for all the 
three genes of gCIII complex (gH, gO and gL). 
 In case of patients, whose multiple specimens showed concordant results, 
one of the specimen was chosen for analysis.  
 In case of patients, whose multiple specimens showed discordant results, the 
specimen showing single genotype for all the three genes, if available, was 
considered. 
7.3.12.2.2 Exclusion criteria for the analysis: 
 The patients who had a negative result for at least one gene of the gCIII 
complex. 
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  The patients who had a mixed genotype for any gene of the gCIII complex. 
 In case of patients, who had a discordant result between clinical specimen, if 
the multiple specimens showed the mixed genotype or negative results, they were 
excluded. 
7.3.12.2.3 Details of Patients included in the analysis: 
 Ninety eight immunocompromised patients (Post renal transplant - 57, HIV 
infected individuals - 20, infants - 18, Bone marrow transplants - 3) were included in 
the analysis. 
7.3.12.2.4 Analysis of results: 
 The patientwise distribution of the variants of gCIII complex was analyzed. 
In case of genetic linkages the distribution of different gL and gO genotypes with 
respect to gH1 and gH2 genotypes and with respect to each other were analyzed. 
Chi-square test was performed to find any significant linkage between the variants 
of different genes. P value <0.05 was considered significant. 
7.4 RESULTS  
7.4.1 Results of standardization of seminested PCR  and PAGE based RFLP for 
gH gene of HCMV  
 The seminested PCR for gH gene generated a first round product of 536 bp 
and second round product of 213 bp with CMV –AD169 strain. The PCR was 
specific for HCMV and sensitive enough to pick up 1pg of HCMV DNA.  The 
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 RFLP of the PCR product of AD169 revealed the following restriction fragments 81, 
75, 29, 20 and 8 bp and belonged to gH1 genotype. 
7.4.2 Results of application of semi-nested PCR and PAGE based RFLP for gH 
gene on 34 clinical specimens: 
 Of the 34 clinical specimens, 25 clinical specimens were positive for gH 
gene. Figure 15 shows the amplified products of gH gene of HCMV applied on 
clinical specimens. The gH 1 genotype gave digested products of following sizes 81, 
75, 29, 20 and 8 bp and gH2 gave 92, 81, 29 and 8 bp (Figure 16). Of the 25 clinical 
specimens, 18 were genotyped as gH1 and 7 as gH2 by PAGE based RFLP. 
7.4.3 Results of the standardization and validation of Agarose gel based RFLP 
for gH gene 
 Genotype gH1 gave 162bp and 51bp fragments with Hpa II and remained 
undigested with Stu I. Genotype gH2 gave 158bp, 52bp fragments with Stu I and 
remained undigested with Hpa II. There was an absolute concordance of results 
between the conventional PAGE based RFLP and Agarose gel based RFLP. The 
latter was used in further studies due to simplicity and rapidity of the procedure.                   
7.4.4 Results of the study on the distribution of gH genotypes in different 
clinical  specimens from immunocompromised patients 
7.4.4.1 Patientwise distribution of gH genotypes 
 Genotyping results of the gH gene was available for 148 (73.6%) of 201 
patients analyzed. The 148 patients consisted of 105 PRTs, 19 infants, 20 HIV 
infected individuals and 4 BMT. Discordances between multiple clinical specimens  
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 Figure 15: Agarose gel electrophoretogram showing the amplified products 
of gH gene of HCMV 
 
 
 
 
 
Lanes: N2- Negative control (II round); N1 - Negative control (I round); 
1,2,3,5 -  Blood positive for gH; 4,6 - Blood negative for gH ; 7- Urine positive for 
gH; 8, 10 - Urine negative for gH; 9 – Respiratory fluid positive for gH; P – Positive 
control (HCMV AD169); MW –Hinf I digest of φX – 174 DNA  
Figure 16: Polyacrylamide gel electrophoretogram showing the results of 
PCR based RFLP for determination of strain variation in gH 
gene sequence 
 
 
 
 
 
 
 
 
Lanes:  1 – Blood specimen (genotype gH 1); 2- Blood specimen (genotype 
gH 2) MW - φX174 DNA /Hinf I digest;  P – HCMV AD 169 strain (genotype gH 
1); Un - Undigested product   
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 were observed in 8 patients (7 PRTs and 1 HIV infected individual). The distribution 
of gH genotypes were analyzed in 140 patients (98 PRTs, 19 HIV infected 
individuals, 19 infants and 4 BMTs). Table 16 shows the distribution of gH 
genotypes in different patient groups. Single genotypes in 135 (96.4%) and mixed 
genotypes in 5 (3.6%) of 140 patients were observed. Among the single genotypes, a 
predominance of gH1 (69.6%) was seen irrespective of the patient groups. When the 
distribution was studied as individual genotypes which comprised of gH1, gH2, and 
gH mix, a statistically significant difference in the distribution of gH genotypes was 
seen among the different patient groups (P<0.05). A higher frequency of gH1 
genotype in PRTs and HIV patients and gH2 genotype in BMT group was observed. 
The distribution of gH1 and gH2 was almost equal in the infant group. The presence 
of mixed gH genotype was observed only in PRT patient group. There was a higher 
frequency of males among the patients. There was no difference in the distribution 
of gH genotypes between males (n = 99) and females (n = 41) in the 140 patients. 
Figure 17 shows the results of PCR –based RFLP of gH gene on clinical specimens. 
7.4.4.2 Discordance in gH genotypes between multiple clinical specimens 
 Figure 18 summarizes the results of the discordance observed with gH 
genotypes in multiple clinical specimens. Discordance between multiple clinical 
specimens was observed in 8 patients (7 PRTs and 1 HIV infected individual). Of 
the 7 PRTs,   a pair of blood and urine was collected from 4 patients; two pairs of 
blood and urine from 2 patients and 3 samples of urine and one blood from one 
patient. Of the four pairs of blood and urine collected, genotyping results were 
available in the blood component alone for 2 patients (one each of gH1 and gH2) ; 
The rest 2 patients harbored, mixed genotype (gH1+gH2) in the blood while single  
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 Table 16: Distribution of gH genotypes in different patient groups 
 
 
Genotypes 
Patient groups  
Total 
PRT Infant HIV BMT 
gH 1 71 9 13 1 94 
gH 2 22 10 6 3 41 
gH mix 5 0 0 0 5 
Total 98 19 19 4 140 
 
Figure 17: Agarose gel electrophoretogram showing the Hpa II and Stu I 
products of gH gene  
 
 
 
 
 
 
Lanes: Un - Undigested product; 1 – Hpa II digest of blood specimen 
(Genotype gH1); 2 – Stu I digest of blood specimen (Genotype gH1); 3 – Hpa II 
digest of blood specimen (Genotype gH2); 4 – Stu I digest of blood specimen 
(Genotype gH2); 5 – Hpa II digest of blood specimen (Genotype gHmix); 6 – Stu I 
digest of blood specimen (Genotype gHmix); 7 – Hpa II digest of HCMV AD- 169 
(Genotype gH1); 8 – Stu I digest of HCMV AD- 169 (Genotype gH1); MW – Hinf I 
digest of φX – 174 DNA 
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Figure 18: Flow chart showing the discordant results observed with  
gH genotypes in multiple clinical specimens from 8 patients  
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genotypes of gH1 and gH2 were shed in the urine specimen of each patient. The 
discordant results in case of further 3 PRTs were as follows: Of the two patients 
from whom 2 pairs of blood and urine were collected, one patient showed presence 
of gH2 genotype in the pairs of blood component alone, while the pairs of urine 
were negative for gH gene. In the second patient, the first three samples (2 blood and 
1 urine) were negative while the final urine sample revealed the presence of gH2 
genotype. The patient from whom 3 samples of urine and a single sample of blood 
was collected harbored gH1 in all samples except the final urine sample. The blood 
and intraocular fluid of the HIV patient revealed mixed genotype in the blood while 
gH1 genotype was shed in the intraocular fluid.  
7.4.4.3 Specimenwise distribution of gH genotypes  
 Results of gH genotypes irrespective of the patient group was available for 
176 specimens (Blood- 122, Urine- 26, Respiratory fluids – 15 and intraocular fluids 
– 13). Table 17 shows the distribution of gH genotypes in different clinical 
specimens. A higher occurrence of gH1 genotype irrespective of the nature of 
specimens was seen. There was no statistically significant difference in the 
distribution of gH genotypes between the different clinical specimens. gH mix was 
exclusively observed in blood specimens. 
7.4.5 Result of DNA sequencing of mixed gH genotype from blood specimen 
Figure 19 shows the result obtained by DNA sequencing of the amplicon of gH 
gene of HCMV from blood specimen that gave gH1+ gH2 genotype. The mixed 
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 Table 17: Distribution of gH genotypes in different clinical specimens 
 
 
 
Genotypes 
Clinical specimens  
Total 
Blood Urine Respiratory 
fluids 
Intraocular 
fluid* 
gH1 82 16 8 9 115 
gH2 32 10 7 4 53 
gHmix 8 0 0 0 8 
 
Total 
 
122 
 
26 
 
15 
 
13 
 
176 
 
*  All the intraocular fluids were obtained from HIV infected individuals 
 Figure 19: DNA sequencing of amplicons obtained by semi-nested PCR for 
gH gene for validation of mixed genotypes obtained by RFLP  
 
 
 
 
 
 
 
 
 
 
 
Mixed bases at the recognition sites of Hpa II and Stu I . The plain box 
shows the recognition site of Stu I enzyme and box with dotted lines show the 
recognition site of Hpa II enzyme. The arrow indicates the mixed bases (T and G) at 
the recognition site of both the enzymes. Multiple sequence alignment with 
consensus sequence is also shown. 
gH2 
gH1 
consensus 
 bases were seen in the recognition sites of Hpa II (CC↓GG) and Stu I (AGG↓CCT) 
enzymes. Multiple sequence alignment of gH1 and gH2 genotypes is also shown. 
7.4.6 Result of standardization of PCR-based RFLP of gO gene of HCMV 
 The AD169 strain belonged to gO1 genotype and generated restriction 
digests of the following sizes for Hpa II enzyme: 345 bp, 25 bp and remained 
undigested with Hae III enzyme. 
7.4.7 Results of the study on distribution of gO genotypes in 
immunocompromised patients 
7.4.7.1 Patientwise distribution of gO genotypes 
 The RFLP patterns obtained for different gO genotypes are provided in 
Appendix II. 
 Genotyping results for the gO gene was available for 132 (74.2%) of 178 
patients analyzed. The 132 patients consisted of 89 PRTs, 20 infants, 20 HIV 
infected individuals and 3 BMTs. Discordances between multiple clinical specimens 
were observed in 8 patients (7 PRTs and 1 HIV infected individual). The distribution 
of gO genotypes was analyzed in 124 patients (82 PRTs, 19 HIV infected 
individuals, 20 infants and 3 BMTs). Table 18 shows the distribution of gO 
genotypes in different patient groups. Single genotypes were observed in 119 (96%) 
of 124 patients and mixed genotypes were observed in 5 (4%) of 124 patients. 
Among the single genotypes a predominance of gO1 (41.1%) and gO4 (31.5%) 
genotypes were seen over gO2 and gO3 irrespective of the patient groups. When the  
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Table 18: Distribution of gO genotypes in different patient groups 
 
Genotypes 
Patient group 
Total 
PRT HIV BMT Infant 
gO1 21 14 3 13 51 
gO2 7 1 0 4 12 
gO3 14 1 0 2 17 
gO4 35 3 0 1 39 
gOmix 5 0 0 0 5 
Total 82 19 3 20 124 
 
 
 distribution was studied as individual genotypes which comprised of gO1, gO2, 
gO3, gO4 and gO mix, a higher frequency of gO4 (42.7%) in PRTs and gO1 in all 
other patient groups (P<0.01) was seen. The presence of mixed gO genotype was 
observed only in PRT patient group. There was a higher frequency of males in the 
study population. There was no significant difference between the gO genotypes 
between males (n = 85) and females (n = 39) in the 124 patients. Figure 20 shows 
the RFLP patterns observed with different gO genotypes. 
7.4.7.2 Discordance in gO genotypes between multiple clinical specimens 
 Figure 21 summarizes the results of the discordance observed with gO 
genotypes in multiple clinical specimens. Discordances between multiple clinical 
specimens were observed in 8 patients (7 PRTs and 1 HIV infected individual). Of 
the 7 PRTs,   a pair of blood and urine was collected from 5 patients; two pairs of 
blood and urine from 2 patients. Of the five pairs of blood and urine collected, 
genotyping results were available in the blood component alone for 2 patients (one 
each of gO3 and gO4); the rest 3 patients harbored, mixed genotype (gO3+gO4) in 
the blood while single genotypes of gO4 were shed in the urine specimen of each 
patient. The discordant results in case of further 2 PRTs were as follows: Of the two 
patients from whom 2 pairs of blood and urine were collected, one patient showed 
presence of gO1 genotype in first samples of blood and urine specimens and 
negative results in the second samples of blood and urine specimens. In the second 
patient, both the samples of blood showed gO1 genotype, while the first urine 
specimen was negative and the second sample of urine showed a mixed genotype of 
gO1+gO3. The blood and intraocular fluid of the HIV patient revealed mixed  
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 Figure 20: Agarose gel electrophoretogram showing the Hpa II and Hae III 
products of gO gene  
 
 
 
 
 
 
 
 
Lanes: Un - Undigested product; 1 – Hpa II digest of blood specimen 
(Genotype gO1); 2 – Hae III digest of blood specimen (Genotype gO1); 3 – Hpa II 
digest of blood specimen (Genotype gO4); 4 – Hae III digest of blood specimen 
(Genotype gO4); 5 – Hpa II digest of blood specimen (Genotype gOmix); 6 – Hae 
III digest of blood specimen (Genotype gOmix); 7 – Hpa II digest of blood 
specimen (Genotype gO3); 8 – Hae III digest of blood specimen (Genotype gO3); 9 
– Hpa II digest of blood specimen (Genotype gO2); 10 – Hae III digest of blood 
specimen (Genotype gO2); 11 – Hpa II digest of HCMV AD- 169 (Genotype gO1); 
12 – Hae III digest of HCMV AD- 169 (Genotype gO1); MW – Hinf I digest of φX 
– 174 DNA 
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Figure 21: Flow chart showing the discordant results observed with gO 
genotypes in multiple clinical specimens from 8 patients  
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 genotype (gO3+4) in the blood while gO3 genotype was shed in the intraocular 
fluid.  
7.4.7.3 Specimenwise distribution of gO genotypes 
 Results of gO genotypes irrespective of the patient group were available for 
162 specimens (Blood- 109, Urine- 28, Respiratory fluids –12 and intraocular fluids 
–13). Table 19 shows the distribution of gO genotypes in different clinical 
specimens. There was a statistically significant difference in the distribution of gO1 
genotype among the different clinical specimens (P<0.05). In the blood specimens, 
gO1 and gO4 were almost equally distributed. In all other clinical specimens there 
was a higher frequency of gO1 over the other genotypes.  
7.4.8 Result of validation of mixed gO genotype by DNA sequencing 
 Of the two blood specimens one was identified as gO1+ gO2 and other as 
gO3+gO4 by DNA sequencing. The specimen carrying gO1+gO2 was amplified by 
gO (AD169) primer only. In case of the specimen carrying gO3+ gO4 genotype, 
amplicons were obtained with both gO (AD169) and gO (Towne) primers. On 
sequencing both the amplicons pure gO3 sequence and gO4 were obtained with gO 
(AD169) and gO (Towne) primers respectively.  Figure 22 shows the results 
obtained by DNA sequencing of the amplicon of gO gene of HCMV from blood 
specimen that gave gO mix (gO1+gO2) genotype. The mixed bases were seen at the 
recognition sites of Hpa II (CC↓GG) and Hae III (GG↓CC) enzymes. Multiple 
sequence alignment of gO1 and gO2 genotypes is also shown.  
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Table 19: Distribution of gO genotypes in different clinical specimens 
 
 
Genotypes 
Clinical specimens 
 
Total Blood Urine 
Respiratory 
fluids 
Intraocular 
fluids* 
gO1 37 15 8 7 67 
gO2 9 3 2 1 15 
gO3 16 3 1 2 22 
gO4 38 6 1 3 48 
gOmix 9 1 0 0 10 
Total 109 28 12 13 162 
 
  * All the intraocular fluids were obtained from HIV infected individuals 
 Figure 22: DNA sequencing of amplicons obtained by duplex PCR for gO 
gene for validation of mixed genotypes obtained by RFLP  
        (a) 
 
 
 
 
 
 
 
         (b) 
 
 
 
 
 
 
 
a) Mixed bases at the recognition sites of Hpa II of gO1+gO2 genotype The 
box shows the recognition site of Hpa II enzyme. The arrow indicates the 
mixed bases (T and C) at the recognition site . Multiple sequence alignment 
with consensus is also shown. 
(b) Mixed bases at the recognition sites of Hae III of gO1+gO2 genotype. 
The box shows the recognition site of Hae III enzyme. The arrow indicates 
the mixed bases (A and G) at the recognition site. Multiple sequence 
alignment with consensus is also shown. 
 
 7.4.9 Results of standardization of nested PCR based RFLP for gL gene of 
HCMV 
 The size of the first round and second round amplicons with AD-169 DNA 
were 556bp and 550bp respectively. The PCR was specific for HCMV and detected 
up to 0.5pg of HCMV DNA.  The RFLP of the gL PCR product of AD169 revealed 
the following restriction fragments 287, 117, 96, 50bp with Rsa I and 386, 156, 8bp 
with Taq I and belonged to gL1 genotype. 
7.4.10 Results of the study on the distribution of gL genotypes in 
immunocompromised patients  
7.4.10.1 Patientwise distribution of gL genotypes 
 The expected RFLP patterns for gL genotypes are provided in Appendix II. 
Genotyping results for the gL gene was available for 128 (71.9%) of 178 patients 
analyzed. The 128 patients consisted of 84 PRTs, 21 infants, 20 HIV infected 
individuals and 3 BMT. Discordances between multiple clinical specimens were 
observed in 5 patients (4 PRTs and 1 HIV infected individuals). The distribution of 
gL genotypes were analyzed in 123 patients (80 PRTs, 19 HIV infected individuals, 
21 infants and 3 BMTs). Table 20 shows the distribution of gL genotypes in 
different patient groups. Single genotypes were observed in 121 (98.4%) of 123 
patients and mixed genotypes were observed in 2 (1.6%) of 123 patients. gL1 and 
gL2 genotypes were not observed in the study population. Difference in the 
distribution of genotypes between PRT, HIV and BMT group were not observed. 
gL4 genotype predominated in all patient groups. There was a higher frequency of 
males among the patients. There was no considerable difference between the gL  
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 Table 20: Distribution of gL genotypes in different patient groups 
 
Genotypes Patient group Total 
PRT Infants  HIV BMT 
gL3 25 9 4 0 38 
gL4 53 12 15 3 83 
gLmix 2 0 0 0 2 
Total 80 21 19 3 123 
 
 
 
 
  genotypes between males (n = 88) and females (n = 35) in the 123 patients. Figure 
23 shows the amplified products of PCR for gL gene. The restriction pattern 
observed in different clinical specimens is shown in Figure 24. 
7.4.10.2 Discordance in gL genotypes between multiple clinical specimens 
 Figure 25 summarizes the results of the discordance observed with gL 
genotypes in multiple clinical specimens. Discordances between multiple clinical 
specimens was observed in 5 patients (4 PRTs and 1 HIV infected individuals). Of 
the 4 PRTs,   a pair of blood and urine was collected from 2 patients; two pairs of 
blood and urine from 1 patient and three samples of urine and one blood from one 
patient. Of the two pairs of blood and urine collected from 2 PRTs, a mixed 
genotype (gL3+4) was observed in the urine component with blood negative in one 
patient, and a mixed genotype (gL3+4) in blood with single genotype of gL4 in the 
urine of the other patient. In case of the PRT from whom two pairs of blood and 
urine were collected, gL4 was observed in both samples of urine and second sample 
of blood, while the first sample of blood was negative for gL gene. The PRT from 
whom three samples of urine and a sample of blood was collected revealed gL4 
genotypes in the first three samples (one blood and two urine) while the final sample 
of urine was negative for gL gene. The blood and intraocular fluid of the HIV 
patient revealed mixed genotype (gL3+4) in the blood while gL4 genotype was shed 
in the intraocular fluid.  
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 Figure 23: Agarose gel electrophoretogram showing the amplified products    
                  of gL gene of HCMV 
 
 
 
 
 
Lanes: N2- Negative control (II round); N1 – Negative control ( I round); 
1,2,6,8 – Blood specimens negative for gL gene; 3-5, 7,9 – Blood specimens 
positive for gL gene; 10, 12 – Urine specimens negative for gL gene; 11 – Urine 
specimen positive for gL gene; PC – Positive control HCMV-AD169; MW – Hinf I 
digest of φX-174 DNA   
 
Figure 24: Agarose gel electrophoretogram showing the restriction 
fragments obtained by nested PCR based RFLP of gL gene of 
HCMV 
(a)                                                                             (b)  
 
(a) Rsa I digests; (b) Taq I digests. Lanes: Un – Undigested product; 1 – Blood 
specimen (Genotype gL4); 2 – Blood specimen (Genotype gL mix (gL3 + 
gL4)); 3 – Blood specimen (Genotype gL3); P - Positive control HCMV AD-
169 (Genotype gL1); MW – Hinf I digest of φX-174 DNA 
 
550 bp 
 Figure 25: Flow chart showing the discordant results observed with gL 
genotypes in multiple clinical specimens from 5 patients 
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 7.4.10.3 Specimenwise distribution of gL genotypes 
 Results of gL genotypes irrespective of the patient group were available for 
161 specimens (Blood- 104, Urine- 32, Respiratory fluids –12 and intraocular fluids 
–13). Table 21 shows the distribution of gL genotypes in different clinical 
specimens. A higher frequency of gL4 genotype over gL3 was observed in all 
groups of specimens. There was no significant difference in the distribution of gL 
genotypes among the different specimen groups.  
7.4.11 Result of validation of mixed gL genotype by DNA sequencing 
 Figure 26 shows the result obtained by DNA sequencing of the amplicon of 
gL gene of HCMV from blood specimen that gave gL mix genotype. The mixed 
bases are seen in the recognition site of Rsa I (GT↓AC) enzyme that differentiates 
gL3 and gL4 genotypes. Multiple sequence alignment of gL3 and gL4 genotypes is 
also shown. 
7.4.12 Results of study on distribution of gCIII complex in 98 
immunocompromised patients 
 Table 22 shows the distribution of genes of gCIII complex in different 
patient groups. Sixteen strains of HCMV could be identified with results of the three 
genes. The number of different strains that existed in each patient population was as 
follows: PRT – 14 strains; HIV – 8 strains; Infants – 9 strains and BMT – 2 strains. 
Only 2 strains were represented in all patient groups. A higher frequency of gH1-
gO1-gL4 strain was observed irrespective of the patient group. Fifty five percent of 
the HIV patients carried strains with gH1-gO1-gL4 configuration.  There was a 
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 Table 21: Distribution of gL genotypes in different clinical specimens 
 
 
Genotypes 
Clinical specimens 
 
Total Blood Urine 
Respiratory 
fluids 
Intraocular 
fluid* 
gL3 31 9 2 4 46 
gL4 69 22 10 9 110 
gL mix 4 1 0 0 5 
Total 104 32 12 13 161 
  *All the intraocular fluids were obtained from HIV infected individuals 
Figure 26: DNA sequencing of amplicon of nested PCR for gL gene 
                        for validation of mixed genotypes obtained by RFLP  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Mixed bases at the recognition site of Rsa I of gL3+gL4 genotype. The 
box shows the recognition site of Rsa I enzyme The arrow indicates the mixed bases 
(G andA) at the recognition site. Multiple sequence alignment with consensus 
sequence is also shown. 
 Table 22: Distribution of genes of gCIII complex in different patient groups 
 
HCMV 
strain based on 
gCIII complex 
Patient groups Total 
PRT HIV Infant BMT 
gH1-gO1-gL4* 10 11 4 1 26 
gH1-gO1-gL3  1 0 1 0 2  
gH1-gO2-gL4 1 0 1 0 2 
gH1-gO2- gL3 1 1 0 0 2 
 gH1-gO3-gL4 3 0 1 0 4 
gH1-gO3-gL3 2 0 0 0 2 
gH1-gO4-gL4 7 1 1 0 9 
gH1-gO4-gL3 12 1 0 0 13 
gH2-gO1-gL4 4 3 4 2 13 
gH2-gO1-gL3* 0 0 4 0 4 
gH2-gO2-gL3 2 0 0 0 2 
gH2-gO2-gL4 1 0 1 0 2 
gH2-gO3-gL3 0 1 1 0 2 
gH2-gO3-gL4 4 1 0 0 5 
gH2-gO4-gL3 2 1 0 0 3 
gH2-gO4-gL4 7 0 0 0 7 
Total 57 20 18 3 98 
    
   *Distribution of the strains differed significantly between different patient groups 
 statistically significant difference in the distribution of gH1-gO1-gL4 and gH2-gO1-
gL3 strains among the different population (P<0.05). Three strains existed only in 
PRT group and one strain existed only in infants.  
7.4.13 Results of the study on genetic linkages among components of the gCIII 
complex: 
 The genotypes of each gene were analyzed with respect to the other genes in 
the gCIII complex. There was no significant association in the distribution of 
individual gO, gL genotypes or both together between gH1 or gH2 groups (Table 
23). When genotypes of gO and gL genes were analyzed irrespective of the gH 
genotype, a statistically significant association of gO1 with gL4 (P<0.001) and gO4 
with gL3 (P<0.05) was observed (Table 24). 
7.5 DISCUSSION 
 The relationship between genetic variants of the genes coding the gCIII 
complex and disease outcome has been the focus of recent studies, because these 
variants are major targets for virus-neutralizing antibody and are essential for some 
functions, such as binding to receptors and cell fusion (Rasmussen, 1999).  
 Limited studies are available showing the different possible genetic 
configurations of genes associated with gCIII complex in different patient groups 
(Rasmussen et al., 2002; Rasmussen et al., 2003). Till now there has been no study 
on the distribution of the genes of gCIII complex in Indian population. Hence, this 
study was undertaken. The methodology for determining the different variants of the 
three genes was devised as the first step to study the distribution of the genotypes of  
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 Table 23: Distribution of different gO and gL genotypes irrespective of the 
patient groups with (a) gH1 and (b) gH2 genotypes 
 
(a) 
gL 
genotypes 
gH1 Total 
gO genotypes 
gO1 gO2 gO3 gO4 
gL3 2 2 2 13 19 
gL4 26 2 4 9 41 
Total 28 4 6 22 60 
 
 
(b) 
gL 
genotypes 
gH2 Total 
gO genotypes 
gO1 gO2 gO3 gO4 
gL3 4 2 2 3 11 
gL4 13 2 5 7 27 
Total 17 4 7 10 38 
 
  
      
Table 24:Distribution of different gO and gL genotypes irrespective of gH  
genotypes 
 
gO genotypes gL genotypes Total 
gL3 gL4 
gO1 6 39* 45 
gO2 4 4 8 
gO3 4 9 13 
gO4 16* 16 32 
Total 30 68 98 
 
 
*A statistically significant association of gO1 with gL4 (P<0.001) and gO4 with gL3 
(P<0.05) was observed. 
 gCIII complex. The uniplex PCR for gH gene was converted to a semi-nested PCR 
to achieve optimal analytical sensitivity. The PAGE based RFLP was replaced by an 
in-house agarose based RFLP for simplifying the process of genotyping. The in-
house agarose based RFLP proved to be a better technique than the PAGE based 
RFLP for genotyping of strain variants of gH gene by being less time consuming, 
easy to perform and cost effective as the latter requires visualization of products on 
PAGE gel followed by silver staining. Also, the mixed genotypes identified by the 
in house agarose based RFLP, might have been missed by the PAGE based RFLP as 
the family of restriction fragments generated in gH1 and gH2 by the use of Hha I 
enzyme did not differ significantly. In case of the gO and gL genes, since the nested 
PCRs were available they were adapted for genotyping of the direct clinical 
specimens. However, the restriction analysis was modified to suit the detection of 
the fragments on agarose gel.  
 After standardization of the methods for genotyping, the distribution of the 
genes of the gCIII complex in various clinical specimens of different patient groups 
were analyzed individually as well as cumulatively. The analysis revealed no 
significant differences in the distribution of the gCIII variants based on gender.  
A predominance of gH1 genotype in PRT and HIV, gO4 in PRT, absence of gL1 
and gL2 genotypes and predominance of gL4 genotype irrespective of the patient 
groups were in disagreement with the limited number of studies that were available. 
(Chou, 1992a; Rasmussen et al., 2002; Rasmussen et al., 2003;  Vogelberg et al., 
1996).  The frequency of the mixed genotypes of the genes of gCIII complex was 
considerably low compared to the mixed genotypes encountered in the genotyping 
of gB gene. The presence of mixed genotypes was validated by subjecting the 
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 amplicons to DNA sequencing. In contrary to gB, gO and gL genes, mixed gH 
genotype was found only in the blood specimens of immuncompromised patients. In 
case of the former genes, though less frequent mixed genotypes were detected at 
least in the urine of the patients. Whether the observations have any clinical 
significance or limited to the difference in the sample size needs to be elucidated. 
 Considering the two variants of gH, four each of gO and gL the number of 
theoretical strains with different gCIII configuration would be 32 strains. Taking 
into account the absence of gL1 and gL2 genotypes in the study, theoretically,  
16 strains is expected to be circulating. In reality, all the sixteen strains were 
represented in the study population irrespective of the patient groups although, 
certain strains were more represented in a particular patient group than others. 
Around 55% of the HIV patients harboured the strains with gH1-gO1-gL4 
configuration, the significance of the same needs to be deciphered. 
 In a study by Rasmussen et al (2002) a strong genetic linkage between the 
gH1 and the gO1; lower frequency of gL2 in gH1 than other gL variants; higher 
frequency of gO2-gL4 in gH2 than gH1 group were found. The study by Rasmussen 
et al (2002) also showed a lack of genetic linkage between most of the gL variants 
with either gH or gO variant. In contrary, in this study the frequency of occurrence 
of gL3 with gO4 and gL4 with gO1 were statistically significant but no significant 
difference in the distribution of either gL, gO or both in gH1/gH2 groups were 
found.  
 The potential for the gCIII complex to exist in different genetic 
configurations in clinical strains may have implications for cellular tropism and 
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 provide some insight into the mechanism of the pantropism of CMV in vivo. It is 
being hypothesized that the different combinations of the gCIII complex may vary in 
their immunological potential with some combinations favouring immune evasion, 
while others promoting a vigorous immune response that favours virus eradication.  
 More studies particularly on cross neutralization of virus strains depending 
on the variability in the gH, gO, and gL components of the gCIII complex may be 
required to prove its significance. Report on the genotype specific immunity have 
been available for gH genotype (Urban et al., 1992).  Should the gCIII complex 
prove to be more important than its single components in the induction of virus-
neutralizing antibody, then it will be important to know whether all genetic variants 
are similarly susceptible to gCIII antibody to a single virus strain. This issue 
becomes relevant when considering the data showing that preexisting immunity to 
CMV does not ensure protection from reinfection as evidenced by the presence of 
mixed genotypes in the study. 
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 8. A STUDY ON THE DISTRIBUTION OF gN 
GENOTYPES IN DIFFERENT CLINICAL      
SPECIMENS FROM IMMUNOCOMPROMISED 
PATIENTS 
8.1 BACKGROUND 
 Glycoprotein N (gpUL73) encoded by the ORF UL73, is a component of the 
envelope gC-II complex in association with gM (Mach et al., 2000; Dal Monte et al., 
2001; Pignatelli et al., 2002) and has the ability to induce neutralizing antibodies 
(Britt and Auger, 1985). UL73 shows four main genomic variants, denoted gN1, 
gN2, gN3 and gN4. gN3 and  gN4 genotype can be further divided into subgroups 
gN3a, gN3b and gN4a, gN4b and gN4c respectively (Pignatelli et al., 2001). The 
UL73 gN-encoding gene is more polymorphic than gB (Pignatelli et al., 2001) and is 
located just upstream of the UL74 gO gene, a hypervariable locus in HCMV 
(Paterson et al., 2002). Pignatelli et al (2003a) studied the geographical distribution 
of gN genotypes of HCMV clinical isolates obtained from regions of Europe, 
Australia, Northern America and China. Recent studies have shown that gN genomic 
variants to be related to CMV-induced immunopathogenesis in the 
immunocompromised host and in congenital infected infants (Pignatelli et al.,2003b; 
Pignatelli et al., 2003c). No reports have been available on the distribution of gN 
genotype from India, hence the study was undertaken. 
8.2 Objectives 
8.2.1  To standardize PCR-based RFLP for gN gene of HCMV 
8.2.2  To study the distribution of gN genotypes in clinical specimens by  
PCR-based RFLP. 
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 8.3  MATERIALS AND METHODS 
8.3.1 Standardization of PCR-based RFLP for gN gene of HCMV 
8.3.1.1 Semi-nested PCR for gN gene 
 A semi-nested PCR was standardized for gN gene of HCMV using  
CMV-AD169 DNA by including an outer forward primer U -73 (Pignatelli et al., 
2001) to an already existing uniplex PCR (Pignatelli et al., 2003a).  A 50µl reaction 
mixture was prepared with 160µM of each dNTPs, 10 picomoles of primers U-73 
and gN2 (primer sequences are provided in Table 25), 1 x buffer  (10mM Tris–HCl 
127(pH 8.3), 50mMKCl, 0.01% gelatin, 2.0mMMgCl2), 1 U of Taq DNA 
polymerase. Ten µl of DNA was used as the template. The thermal profile followed 
is as shown in Table 25. The second round of amplification was carried out with 
reaction mixture similar to the first round with 10 picomoles each of primers gN1 
and gN2. Five µl from the first round amplicon was used as the template for the 
second round of amplification. The thermal profile followed for the second round is 
provided in Table 25. Amplicons were analyzed by electrophoresis on a 2% agarose 
gel incorporated with ethidium bromide (Appendix II). Sensitivity and specificity of 
the PCR was determined as described in Appendix II. 
8.3.1.2 Standardization of RFLP of gN gene product 
 Ten µl of unpurified second round amplicon of HCMV AD 169 was 
subjected to digestion with Sal I, Sac I and Sca I in separate reactions (25 µl). The 
concentration of the enzyme, buffer composition and temperature for incubation 
used are provided in Appendix II.  A control reaction containing the amplicon and 
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 Table 25: Primer sequences, thermal profile and amplicon size for PCR 
targeting gN genes of HCMV 
 
GENE PRIMER SEQUENCES THERMAL  
PROFILE 
AMPLICON 
SIZE  
 
 
 
 
 
 
gN 
 
 
 
 
 
U73: 5'ttcggtcggtcaacatcgtaag 3' 
 
gN1: 5'tggtgtgatggagtggaac3' 
 
gN2:5'-tagcctttggtggtggttgc3' 
 
I round: (30 cycles) 
 
  94°C   -   5  minutes 
  94°C   -  45 seconds 
  55°C   -   45 seconds          
   72°C  -   45 seconds 
  72°C   -   10 minutes 
 
II round:  (20 cycles) 
 
Profile Same as I 
round 
 
 
I round 
 
453bp 
 
 
 
 
 
II round 
 
411-420bp 
 
 
 buffer was included during each digestion. The products were visualized on a 4% 
agarose gel incorporated with ethidium bromide (Appendix II).  
 8.3.2 Distribution of gN genotypes in different clinical specimens from    
immunocompromised patients  
8.3.2.1 Clinical specimens and patients 
 The same group of clinical specimens and patients included for the analysis 
of gO genotypes (section 7.3.7.1) was subjected to analysis of gN genotypes. 
8.3.2.2 PCR based RFLP for gN gene 
 PCR based-RFLP was carried out on the extracted DNA of the clinical 
specimens as described in section 8.3.1. The results were analyzed similar to gB 
gene (section 6.3.6.3). 
8.3.3 Validation of mixed genotypes of gN gene by DNA sequencing 
 A blood specimen that gave mixed genotypes by PCR-based RFLP for gN 
gene was subjected to DNA sequencing. The DNA sequencing was performed as 
described in Appendix II. 
8.4 RESULTS 
8.4.1 Results of standardization of seminested PCR-based RFLP of gN gene of 
HCMV 
 The size of the first round and second round amplicons with AD-169 DNA 
were 453 bp and 420bp respectively.  The PCR was specific for HCMV and 
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 sensitive enough to pick up 50fg of HCMV DNA.  The RFLP of the gN PCR 
product of AD169 revealed the following restriction fragments:  297, 123bp with 
Sac I and remained undigested with Sal I and Sca I and belonged to gN1 genotype. 
8.4.2 Results of the study on distribution of gN genotypes in 
immunocompromised patients 
8.4.2.1 Patientwise distribution of gN genotypes 
 The different RFLP patterns observed with the different gN genotypes is 
provided in Appendix II. Genotyping results for the gN gene was available for 157 
(88.2 %) of 178 patients analyzed. The 157 patients consisted of 112 PRTs, 21 
infants, 20 HIV infected individuals and 4 BMT. Discordances between multiple 
clinical specimens were observed in 2 patients (one each of PRT and HIV infected 
individuals). The distribution of gN genotypes were analyzed in 155 patients 
(111PRTs, 19 HIV infected individuals, 21 infants and 4 BMTs). Table 26 shows 
the distribution of gN genotypes in different patient groups. Single genotypes were 
observed in 152 (98.1 %) of 155 patients and mixed genotypes were observed in 3 
(1.9 %) of 155 patients. Among the single genotypes a predominance of gN4c 
genotype was seen irrespective of the patient groups. There was a statistically 
significant difference in the frequency of gN4c among the different patient groups 
(P<0.05). gN2, gN3b and gN mix were found only in PRT group. There was a 
higher frequency of males among the patients. There was no difference between the 
distribution of gN genotypes between males (n = 112) and females (n = 43) in the 
155 patients. Figure 27 shows the amplified products of PCR for gN gene. The 
restriction pattern observed in different clinical specimens is shown in Figure 28. 
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 Table 26: Distribution of gN genotypes in different patient groups 
 
gN 
genotypes 
Patient groups Total 
PRT HIV Infants BMT 
gN1 21 2 6 1 30 
gN2 2 0 0 0 2 
gN3a 12 2 3 0 17 
gN3b 8 0 0 0 8 
gN4a 9 3 2 0 14 
gN4b 19 0 1 0 20 
gN4c 37 12 9 3 61 
gNmix 3 0 0 0 3 
Total 111 19 21 4 155 
 
 Figure 27 : Agarose gel electrophoretogram showing the amplified products  
of PCR for gN gene of HCMV 
 
 
 
 
 
Lanes: N2- Negative controls (II round); N1 – Negative control ( I round); 
1,4,7,9 – Blood specimens negative for gN gene; 2,3,5,6 – Blood specimens positive 
for gN gene ; 8- Urine positive for gN gene; P – Positive control HCMV – AD169; 
MW – Hinf I digest of φX-174 DNA 
 
Figure 28: Agarose gel electrophoretogram showing RFLP products of gN 
gene of HCMV 
Lanes: Un - Undigested product; 1 – Sal I digest (Genotype gN4b); 2 – Sac I 
digest (Genotype gN 4b );  3 - Sca I digest (Genotype gN 4b); 4 – Sal I digest 
(Genotype gN1) 5 – Sac I digest (Genotype gN 1 ); 6- Sca I digest (Genotype gN 1); 
7 – Sal I digest (Genotype gN3a); 8 – Sac I digest (Genotype gN3a );  9- Sca I digest 
(Genotype gN3a) 10 – Sal I digest (Genotype gN4c); 11 – Sac I digest  (Genotype 
gN4c ) ; 12- Sca I digest (Genotype gN4c);  MW – Hinf I digest of φX – 174 DNA 
 
 
 8.4.2.2 Discordance in gN genotypes between multiple clinical specimens  
 Figure 29 summarizes the results of the discordance observed with gN 
genotypes in multiple clinical specimens. Discordance between multiple clinical 
specimens was observed in 2 patients (one each of PRT and HIV infected 
individual). In case of a pair of blood and urine from PRT, gN4c genotype was 
observed in blood while the urine was negative. The blood and intraocular fluid of 
the HIV patient revealed mixed genotype in the blood while gN4b genotype was 
shed in the intraocular fluid.  
8.4.2.3 Specimenwise distribution of gN genotypes 
 Results of gN genotypes irrespective of the patient group was available for 
194 specimens (Blood- 134, Urine- 34, Respiratory fluids –13 and intraocular fluids 
–13). Table 27 summarizes the distribution of gN genotypes in different clinical 
specimens. A higher frequency of gN4c genotype over other genotypes was 
observed irrespective of the clinical specimens. There was no significant difference 
in the distribution of gN genotypes between the different specimen groups. 
8.4.3 Results of DNA sequencing of mixed genotype of gN gene of HCMV 
 Figure 30 shows the result obtained by DNA sequencing of the amplicon of 
gN gene of HCMV from blood specimen that gave gN mix genotype. The mixed 
bases are seen in the recognition sites of Sca I (AGT↓ACT). The Sal I and Sac I also 
showed mixed bases which were not clear due to the frame shifts that occurred due 
to the deletion of bases before the restriction sites. The mixed genotype was found to 
be gN1 + gN4c.  
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 Figure 29: Flow chart showing the discordant results observed with  
gN genotypes in multiple clinical specimens from 2 patients 
 
 
 
 
 
 
 
 
 
 
Table 27: Distribution of gN genotypes in different clinical specimens 
 
gN 
genotypes 
Patient groups Total 
Blood Urine Respiratory  
fluid 
Intraocular 
fluids* 
gN1 
24 8 4 2 38 
gN2 
2 0 0 0 2 
gN3a 
15 4 0 1 20 
gN3b 
8 0 0 0 8 
gN4a 
12 3 1 3 19 
gN4b 
19 2 0 1 22 
gN4c 
50 17 8 6 81 
gNmix 
4 0 0 0 4 
Total 134 34 13 13 194 
* All the intraocular fluids were obtained from HIV infected individuals. 
 
Blood – gN mix 
Intraocular  
fluid - gN 4b 
Pair of intraocular fluid 
and blood 
from 1 patient 
 
 
Pair of 
blood and urine 
from  1 patient 
Blood – gN 4c 
Urine – Negative  
Discordance 
2 patients 
 
PRT =1 
 
HIV = 1 
 
  
Figure 30: DNA sequencing of amplicon of nested PCR for gN gene  
for validation of mixed genotypes obtained by RFLP  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mixed bases at the recognition site of Sca I. The box shows the recognition 
site of Sca I. The arrows represent mixed bases at the recognition site and bars (-) 
represent mixed bases outside the recognition site. Multiple sequence alignment with 
the consensus sequence is also shown. 
 
 
 8.5 DISCUSSION 
 
 The polymorphic locus ORF -73 has been the next best studied loci after gB 
and gH. Previous reports (Mach et al., 2000) have demonstrated that gN associates 
with its glycosylated counterpart, gM, forming a highly immunogenic envelope 
complex, gCII (Kari et al., 1986). It has been shown that gM is highly conserved 
(Lehner et al., 1991) and that the polymorphic gpUL73 (gN) could be the main 
protein responsible for the immunogenicity of gCII. UL73 also seems to be more 
variable than gB in the HCMV genome (Pignatelli et al., 2001), and hence proven to 
be an efficient marker for epidemiological studies. Studies are emerging from all 
regions of the world on the association of gN genotypes with clinical outcome of 
HCMV. In this study, an existing uniplex PCR-based RFLP was converted to a 
semi-nested PCR based RFLP for anlaysing the distribution of gN genotypes of 
HCMV from direct clinical specimens. All the gN genotypes known till now was 
represented in the study population. When the distribution was considered as gN1, 
gN2, gN3 and gN4 the distribution of the genotypes irrespective of the patient 
groups were 19.4%, 1.3%, 16.1% and 61.3% respectively. The frequencies of the 
genotypes of this study is in accordance to the previous studies suggesting that in 
immunocompromised patients with active HCMV infections, the gN4 genotype was 
the most common and gN 2 was the rarest (Pignatelli et al., 2003a; Pignatelli et al., 
2003 b). Considering the geographical distribution of the gN genotypes, the 
distribution of the gN genotypes in this study is in accordance with that of Europe 
(Pignatelli et al., 2003a). The difference in the frequency of occurrence of gN2 
genotype was observed with other regions of the world. In this study gN2 occurred 
in a low frequency of 1.3%.  A total absence of gN2 was seen in the clinical strains 
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 from Australia and China while the same was well represented in the Northern 
America in the study by Pignatelli et al (2003a). The study showed a higher 
frequency of gN4c subtype irrespective of the specimens analyzed. There was no 
statistically significant difference in the distribution of gN genotypes in different 
clinical specimens though a statistically significant difference in the distribution of 
gN4c among the patient groups was seen. The genotypes gN2 and gN3b occurred 
only in the PRT group in this study. Whether the finding has any significance or 
limited to the difference in the sample sizes of different patient groups needs to be 
further explored though these genotypes were encountered in intrauterine infections 
by Pignatelli et al (2003b). There has been reports on the prevalence of gN1 
genotype in HIV patients as these strains seem to replicate favourably in these 
immunocompromised hosts (Pignatelli et al., 2003c), however this study did not 
confirm the finding since gN1 genotype occurred at a frequency of 10.3% in HIV 
patients with 63% of HIV patients infected with gN4c genotype. There has been a 
consensus in the association of gN4 genotype with severe clinical outcome of 
HCMV disease in immunocompromised patients and gN1 with more favourable 
outcome (Pignatelli et al., 2003b).  Such conclusions could not be arrived at due to 
unavailability of well documented clinical details of the patients. Studies have also 
shown that gN1 was detected at a higher rate in the monocytes of immunocompetent 
patients with latent HCMV infections (Pignatelli et al., 2006) and gN4b was more 
associated with a peak pp65 antigenemia in patients (Rossini et al., 2005). Such 
analysis was out of scope of the present study. The association of a specific gN 
genotype with levels of pp65 could not be performed due to short supply of the 
monoclonals during the study, also, the cross sectional nature of the study was a 
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 major limitation in establishing such conclusions. In this study, the discordant 
results were limited to two patients, of which the HIV patient showed a mixed 
genotype in blood, shedding a single genotype in the intraocular fluid. Two different 
strains of gN genotypes have been detected in saliva and urine in a patient by 
Pignatelli et al (2001). Hence, it can be concluded that in accordance with the recent 
studies, gN is more polymorphic than the other loci of HCMV genome studied till 
now and all the genotypes of gN known till now are represented in the Indian 
population as well.  
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 9. A STUDY ON THE DISTRIBUTION OF gB-gCIII-gN 
VARIANTS IN  IMMUNOCOMPROMISED PATIENTS 
AND A STUDY ON THE LINKAGE OF THE GENE 
COMPONENTS 
9.1 BACKGROUND 
 Several investigators have associated polymorphisms in single loci of 
HCMV genomes to cell tropism and pathogenesis of HCMV in different patient 
groups. (Bale et al., 2000; Barbi et al., 2001; Trincado et al., 2000). However, other 
investigators have disapproved such associations and related it to some other loci of 
HCMV genome. Considering the large variety of virus–host interactions that are 
mediated by the numerous viral gene products, it seems difficult to predict most 
significant CMV gene influencing a defined clinical situation. It is being 
hypothesized that CMV pathogenesis may involve interactions of multiple genes.  
Use of multiple genetic markers have been suggested to be more useful in predicting 
the outcome of CMV infection (Rasmussen et al., 2003). Also, since certain studies 
show genetic linkages between the genes of the three glycoprotein complexes a 
study was taken up to analyze the distribution and presence of linkage in the genetic 
markers such as gB, gH, gO, gL and gN in different immunocompromised patient 
groups. 
9.2 OBJECTIVE 
9.2.1  To study the distribution of HCMV variants with respect to gB, gCIII and gN 
genes.           
9.2.2 To study the possible genetic linkages with respect to gB, gCIII and gN 
variants.         
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 9.3 MATERIALS AND METHODS 
9.3.1 Study design: Retrospective study. 
9.3.2 Study Population 
9.3.2.1 Inclusion criteria for the analysis 
 Patients who had a positive result and harbored a single genotype for all the 
five genes viz. gB, gH, gO, gL and gN. In case of patients whose multiple specimens 
showed concordant results, one of the specimens was chosen for analysis. In case of 
patients, whose multiple specimens showed discordant results, the specimen 
showing single genotype for all the five genes, if available, was considered. 
9.3.2.2 Exclusion criteria for the analysis 
 The patients who had a negative result for at least one gene.  
 The patients who had a mixed genotype for any of the five genes. 
 In case of patients, who had a discordant result between clinical specimen, if 
the multiple clinical specimens showed the mixed genotype or negative results, they 
were excluded.    
9.3.2.3 Details of Patients included in the analysis 
 Seventy one immunocompromised patients (Post renal transplant - 36, HIV 
infected individuals - 15, infants - 18, Bone marrow transplants - 2) were included in 
the analysis. These patients were selected from a group of 178 patients (section 
7.3.7.1) based on the criteria for analysis. 
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 9.3.2.4 Analysis of results 
 The patientwise distribution of HCMV variants was analyzed. In case of 
genetic linkages the results obtained were subjected to pairwise analysis. The results 
were cross tabulated. Chi-square test was performed to find any significant linkage 
between the variants of different genes. P value <0.05 was considered significant. 
9.4 RESULTS 
9.4.1 Patientwise distribution of HCMV variants with respect to the five genes 
 Forty eight strains of HCMV could be identified with results of the five 
genes. The number of different strains that existed in each patient population was as 
follows: PRT – 29 strains; HIV – 11 strains; Infants – 14 strains and BMT – 2 
strains. There was not a single strain that was represented in all the patient groups. 
Of the 48 strains, 25 strains were exclusively detected in PRT, 9 in infants and 7 in 
HIV patient group. Only 7 strains were represented in more than one patient group. 
There was no significant association of HCMV strains with any patient population. 
Table 28 shows the different strains encountered in different patient groups. 
9.4.2 Genetic linkages among gB, gN and gCIII complex 
 For simplification, a pairwise analysis was carried out. Statistically 
significant associations were seen in the distribution of gB3 with gL3; gN3b  
with gH2; gN 4b with gH1; gO1 with gL4 and gO4 with gL3; gO2 with gN1  
and gO3 with gN4c (P<0.05). The results are shown in the cross tabulations.  
(Table 29 (a to j). 
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 Table 28: Distribution of 48 different HCMV strains in different patient groups 
 
HCMV 
strains based on five genes of HCMV 
Patient groups 
Total 
PRT HIV Infant BMT 
gH1-gO1-gL4-gN4c-gB1* Nil 2 2 1 5 
gH1-gO1-gL4-gN3a-gB1 Nil Nil 2 Nil 2 
gH1-gO1-gL4-gN4c-gB2* 1 2 Nil Nil 3 
gH1-gO1-gL4-gN4a-gB1 1 Nil Nil Nil 1 
gH1-gO1-gL4-gN4a-gB3 1 Nil Nil Nil 1 
gH1-gO1-gL4-gN4b-gB2 2 Nil Nil Nil 2 
gH1-gO1-gL4-gN4a-gB2 Nil 2 Nil Nil 2 
gH1-gO1-gL4-gN3a-gB2 1 Nil Nil Nil 1 
gH1-gO1-gL3-gN1-gB3 Nil Nil 1 Nil 1 
gH1-gO1-gL3-gN1-gB1 1 Nil Nil Nil 1 
gH1-gO2-gL4-gN1-gB2 Nil Nil 1 Nil 1 
gH1-gO2-gL3-gN1-gB1 Nil 1 Nil Nil 1 
gH1-gO3-gL4-gN4a-gB1 1 Nil Nil Nil 1 
gH1-gO3-gL4-gN4c-gB2 Nil Nil 1 Nil 1 
gH1-gO3-gL3-gN4c-gB1 1 Nil Nil Nil 1 
gH1-gO4-gL4-gN4c-gB1* 1 Nil 1 Nil 2 
gH1-gO4-gL4-gN1-gB2 Nil 1 Nil Nil 1 
gH1-gO4-gL4-gN3a-gB1 2 Nil Nil Nil 2 
gH1-gO4-gL4-gN4b-gB3 1 Nil Nil Nil 1 
gH1-gO4-gL4-gN2-gB3 1 Nil Nil Nil 1 
gH1-gO4-gL3-gN4a-gB3 Nil 1 Nil Nil 1 
gH1-gO4-gL3-gN4b-gB1 2 Nil Nil Nil 2 
gH1-gO4-gL3-gN4a-gB1 2 Nil Nil Nil 2 
gH1-gO4-gL3-gN3a-gB1 1 Nil Nil Nil 1 
gH1-gO4-gL3-gN4c-gB1 1 Nil Nil Nil 1 
gH1-gO4-gL3-gN4a-gB2 1 Nil Nil Nil 1 
gH1-gO4-gL3-gN4c-gB2 1 Nil Nil Nil 1 
gH1-gO4-gL3-gN4b-gB3 2 Nil Nil Nil 2 
gH2-gO1-gL4-gN4c-gB1* Nil Nil 2 1 3 
gH2-gO1-gL4-gN4c-gB2* Nil 2 1 Nil 3 
gH2-gO1-gL4-gN4c-gB3 Nil Nil 1 Nil 1 
gH2-gO1-gL4-gN3a-gB2* 1 1 Nil Nil 2 
gH2-gO1-gL4-gN1-gB3 1 Nil Nil Nil 1 
gH2-gO1-gL4-gN4a-gB2 2 Nil Nil Nil 2 
gH2-gO1-gL3-gN4a-gB3 Nil Nil 1 Nil 1 
gH2-gO1-gL3-gN1-gB1 Nil Nil 1 Nil 1 
gH2-gO1-gL3-gN1-gB3 Nil Nil 2 Nil 2 
gH2-gO2-gL4-gN1-gB1* 1 Nil 1 Nil 2 
gH2-gO2-gL3-gN3b-gB2 1 Nil Nil Nil 1 
gH2-gO3-gL4-gN4c-gB1 1 Nil Nil Nil 1 
gH2-gO3-gL4-gN4c-gB3 Nil 1 Nil Nil 1 
gH2-gO3-gL3-gN4c-gB3 Nil 1 Nil Nil 1 
gH2-gO3-gL3-gN4a-gB2 Nil Nil 1 Nil 1 
gH2-gO4-gL4-gN3b-gB1 1 Nil Nil Nil 1 
gH2-gO4-gL4-gN4a-gB2 1 Nil Nil Nil 1 
gH2-gO4-gL4-gN4c-gB1 1 Nil Nil Nil 1 
gH2-gO4-gL3-gN3b-gB1 2 Nil Nil Nil 2 
gH2-gO4-gL3-gN3a-gB3 Nil 1 Nil Nil 1 
                * Strains represented in more than one patient group 
 Table 29: Results of pairwise analysis of different glycoprotein genes to 
ascertain genetic linkage 
 
 (a)  gH vs gO      (b) gH vs gL 
  
 
(c)gH vs gB       (d) gL vs gO 
      
 
*  Association of the genotypes were statistically significant  
(P< 0.05,Chi-square test).  
 
gH 
genotype 
gL genotype 
Total 
gL3 gL4 
gH1 15 27 42 
gH2 9 20 29 
Total 24 47 71 
gH 
genotype 
gO genotype 
Total 
gO1 gO2 gO3 gO4 
gH1 19 2 3 18 42 
gH2 15 3 5 6 29 
Total 34 5 8 24 71 
gH  
genotype 
gB genotype Total 
gB1 gB2 gB3 
gH1 22 13 7 42 
gH2 12 9 8 29 
Total 34 22 15 71 
gL  
genotype 
gO genotype Total 
gO1 gO2 gO3 gO4 
gL3 6 2 3 13* 24 
gL4 28* 3 5 11 47 
Total 34 5 8 24 71 
 (e) gL vs gB     (f) gB vs gO 
 
 
 
 
 
(g) gN vs gL     (h) gN vs gH 
 
 *      Association of the genotypes were statistically significant  
(P< 0.05,Chi-square test).  
 
gL  
genotype 
gB genotype Total 
gB1 gB2 gB3 
gL3 11 4 9* 24 
gL4 23 18 6 47 
Total 34 22 15 71 
gB  
genotype 
gO genotype Total 
gO1 gO2 gO3 gO4 
gB1 13 3 4 14 34 
gB2 14 2 2 4 22 
gB3 7 0 2 6 15 
Total 34 5 8 24 71 
gN  
genotype 
gL genotype Total 
gL3 gL4 
gN1 6 5 11 
gN2 0 1 1 
gN3a 2 7 9 
gN3b 2 2 4 
gN4a 6 7 13 
gN4b 4 3 7 
gN4c 4 22 26 
Total 24 47 71 
gN  
genotype 
gH genotype Total 
gH1 gH2 
gN1 5 6 11 
gN2 1 0 1 
gN3a 6 3 9 
gN3b 0 4* 4 
gN4a 9 4 13 
gN4b 7* 0 7 
gN4c 14 12 26 
Total 42 29 71 
  
 
(i) gN vs gB     (j) gN vs gO 
    
*  Association of the genotypes were statistically significant  
(P< 0.05,Chi-square test).  
 
 
gN  
genotype 
gB genotype Total 
gB1 gB2 gB3 
gN1 5 2 4 11 
gN2 0 0 1 1 
gN3a 5 3 1 9 
gN3b 3 1 0 4 
gN4a 4 6 3 13 
gN4b 2 2 3 7 
gN4c 15 8 3 26 
Total 34 22 15 71 
gN 
genotype 
gO genotype Total 
gO1 gO2 gO3 gO4 
gN1 6 4* 0 1 11 
gN2 0 0 0 1 1 
gN3a 5 0 0 4 9 
gN3b 0 1 0 3 4 
gN4a 6 0 2 5 13 
gN4b 2 0 0 5 7 
gN4c 15 0 6* 5 26 
Total 34 5 8 24 71 
 9.5 DISCUSSION  
 Several epidemiologic studies have focused on the importance of variation in 
the glycoprotein genes as a factor in the ability of HCMV to infect various cells in 
vivo and to cause multiple organ manifestations. However, the conclusions of 
studies seeking an association of either gB, gN or variants of gCIII complex with 
either the outcome of CMV infection or to cellular tropism are inconsistent. 
Demographic characteristics of infected individuals have been attributed as one of 
the factor that may explain some of the discrepancies. For example, the association 
of gB genotype 2 with retinitis was related to a high prevalence of gB2 among 
patients with AIDS (Zipeto et al., 1998).  
 Taking into consideration the existing numbers of variants for each gene, 
theoretically 1120 strains of HCMV must exist. Considering the absence of certain 
genotypes such as gB4, gB5, gL1 and gL2 in the study population as shown in 
preceding sections; there was a possibility of 336 strains in the study population. 
Forty eight (14.3%) of these 336 strains were found in the analysis of all the five 
genes. The lower representation of the number of different strain is attributable to 
the inadequate sample size and the study design. In the beginning of the analysis 
there were 178 patients (study population provided in section 7.3.7.1) for whom 
genotyping results for all the genes were available. Of which, 107 had to be 
excluded due to non – compliance to the inclusion criteria. Little more than half of 
these 107 harboured mixture of genotypes in the specimens analyzed. One of the 
most important finding was that mixed genotypes in any loci was not observed in the 
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 infants. It may be hypothesized from the finding that increase in age may be directly 
proportional to a higher re-infection episodes. 
 The study also revealed the presence of certain strains exclusively in a 
particular patient group. Whether the observation would hold good with an 
increasing sample size is a question in itself. But, the result suggests that infinite 
number of strains may circulate at a given period and any conclusion drawn based 
on single loci of the genome with regard to its biological properties may not be of 
much utility considering the huge genomic background of HCMV. At the start of the 
study it was hypothesized that any variation in a single loci of HCMV genome may 
not reflect changes occurring in other loci of the genome and genetic linkages were 
rare. Earlier studies in this ground have shown that genetic linkages are seen among 
the clinical isolates with respect to the glycoprotein genes. Genotypes gB 2 and gB4 
have been shown to occur frequently in isolates with gH-1 (Fries et al., 1994), and 
the gO-1 genotype appears to be linked to the gH-1 genotype in the genes encoding 
the gCIII complex. Recently, discrete association have been shown between the gO 
and gN variants in isolates collected from different parts of the world (Mattick et al., 
2004). In the present study, significant association were seen between the gO and gL 
genes of gCIII complex; gO and gN genes; gN with gH and gB with gL. The 
association between gO, gN and gH may be attributable to the vicinity of the ORFs 
(gN- UL73; gO – UL74 and gH – UL 75). The associations of gO and gL may be 
attributable to their function since both their products constitute the gCIII complex. 
The importance of such associations requires confirmation.  
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  The data in the present study lead to the conclusion that HCMV are highly 
heterogenous group of viruses and exhibit several genetic combinations, study of a 
single gene is inadequate for investigating the molecular epidemiology of HCMV as 
the changes at one genetic locus do not necessarily reflect changes at other sites 
since genetic linkages are limited. Also, preexisting immunity to a HCMV strain 
may not protect from reinfection with a new strain as evident from the detection of 
mixed genotypes in the patient groups. At present, the standard strains AD-169 and 
Towne have been recommended as vaccine candidates, this means their genetic 
configuration with respect to the five genes under study would be gB2-gH1-gO1-
gL1-gN1 and gB1-gH2-gO4-gL2-gN4b. The genetic configuration of strains similar 
to AD-169 or Towne was not encountered in the study. However, the biological or 
functional impact of the variability of these genes requires direct analysis before 
arriving at any conclusion. One approach is to construct experimentally modified 
recombinant viruses and to develop in vitro systems that can functionally 
differentiate the genetic variants. Based on the functional differences the genetic 
variants related to morbid clinical outcomes may be identified and chosen to design 
vaccine to achieve maximum protection against important HCMV strains.  
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 10.  A STUDY ON THE RELATIONSHIP OF HCMV 
GENOTYPES WITH VIRAL LOADS 
10.1  BACKGROUND 
 Several studies have proved an association of high viral load and HCMV 
diseases in different immunocompromised patient groups. The CMV load is also a 
predictor for the development of CMV disease and response to treatment, and a high 
CMV load is an independent predictor of poor survival in most studies (Boeckh and 
Boivin, 1998). Independent studies on the association of different HCMV genotypes 
with clinical outcome of the patients with HCMV disease have also been available. 
It is still unclear, whether presence of a single HCMV or mixed infections with 
multiple HCMV strains is associated with an increased frequency of disease. 
Previous study on mixed gB genotypes with viral load as determined by a semi-
quantitative PCR and Real –time PCR has shown that presence of mixed genotypes 
are associated with a high viral load (Coaquette et al., 2004). Since, the analysis on 
the loci other than gB can also show the presence of mixed genotype, the present 
study was undertaken to find if there is any association of mixed genotypes in any 
loci of HCMV genome with the viral loads in clinical specimens from different 
patient groups. 
10.2 OBJECTIVES 
10.2.1 To study the possible relationship of HCMV genotypes with the viral load.   
10.2.2 To analyze the distribution of genotypes with respect to the five glycoprotein 
genes of HCMV in paired clinical specimens obtained from different patient 
groups. 
183 
 10.3 MATERIALS AND METHODS 
10.3.1 Study on the relationship of genotypes with viral load 
10.3.1.1 Clinical specimens and Patients 
 Seventy three clinical specimens (Peripheral blood -58, Urine - 10, 
Respiratory fluids - 3, intraocular fluids - 2) from 63 immunocompromised patients 
(PRT - 56, HIV -2, Infants - 5) were included in the study. Single specimens were 
obtained from 53 patients (PRT – 50, infants – 3). Multiple specimens were obtained 
from 10 patients. PRT – 6 (Pair of blood and urine from 6 patients), HIV infected 
patients – 2 (pair of blood and intraocular fluid from 2 patients) and infants – 2 (a 
pair of blood and urine from 2 patients). In case of blood specimens the leucocyte 
fraction and plasma fraction were analyzed separately. 
10.3.1.2 Genotyping and Taqman probe based real – time PCR 
 Multiplex PCR for gB, PCR based RFLP for gH, gO, gL and gN genes were 
carried out on all the 73 clinical specimens as described in sections 6.3.3; 7.3.1.1; 
7.3.3; 7.3.6; 7.3.9 and 8.3.1 respectively. The leucocyte and plasma fractions of the 
peripheral blood were analyzed separately to determine the genotypes. Taqman 
probe based Real-time PCR was performed on the 73 clinical specimen as described 
in the section 5.3.4. In case of the peripheral blood specimens, the Taqman probe 
based Real-time PCR was applied only on the leucocyte fractions. 
10.3.1.3Analysis of results 
 Specimen wise genotyping results of 73 clinical specimens obtained from 63 
immunocompromised patients were compared to the viral load as established by 
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 Taqman probe based Real time PCR. The clinical specimens were grouped into three 
for simplification of the analysis. Group I consisted of clinical specimens showing 
positivity for all the five regions with mixed genotypes in at least one region, Group 
II consisted of clinical specimens with single genotypes for all five regions; Group 
III consisted of clinical specimens with negativity in one or more regions. The 
analysis of the genotyping results of leucocyte and plasma fractions of the 58 
peripheral blood were performed separately. The distribution of genotypes were 
categorized as described earlier as Group I, Group II and Group III for both 
leucocyte and plasma fractions individually. The median viral loads obtained 
between the groups with respect to leucocyte and plasma fractions were also 
compared. Mann–Whitney test was used for the statistical analysis of results of 
genotyping with viral load. The results were expressed as medians and P values 
<0.05 were considered significant. 
10.3.2 Distribution of genotypes in the five glycoprotein genes of HCMV strain 
in paired clinical specimens obtained from different patient groups 
10.3.2.1 Study design and Study population 
 A retrospective analysis was carried out on paired clinical specimens 
obtained from different patient groups. Fifty four paired clinical specimens from 27 
patients out of the 58 clinical specimens from 29 patients as described in section 
7.3.7.1. was included in the analysis. A pair of blood specimens from a PRT and a 
pair of urine and respiratory fluid from BMT (section 7.3.7.1) were excluded from 
the analysis. The details of clinical specimens and patients included for the analysis 
is as follows: Fifty four clinical specimens (Peripheral blood – 27, Urine – 18, 
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 Intraocular fluids – 9) from 27 patients (PRT- 16, Infants – 2 and HIV -9) was 
carried out. The specimens included pairs of blood and urine from 16 PRTs and 2 
infants, pairs of blood and intraocular fluids from 9 HIV infected individuals. 
10.3.2.2 Analysis of results 
 The results of genotyping obtained with blood and paired clinical specimens 
such as urine or intraocular fluids was analyzed for discordances in the distribution 
of genotypes with respect to the number (whether discrepancy in single or multiple 
loci) and nature of genetic loci (whether gB/gCIII/gN) and variety of discrepancy 
(mixed genotype in one with single genotype in other etc.).  
10.4 RESULTS 
10.4.1 Comparison of results of specimenwise genotyping with viral load on the 
73 clinical specimens from 63 patients 
 The results obtained with the three groups of clinical specimens based on the 
genotypes in five genes of HCMV and the median number of viral copies/ml and 
median log10 copies/ml as determined by the real-time PCR are shown in Table 30. 
The median number of viral copies/ml differed significantly between the groups  
(P < 0.0001, Mann–Whitney test) (Figure 31). 
10.4.2 Comparison of genotyping results of leucocyte and plasma fraction of 
peripheral blood for genotyping of the five genetic loci of HCMV 
 Table 31 shows the distribution of genotypes with respect to the groups 
described in section 10.3.1.3 between plasma and leucocyte fraction of peripheral  
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 Table 30: Results of 73 clinical specimens from 63 immunocompromised 
patients showing the comparison of three groups of clinical 
specimens with viral load as ascertained by Taqman probe based 
real-time PCR 
 
 
Group of 
clinical 
specimen 
 
No. of clinical 
specimens 
 
Median copy number/ml (Median log10 
copy number/ml) by Real-time PCR 
 
Group I 22 3.9 X 106  (6.5911) 
Group II 23 9.8X 105 (5.9912) 
Group III 28 8.0X 103 (3.9031) 
   
 The difference between the median viral copies/ml present in different 
groups of clinical specimens is statistically significant (P<0.0001). Group I consists 
of clinical specimens positive in all genes with mixed genotype in at least one gene, 
Group II consists of clinical specimens with single genotypes in all genes, Group III 
consists of clinical specimens with negativity at least in one gene 
 
Table 31: Distribution of genotypes between leucocyte and plasma fractions of 
58 peripheral blood 
 
Genotypes determined 
from blood plasma 
Genotypes determined from blood 
leucocytes 
 
Total 
Group I Group II Group III 
Group I 5 0 0 5 
Group II 12 3 0 15 
Group III 3 13 22 38 
Total 20 16 22 58 
 Figure 31: Comparison of viral load with distribution of genotypes in 73 
clinical specimens from 63 immunocompromised patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
             Bars indicate the median values. The difference between the median viral 
loads between the groups was statistically significant. (P<0.0001, Mann Whitney 
test). 
 
  
blood specimens from 58 patients. Discrepancy with respect to the detection of 
mixed genotypes (Group I) and single genotypes (Group II) were observed between 
the leucocytes and plasma fraction of the peripheral blood samples from the patients. 
Seventy five percent of mixed genotype (Group I) as evident from the leucocyte 
fractions were characterized as single genotype (Group II) or negative (Group III) 
when the plasma fraction was analyzed. Sixteen (42.1%) of 38 clinical specimens 
that had a mixed or single genotype as per the analysis of leucocyte fraction was 
classified as negative when plasma fraction was analysed. The results of genotyping 
obtained with the three groups between the plasma and leucocyte fractions and the 
median number of viral copies/ml and median log10 copies/ml as determined by the 
real-time PCR applied on leucocyte fractions of the 58 peripheral blood is provided 
in Table 32. The median number of viral copies/ml was compared between each of 
the three groups for plasma and leucocyte fractions of peripheral blood. The median 
values differed significantly between each group of plasma and leucocyte fractions 
(P < 0.0001 for group I and group II; P<0.01 for group III, Mann–Whitney test) 
(Figure 32). 
10.4.3 Results of genotyping between blood and paired clinical specimens  
 Concordant results between all the loci analyzed were obtained in case of 10 
(37.0%) of 27 patients (PRT- 4; HIV- 4 and Infants – 2). Table 33 shows the 
discordance in the distribution of genotypes with respect to the number and nature of 
genetic loci in PRT (n = 12) and HIV (n = 5) group. A variety of discrepancies were 
observed that included detection of mixed genotypes in one specimen with detection  
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 Table 32: Results of comparison of the viral load with genotypes 
between plasma and leucocytes fractions of peripheral blood of 58 
patients  
 
  
 The difference between the median viral copies/ml present within the groups 
between the plasma and leucocyte fractions was significant (Group I and Group II 
P<0.0001; Group III P<0.01). Group I consists of clinical specimens positive in all 
genes with mixed genotype in atleast one gene, Group II consists of clinical 
specimens with single genotypes in all genes, Group III consists of clinical 
specimens with negativity at least in one gene. 
 
 
Group of 
clinical 
specimen 
 
No. of clinical 
specimens 
 
 
Median copy number/ml (Median 
log10 copy number/ml) by Real-time 
PCR 
Leucocytes Plasma Leucocytes Plasma 
Group I 20 5 4.6x106  (6.6628) 3.6x107 (7.5563) 
Group II 16 15 3.6x105 (5.5563) 3.2x106 (6.5052) 
Group III 22 38 1.38x104 (4.1399) 2.65x104 (4.4232) 
 Figure 32: Comparison of viral loads with distribution of genotypes in 
leucocyte and plasma fractions of 58 peripheral blood specimens 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
             Bars indicate the median values. The difference between the median viral 
loads within groups between plasma and leucocyte fraction was statistically 
significant (P<0.0001, Mann Whitney test). The actual median for each group is 
shown within brackets ( ).  
       
 
 Table 33: Discordances in the distribution of genotypes with respect to the 
number and nature of genetic loci in 17 patients (PRT-12; HIV-5) 
 
Number  and 
nature of loci 
Patient group 
PRT HIV 
One gB 3 (2) 2 (2) 
gH 1 (0) 0 
gO 2 (2) 0 
gL 0 1(1) 
Two gB & gH 1* 0 
gB& gO 1(1) 1(1) 
gB & gN 1(0) 0 
gH & gL 1(1) 0 
gH & gO 1** 0 
gO & gL 1** 0 
gH & gN 0 1(1)*** 
Total 12(9***) 5 (5) 
 
 The value in the brackets () represent the number of discrepancy with regard 
to mixed genotypes in a clinical specimen with single genotype or negativity in the 
paired clinical specimen. 
*  Discrepancy with regard to mixed genotypes seen in gB loci alone 
**  Discrepancy with regard to mixed genotypes seen in loci other than gO 
***  Mixed genotype with respect to gB was found in both blood and intraocular 
fluid 
****  Includes the patients who showed discrepancy with regard to mixed 
genotype in at least one loci  
 of single genotypes in other; negativity in one specimen with detection of mixed or 
single genotypes in the other. The distribution of nature of discrepancies in different 
genetic loci irrespective of patient group is shown in Figure 33. All the 
discrepancies in case of the HIV patient were of a single kind viz. detection of 
mixed genotypes in blood with detection of single genotypes in the intraocular 
fluids.  Discrepancy with the detection of mixed genotypes was observed in 18 loci 
of 14 patients (Table 34). The results show that mixed genotypes irrespective of the 
loci was found more in the blood than the paired clinical specimens in PRT and HIV 
patients. 
10.5 DISCUSSION 
 Prospective studies of immunocompromised patients have shown that CMV 
viral detection and quantification are useful for identifying those individuals at 
highest risk for disease but do not consistently predict clinical outcome. Some 
individuals develop symptomatic CMV disease with a relatively low viral load, 
while others maintain chronic high-level viremia yet remain free of symptomatic 
disease. Thus, factors in association with, or in addition to, viral load will affect the 
development of symptomatic CMV disease. Reports are emerging on relationship of 
strain differences in HCMV associated with virulence (Torok – Storb et al., 1997; 
Fries et al., 1994; Shepp et al., 1996). Earlier studies have thrown light on the fact 
that reinfections with different HCMV strains are common in different patient 
groups. CMV reinfections have been shown to lead to an accumulation of more than 
one latent virus in a host (Bale et al., 1996; Chandler et al., 1987). Multiple CMV 
gB-genotypes have been detected even in the tissues of immunocompetent patients  
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 Figure 33: Distribution of discrepancies in different genetic loci irrespective   
of patient group 
 
 
 
 
 
 
 
 
 
 
 
 
Table 34: Discrepancies in detecting mixed infections at different genetic loci in 
paired clinical specimens from 9 PRT and 5 HIV patients 
Patient  
group 
Number of patients 
showing discrepancies 
with respect to detection 
of mixed genotypes 
Number of 
genetic loci 
showing 
discrepancy 
Clinical specimens in which 
mixed genotype was detected 
Blood Urine/ 
Intraocular 
fluids* 
HIV 5 7 7 0 
PRT 9 11 8 3 
Total 14 18 15 3 
 
*Urine and intraocular fluids were analyzed in case of PRT and HIV respectively. 
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 (Meyer-Konig et al., 1998a, Meyer-Konig et al., 1998b). It is known that HIV 
patients may harbor a number of different CMV strains, which reactivate especially 
during stages of significant immunosuppression (Spector et al., 1984). In post – 
organ transplant recipients a variety of CMV strains may be involved, including 
strains of the recipient acquired during the course of pre-transplantation life as well 
as ones that were acquired, possibly in substantial amounts, by receiving an organ 
from a CMV-seropositive donor. Most of these studies were based on genotyping of 
single genetic loci, particularly gB gene of HCMV. In this study the results have 
shown that the mixed infections with multiple genotypes of HCMV are found 
though at a low frequency in the genetic loci other than gB gene of HCMV. The 
identification of such mixed genotypes would have been missed if only one gene 
was studied at a time. In this study, detection of the mixed genotypes in minimum of 
6 and maximum of 16 patients would have been missed if only one genetic loci was 
studied. The order of genetic loci suitable for detection of mixed genotype as 
confirmed by the study is gB>gO>gH=gL>gN. The higher rate of detection of 
mixed genotypes in the gB gene may be partly attributed to use of multiplex PCR 
for detection of genotypes. PCR- RFLP may be less sensitive in detection of the 
mixed genotypes although, the method was devised with great care for particularly 
identifying the mixed genotypes by choosing the restriction enzymes that would 
provide maximum difference between the existing genotypes for a particular genetic 
locus.  
 A statistically significant difference was observed in the viral loads as 
determined by Taqman probe-based real time PCR between the specimens carrying 
single genotype and multiple genotypes. This finding is in accordance with a 
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 previous study where in identification of mixed infections with multiple gB 
genotypes of HCMV was associated with an increase in viral load, graft rejection 
and disease progression (Coaquette et al., 2004). Hence, detection of mixed 
genotypes in the hypervariable regions of HCMV can be a surrogate marker to an 
increase in viral load and disease progression.  
 It becomes increasingly important to identify the right clinical specimen for 
detection of the mixed genotypes. This study shows that peripheral blood may be 
more useful in the detection of mixed genotypes than other clinical specimens in 
case of PRT and HIV. Different fractions of the peripheral blood such as leucocyte, 
plasma or whole blood have been used by several investigators for the purpose of 
genotyping. The study shows that the results of genotyping may depend on the 
fraction of the blood analyzed. The leucocyte fraction of the peripheral blood may 
be more suitable for identification of the mixed genotypes than the plasma fraction. 
The analysis of the viral load in the samples revealed that the mixed genotypes were 
detected in the plasma when the median viral load was greater than that required for 
their detection in the leucocytes. The utility of whole blood in this regard needs to be 
deciphered. 
 The discrepancies observed between the distribution of genotypes in the 
intraocular fluids and peripheral blood of HIV patients in this study was quite 
different from that reported in other studies.  In studies by Peek et al (1998) and 
Verbraak et al (1998), total compartmentalization of different CMV genotypes in 
blood and eye components, for eg. gB4 in eye and gB3 in blood of a patient was 
observed. The studies hypothesized that the intraocular cytomegalovirus strain was a 
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 persistent CMV genotype of a previous viremia that has already been cleared from 
the blood attributed to limited ocular penetration of systemically administered 
ganciclovir in these patients. Both the studies were from developed countries where 
the treatment modality is different from that in India. Since, intravitreous ganciclovir 
without systemic administration is the standard therapy for treating CMV retinitis in 
developing countries, selective elimination of HCMV strain in the eye without being 
eliminated from the blood could partially answer the presence of mixed genotype in 
the blood with single genotypes in the intraocular fluids. But, in case of all the five 
HIV patients in this study, the clinical specimens were collected prior to any 
intravitreal treatment, hence ruling out the hypothesis. Alternatively, after a first 
infection with CMV, infection with a new CMV strain can occur, which, although 
present in blood, might not have reached the eye. If the patient is followed up for a 
brief period, it might be possible to identify the mixed genotypes in the intraocular 
fluids also, as seen with one of the HIV patient in this study.  
 Another interesting observation with regard to the HIV patients showing 
mixed genotype in blood with single genotypes in intraocular fluid is with respect to 
pattern of gB genotypes. In all the 3 HIV patients with discrepancies at gB loci, gB1 
genotype was associated with blood and gB2 or gB3 were shed in the intraocular 
fluid. The study on the distribution of the gB genotypes in the intraocular fluids 
from HIV patients (Table 14 ) revealed 10/13 with gB2 and gB3 genotypes. Also, 
the plasma fraction of the three blood analyzed from these HIV patients showed the 
genotypes that were shed in the intraocular fluid. Hence, whether the observation is 
to be related to tropism or spread of a genotype predominant in the blood to the 
intraocular fluid needs to be ascertained. However, reports on the association of a 
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 certain CMV genotype in patients with CMV retinitis is ambiguous (Shepp et al., 
1996; Rasmussen et al., 1997; Drew et al., 2002; Bongarts et al., 1996).  
 The discrepancies in finding mixed genotypes in blood and urine 
components of PRT can also be addressed similarly. A longitudintal study with 
proper clinical data is advocated to establish whether therapy, or load or tropism has 
any role to play in such pattern of shedding. Due to the cross sectional nature of the 
study, lack of clinical data and lower sample size no solid conclusions could be 
made with such observations. 
 With respect to the biological aspects of the presence of more than one 
strain, the presence of  mixed strains may  allow transcomplementation between the 
strains with defects or disadvantageous polymorphisms of one virus strain being 
overcome by the co infecting strains thus greatly enchancing the virus tropism, 
replication, or immune evasion (Cicin –Sain et al., 2005). It was also observed that 
recombination events between CMV strains can occur, leading to the generation of 
recombinant strains (Steininger et al., 2005) that could further influence the 
evolutionary development of CMV strains.  
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 11.  ISOLATION AND CHARACTERIZATION OF 
VIRAL ISOLATES 
11.1  BACKGROUND 
 Most of the studies in literature on the characterization of HCMV strains 
utilize nucleotide sequencing of specific genes from HCMV isolates (Rasmussen et 
al., 2002; Pignatelli et al., 2001; Tanaka et al., 2005).  Isolation of the virus from 
clinical specimen indicates the active replication of the virus in vitro. In India, there 
has been paucity on the isolation of HCMV from clinical specimens due to non-
availability of good quality Human diploid fibroblast cell lines. Hence, in this study 
an attempt was made to isolate HCMV from clinical specimens on Tenon’s capsule 
fibroblast cell line. Nucleotide sequencing of HCMV isolates have been attempted to 
establish emergence of recombinant strains of HCMV in HIV patients, to screen for 
novel mutations with respect to antiviral resistance and to establish the evolutionary 
patterns of clinical strain with respect to prototype strains (Steininger et al., 2005; 
Lurain et al., 2001; Rasmussen et al., 2002; Pignatelli et al., 2001). In this study, 
nucleotide sequencing and phylogenetic analysis of clinical isolates and other 
clinical strains from direct clinical specimens was attempted to validate the results of 
other genotyping methods (multiplex PCR and PCR-based RFLP) and to establish 
presence of novel strains if encountered in the study population. 
11.2   OBJECTIVE 
 (i) To isolate HCMV from clinical specimens and to characterize the isolates. 
193 
 11.3 MATERIALS AND METHODS 
11.3.1 Clinical specimens and Patients 
 Twelve clinical specimens (pairs of peripheral blood leucocytes and urine 
specimens) from 6 patients were included in the study. All the twelve clinical 
specimens were subjected to virus isolation. Fifteen other clinical specimens 
carrying different HCMV strains as revealed by genotyping of the five glycoprotein 
genes were also included. The details of the fifteen different HCMV strains included 
in the study are provided in Table 35. 
11.3.2 Virus isolation 
  Virus isolation was performed using rapid shell vial technique. Human 
Tenon’s capsule fibroblasts (Dr. Michelle C Madiagan, Save Sight Institute, Sydney) 
grown on cover slips were inoculated with the clinical specimens. For inoculation, 
100µl of peripheral blood leukocyte suspension of blood specimens and 100µl of 
decontaminated centrifuged deposits of the urine specimens were used. The details 
of processing of clinical specimens are provided in Appendix I. The cover slips were 
stained at 48 hours with mouse monoclonal antibody (DAKO, A/S, Denmark) raised 
against the early antigen of HCMV and rabbit anti-mouse fluorescein iso thiocyanate 
conjugate (DAKO, A/S, Denmark). One or more positive fluorescent nuclei 
indicated positive result. The test was carried out in duplicates. One of the shell vial 
was used for confirming the presence of the virus. The contents of the second shell 
vial was harvested and used for subsequent passages. The specimens were 
considered negative after three passages. Those that became positive, the culture 
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 Table 35: Details of the patient group, clinical specimens of the fifteen HCMV  
strains 
 
Strain 
number 
Strain Patient 
group 
Clinical specimen 
1 gH2-gO1-gL4-gN4c-gB2 HIV Blood 
2 gH1-gO1-gL4-gN4c-gB1 HIV Blood 
3 gH1-gO4-gL4-gN4c-gB1 PRT Urine 
4 gH2-gO1-gL4-gN4c-gB1 Infant Respiratory fluid 
5 gH2-gO2-gL4-gN1-gB1 PRT Blood 
6 gH2-gO3-gL4-gN4c-gB1 PRT Blood 
7 gH1-gO1-gL4-gN4a-gB1 PRT Blood 
8 gH2-gO4-gL4-gN3b-gB1 PRT Blood 
9 gH2-gO1-gL3-gN1-gB1 Infant Respiratory fluid 
10 gH1-gO1-gL4-gN4c-gB2 HIV Intraocular fluid 
11 gH2-gO1-gL4-gN4a-gB2 PRT Blood 
12 gH1-gO4-gL3-gN4b-gB1 PRT Blood 
13 gH2-gO1-gL4-gN3a-gB2 HIV Blood 
14 gH2-gO3-gL4-gN4c-gB3 HIV Intraocular fluid 
15 gH2-gO4-gL3-gN3a-gB3 HIV Blood 
 
 harvests of the first and subsequent passages were pooled and utilized for 
genotyping. The culture harvests were stored at -80oC till further processing. 
11.3.3 Genotyping of HCMV isolates 
 Multiplex PCR for gB gene and PCR based-RFLP for gB gene, genes of 
gCIII complex and gN gene of HCMV were performed as described in the sections 
6.3.3; 6.3.2.2; 7.3.1.1,7.3.3, 7.3.6,7.3.9 and 8.3.1 respectively. 
11.3.4 DNA sequencing 
 The viral isolates and the fifteen other HCMV strains were subjected to DNA 
sequencing. DNA sequencing on the second round amplicons of semi-nested PCR 
for gH, gL and gN gene were carried out as described in Appendix II. In case of the 
gB gene, the amplicon generated by semi-nested PCR was sequenced. With respect 
to the gO gene, the PCRs for gO (AD-169) and gO (Towne) were performed 
individually and not as duplex. The amplicon generated in the respective PCRs were 
sequenced.  
11.3.5 Phylogenetic analysis 
 DNA sequences of the five glycoprotein genes (gB, gH, gO, gL and gN) 
were aligned and analyzed using MEGA version 4.0 software for analysis of 
relationships by the generation of phylogenetic trees using Neighbour joining 
methods. The evolutionary distances were computed using the Kimura 2-parameter 
method. For each gene, a single tree with 1000 bootstrap values was generated. 
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 11.3.6 Nucleotide sequence accession numbers included in the analysis 
gB gene :  AD169 - X17403,  Towne - AY315197  
Prototypes :  gB 1 - M60929,  gB2 - M60932, gB3 -  M60934, gB4 - M60924 
gH gene:  AD 169 - AC146999,  Towne - AY315197 ,  Toledo - AC146905  
Prototypes : gH1 - M94236, gH2 - M94229 
gL gene: AD169 - AF530173, Towne - AY315197,  Toledo -AF530182 
gL1 -AF530172, gL2-  AF530169, gL3 - AF530175, gL4 - AF530181 
gO gene: AD169 - AF531331, Towne - AF531356,  Toledo - AF531355  
Protoypes : gO1 - AF531340, gO2 - AF531353, indeterminate type - AF531321, 
gO3 -AF531352,  gO4 - AF531323 
gN gene: AD169 - X17403, Towne - AF224677, Toledo - AY486475 
Prototypes: gN1 - AF309974, gN2 - AF309976, gN3a - AF309980, gN3b – 
AF390802 gN4a - AF309993, gN4b - AF309996, gN4c - AF310006 
11.4 RESULTS  
11.4.1 Virus isolation 
 HCMV was isolated from 4 (33.3%) of 12 specimens. One peripheral blood 
and urine from one patient and urine specimens from two other patients were 
positive for isolation.  
11.4.2 Results of genotyping by multiplex PCR, PCR based RFLP of the isolates 
 The four isolates were characterized for all the five genes. The genotyping 
results of the four isolates were as follows: 
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 Isolate 1 from urine gB1-gH1-gO4- gL4- gN4c 
Isolate 2 from blood gB1-gH1-gO4- gL4- gN4c 
Isolate 3 from urine gB1-gH1-gO1-gL4 -gN1 
Isolate 4 from urine gB3-gH2-gO1- gL4- gN4c 
The result of genotyping on the direct clinical specimens from which the HCMV 
was isolated was available only for the gB gene. The direct clinical specimens of 
isolate 3 and 4 were genotyped as mixed genotypes gB1+gB3 by multiplex PCR 
while isolates 1 and 2 were genotyped as gB1. 
11.4.3 Phylogenetic analysis of the four HCMV isolates and 15 strains from 
direct clinical specimens 
 The analysis of the phylogenetic relationships for intragenic variants of the 
five glycoprotein genes of the four HCMV isolates and 15 other HCMV strains are 
depicted in Figure 34 a to e. Bootstrap values of greater than or equal to 50% are 
shown above the branches of the phylogenetic trees. With respect to gB, gH, gL and 
gN genes, there were no discrepancy in determination of the genotypes between 
DNA sequencing and other methods of genotyping. Chromatographic evidence of 
mixed genotypes was not seen in any of the strains sequenced. 
 In case of the gO gene, the strains 6 and 14 that were genotyped as gO3 by 
PCR- based RFLP did not cluster with any of the four prototype strains. To 
characterize these two sequences further, they were compared with sequences of 
HCMV strains available in the Genbank database by a BLAST search. In this 
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 Figure 34: Phylogenetic analysis of the four isolates and 15 CMV strains 
from direct clinical specimens  
(a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(a) Results of phylogenetic analysis of the gB DNA sequences. The tree was 
generated using the MEGA version 4.0 software. Scale measures distance 
among sequences. The reliability of the branching orders was estimated by 
bootstrapping (1000 re-iterations). Bootstrap values (>50 % after 1000 
iterations) for branches are shown.  
 
  
 
 
(b)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(b) Results of phylogenetic analysis of the gH DNA sequences. The tree was 
generated using the MEGA version 4.0 software. Scale measures distance 
among sequences. The reliability of the branching orders was estimated by 
bootstrapping (1000 re-iterations). Bootstrap values (>50 % after 1000 
iterations) for major branches are shown.  
 
  
 
(c)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(c) Results of phylogenetic analysis of the gO DNA sequences. The tree was 
generated using the MEGA version 4.0 software. Scale measures distance 
among sequences. The reliability of the branching orders was estimated by 
bootstrapping (1000 re-iterations). Bootstrap values (>50 % after 1000 
iterations) for branches are shown.  
 
  
 
 
(d)  
 
 
 
 
 
 
 
 
 
 
 
 
 
d) Results of phylogenetic analysis of the gL DNA sequences. The tree was 
generated using the MEGA version 4.0 software. Scale measures distance 
among sequences. The reliability of the branching orders was estimated by 
bootstrapping (1000 re-iterations). Bootstrap values (>50  % after 1000 
iterations) for  branches are shown.  
 
 
  
 
(e)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(e) Results of phylogenetic analysis of the gN DNA sequences.The tree was 
generated using the MEGA version 4.0 software. Scale measures distance 
among sequences. The reliability of the branching orders was estimated by 
bootstrapping (1000 re-iterations). Bootstrap values (>50 % after 1000 
iterations) for branches are shown.  
 analysis, CMV strain 3052 (GenBank accession no. AF 531321) (Rasmussen et al., 
2002) and Merlin strain (AY446894) were closest to strains 6 and 14. Strains 6 and 
14 showed a 99% homology to the strains Merlin and strain 3052. The sequences at 
the Hpa II and Hae III recognition sites of the strain 3052 was similar to that of 
genotype gO3. The homology of the strains 6 and 14 with prototype gO3 however 
was 85%. The difference with regard to gO genotype of the two strains was not 
associated with any particular patient group or clinical specimen. 
11.5 DISCUSSION 
 To our knowledge, this is the first study in which isolation of HCMV was 
attempted on Tenon’s capsule fibroblast cell line. About 33.33% of the clinical 
specimens were positive for isolation. Urine was a better specimen than peripheral 
blood for the purpose of isolation in Tenon’s capsule fibroblast. All the three 
patients from whom HCMV was isolated had a pp65 antigenemia > 100 cells and 
showed Pattern I of multiplex PCR suggestive of a high viral load. 
 More specimens could not be subjected to isolation due to lack of quality 
fibroblast cell lines in this part of the world. The genotyping results of three of the 
four isolates by PCR-based RFLP, multiplex PCR and DNA sequencing revealed 
one of the 48 strains encountered in the previous study ( Table 28 ).  Isolate 3 
showed a pattern of gB1-gH1-gO1-gL4 -gN1 which was not encountered in the 
study (Table 28). This may be attributed to the non-inclusion of mixed genotypes in 
the analysis. It is assumed that the above mentioned strain could have occurred in 
combination with another strain.  
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  There was a difference in the genotyping results of gB gene of the isolates 3 
and 4 and the corresponding direct clinical specimens. It is assumed that there might 
be a selection of the strain based on their predominance in the clinical specimen. It is 
hypothesized that the strain that is in a higher proportion has a higher chance of 
getting isolated, since; the fibroblast cell line is known to support growth of all the 
CMV strains.  
 It was hypothesized in the beginning of the study that the use of RFLP or 
multiplex PCR in the study to identify genotypes may lead to underestimation of the 
true number of sequence variants or genotypes, since these methods detect only a 
limited number of variant nucleotides specific to the recognition site of the 
restriction enzyme or primer binding site. Strain variation may be even more 
extensive than that indicated by these genotyping methods. 
 Hence, DNA sequencing was considered for characterizing the isolates and 
other clinical strains. Due to the high cost of DNA sequencing fifteen different 
HCMV strains were selected for sequencing of the five glycoprotein genes. The 
selection of the strains was made on the basis of including almost all the genotypes 
for a given gene from different patient groups. The result of nucleotide sequencing 
however was in accordance with the other methods of genotyping in case of all the 
genes except gO. 
 The phylogenetic analysis of the gO gene of strains 6 and 14 revealed that 
these strains did not cluster with the known genotypes and on BLAST analysis 
showed similarity to strain 3052 described by Rasmussen et al (2002). The strain 
3052 as described by Rasmussen et al (2002) was indeterminate type but the study 
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 ruled out it from being a recombinant. The RFLP pattern of strain 3052 as 
determined by web based program (http://www.restrictionmapper.org) showed a 
gO3 pattern as seen with strains 6 and 14 in this study. This study confirms the 
earlier finding that intragenic variations in gO gene may be very high compared to 
other genes of gCIII complex. 
 Thus the DNA sequencing of the HCMV strains in this study, does favour 
the already established genotyping system for all the five genes. No new genotype 
was detected with respect to any of the five glycoprotein genes, though strains 
diverging from prototype strains were encountered in the phylogenetic analysis 
pertaining to gO gene of HCMV. However, in lieu of a moderate frequency of 
mixed genotypes encountered in the HIV and PRT patients in the study, intragenic 
recombination between the different CMV strains may be common in these patients 
and may act as a source of new CMV strains with altered biological properties. 
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 12.  SUMMARY AND CONCLUSIONS 
 The main objective of the study was to develop and establish the usefulness 
of nucleic acid based molecular methods for detection and quantitation of HCMV in 
various clinical specimens from patients with clinically suspected HCMV infections. 
In addition the HCMV strains encountered in these patients were characterized 
based on five different glycoprotein genes viz. glycoprotein B belonging to gCI 
complex; glycoprotein H, glycoprotein O and glycoprotein L belonging to gCIII 
complex and glycoprotein N belonging to gCII complex. 
♦ pp65 antigenemia assay, a rapid, sensitive and semi-quantitative assay based 
on the detection and quantitation of lower matrix protein pp65 of HCMV for 
detection of active HCMV infection was standardized. Initially, two different 
methods namely the Conventional Dextran sedimentation (CDS) and Direct 
erythrocyte lysis (DEL) were compared for isolation of leucocyte from 
peripheral blood. Since, a good agreement in the quantitation of pp65 
positive cells was found between the two methods, they were alternatively 
used in the rest of the study. pp65 antigen  was not detectable in the 
peripheral blood of the controls (healthy blood donors seropositive for 
HCMV) confirming the earlier view that detection of the antigen in a patient 
is an evidence for active HCMV infection.  
♦ Since, nucleic acid based molecular methods showed great promise in 
detection of several viruses and also reports suggesting that the region of 
interest can affect the sensitivity of the Polymerase chain reaction, three 
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 different targets viz. mtrII, UL-83 and gO gene of HCMV were evaluated 
against pp65 antigenemia assay as ‘gold standard’. PCR for mtr II was found 
to be more suitable for qualitative detection of HCMV in Chennai region, 
India. The other findings from the study include the inability of the 
qualitative PCRs to detect latent viruses circulating in the seropositive 
controls and all the three regions becoming positive with high level of 
antigenemia (>50 cells/ 2x 105 PBLs).  
♦ Since, Post renal transplant recipients and HIV patients with HCMV 
infections remain asymptomatic with lower viral load, quantitation of 
HCMV in these patient groups become increasingly important. Also, since 
the results of the previous study suggested a high viral load when all the 
three regions became positive, multiplexing of the three primers were 
attempted. The multiplex PCR for the three regions of HCMV proved to be 
useful in quantitation of HCMV since it generated four different patterns that 
segregated with different pp65 antigenemia levels. 
♦ Taqman probe based Real-time PCR was standardized for the mtrII region of 
HCMV. The mtr II region was chosen as it provided 100% sensitivity for 
detection of HCMV DNA in immunocompromised patients. The real-time 
PCR was sensitive, rapid (results available in 2 hours) and had a high 
reproducibility. It had an ability to detect the HCMV genome circulating in 
peripheral blood specimens of healthy controls. The median viral load in the 
healthy controls was 26.5 copies/ml.  
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 ♦ The multiplex PCR was evaluated against pp65 antigenemia assay and 
Taqman-probe based real time PCR for its efficacy in quantitation of 
HCMV. Each pattern of the multiplex PCR was assigned a viral load based 
on the results of Taqman-probe based real time PCR. The median 
antigenemia levels and viral loads in clinical specimens showing Pattern I 
and Pattern II of the multiplex PCR was significantly higher than Pattern III 
and Pattern IV. A moderate positive correlation ((rs) = 0. 7778) was seen 
between the results of pp65 antigenemia assay and Taqman – probe based 
real time PCR in the study. The multiplex PCR was less expensive and had 
the ability to distinguish clinical specimens with high and low viral load 
which may be effective in predicting patients who might develop HCMV 
disease and to monitor effectiveness of antiviral therapy.  
♦ Since, the genotypic difference of HCMV affects pathogenesis and tropism 
of HCMV, the genotypic methods for determining the distribution of HCMV 
genotypes in the study population was developed and evaluated. 
♦ Initially, a nested PCR based RFLP for gB gene was attempted however the 
method was unable to identify genotype gB3 in the study population. The 
study indicated that the sequence variations in the gB genome of HCMV 
may complicate genotyping of HCMV. Confirmation of primer specificity by 
the BLAST program may not suffice for the genotyping studies. Complete 
alignment of the prototype sequences of all the genotypes that exist for the 
gene of interest by a multiple alignment program with the primers used for 
amplification may be necessary for genotyping of HCMV. 
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 ♦ Later, seminested PCR-based RFLP and multiplex PCR were developed for 
genotyping of gB gene. Multiplex nested PCR for gB gene was more 
advantageous than the commonly employed PCR based RFLP for gB 
genotyping since it was rapid and allowed easier detection of mixed 
infections with multiple gB genotypes in clinical specimens. 
♦ In the study determining the distribution of gB genotypes by multiplex PCR 
a predominance of gB1 genotype followed by gB3 and gB2 irrespective of 
the patient group or specimen type was found. Absence of gB4 and gB5 in 
the study population and gB mix in the infant group was observed.  Presence 
of gB2 in the intraocular fluid was statistically significant. No absolute 
segregation of gB genotype based on gender or patient group was observed. 
In the HIV patient group with discordant results between the blood and 
intraocular fluids, the genotype other than gB1 in the blood, was detected in 
the intraocular fluid. 
♦ PCR-based RFLPs were standardized to determine the distribution of 
genotypes pertaining to the genes of gCIII complex viz. gH, gL and gO. In 
all the three cases, the existing protocols were modified to achieve the 
following: direct application on clinical specimen without requirement for 
isolation, detection of mixed genotypes and visualization of restriction 
products on agarose gel. 
♦ The analysis revealed no significant differences in the distribution of the 
gCIII variants based on gender. Statistically significant difference in the 
distribution of gH genotypes and gO genotypes were found in different 
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 patient groups. gL1 and gL2 genotypes were not found in the study 
population and predominance of gL4 genotype irrespective of the patient 
groups and specimen types were also observed. Fifty percent of HIV patients 
in the study was shown to harbour HCMV strains with gH1-gO1-gL4 
configuration. 
♦ An existing uniplex PCR based RFLP was converted to seminested PCR 
based RFLP to attain optimal sensitivity for genotyping gN gene of HCMV 
strains from direct clinical specimens without the need for viral isolation. 
The distribution of gN genotypes in the study population was in accordance 
to the distribution seen in other geographical areas. There was no statistically 
significant difference in the distribution of gN genotypes with respect to 
gender or clinical specimens. The genotype gN4c predominated among the 
genotypes irrespective of the patient types or specimen though its frequency 
was little less in PRT than other groups of patients. 
♦ Following conclusions were drawn from the studies on cumulative 
genotyping of the five regions of HCMV:  
Ø The study confirms that HCMV are highly heterogenous group of 
viruses and exhibit several genetic combinations. Theoretically 1120 
strains may exist based on the assumption of number of genotypes 
existing for the five glycoprotein genes and the present study showed 
48 different strains circulating in the study population. 
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 Ø Genetic linkages are limited though some associations of genotypes 
occur more frequently than others. Hence, variation in one part of the 
gene does not reflect variations in other parts of HCMV genome. 
Analysis of single genes may not aid in understanding the tissue 
tropism or pathogenesis of HCMV.  
Ø Infection with one HCMV strain does not provide protection against 
reinfection with a new strain, since a higher number of mixed 
infections with multiple genotypes were encountered in Post-renal 
transplant patients and HIV infected individuals.  
Ø The order of genetic loci suitable for detection of mixed genotype as 
confirmed by the study is gB>gO>gH=gL>gN. The leucocyte fraction 
of peripheral blood is recommended for detection of mixed genotypes 
in PRT and HIV patients. 
Ø A statistically significant difference was observed in the viral loads as 
determined by Taqman probe-based real time PCR between the 
specimens carrying single genotype and multiple genotypes. Hence, 
detection of mixed genotypes in the hypervariable regions of HCMV 
genome can be a surrogate marker for increase in viral load. 
Ø The mixed genotype in any loci was not observed in the infant group in 
this study.   
♦ Phylogenetic analysis of the four isolates and fifteen other HCMV strains 
revealed that no novel variant existed with respect to the regions of the gene 
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 analyzed and all the strains could be accommodated into one or the other 
genotypes already established.  
12.1 LIMITATIONS OF THE PRESENT STUDY 
♦ The study was carried out on the clinical specimens submitted to the Clinical 
laboratory of L&T Microbiology Research Centre for the investigation of 
suspected HCMV infections. 
♦ The clinical details of the patients except for their age, gender and status (eg. 
HIV infected individual, organ transplant recipient etc.) were not available for 
many and hence, clinical correlations with the results were not possible.  
♦ The study was cross-sectional and the discrepancies in the sample sizes of the 
patient groups and clinical specimens hindered useful conclusions that could be 
drawn from the observations.  
12.2 FUTURE RECOMMENDATIONS 
♦ The pp65 antigenemia assay, multiplex PCR can be applied prospectively on 
serial clinical specimens collected from PRTs and HIV infected individuals 
in conjunction with clinical data. Such a longitudinal study if planned can 
help in establishing the cut-off value for antigenemia assay and multiplex 
PCR that can aid in initiating, monitoring and terminating the antiviral 
treatment. The antigenemia levels > 10 cells is advised for the renal 
transplant patients based on reports from outside India. Whether the same 
holds good for the patients in this region can then be established. 
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 ♦ The patients showing an increase in the antigenemia load or the viral load by 
multiplex PCR can be further screened for antiviral resistance by sequencing 
DNA polymerase gene (UL-54) and/or phosphotransferase gene (UL-97). 
♦ The DNA sequencing of the genes of glycoproteins included in the study on 
serial samples of patients carrying mixed genotypes can be performed to 
establish any recombinant or novel strain that may be emerging.  
♦ Follow-up of the patients whose paired clinical specimens show discrepant 
results with respect to mixed genotypes in conjunction with clinical data and 
treatment modality can throw light on the hypothesis of whether therapy or 
viral load or tropism have  role to play in such pattern of shedding. 
♦ Monocyte subfractions from seropositive healthy blood donors may be 
concentrated; DNA extraction and methods of genotyping can be 
restandardized to ascertain the genotypes of latent CMV strains circulating in 
them. The standardized methodology can then be applied on 
Donor/Recipients in case of transplant patients, mother/foetus in case of 
pregnant women to identify the prevalence of reactivations and reinfections 
of HCMV. 
♦ Experimentally modified recombinant viruses identical in all genetic aspects 
except for the altered region of the hypervariable gene can be constructed. 
These viruses can then be studied in either in vivo or in vitro model systems 
to pinpoint genes that are crucial for virulence.  
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 APPENDIX I 
 
 
COLLECTION AND TRANSPORT OF SPECIMENS 
 
Non-ocular specimens 
 
 All non-ocular specimens were transported in a sterile container as soon as 
they were collected to Clinical Microbiology Laboratory, L&T Microbiology 
Research Centre, Vision Research Foundation, Sankara Nethralaya, Chennai.  
In case of any delay the clinical specimens were transported in ice. 
 
Intraocular specimens 
 Vitreous fluids were collected aseptically and transported to the laboratory 
immediately in syringes in which they were collected after expelling the air inside 
the syringe and capping the needle with a sterile rubber bung. Aqueous humors were 
collected aseptically in a tuberculin syringe with a 30G needle and sent to laboratory 
immediately for processing. 
 
PROCESSING OF CLINICAL SPECIMENS 
 
Peripheral blood 
 
 The processing of specimens for pp65 antigenemia assay is provided in 
section 3.3.3. The leucocytes remaining after the pp65 antigenemia assay was 
centrifuged and the deposits were reconstituted in 1 ml of Dulbeccos modified 
eagles’ medium (DMEM) (HiMedia, India), containing 3% foetal bovine serum 
(FBS) (HiMedia, India). For isolation, 100 µl of the leucocytes was utilized. For 
PCR 200 µl of buffy coat fraction was used unless and otherwise specified. 
 
 
 
i 
 Intraocular fluids 
 Hundred microlitres of the undiluted clinical specimen was taken for 
polymerase chain reaction (PCR).  The rest of the specimen was stored at -80°C for 
future use. If the volume available was less than 100µl, the whole specimen was 
taken as such for extraction of DNA. 
 
Urine  
 The specimen was centrifuged at 3000rpm for 15 minutes.  For PCR, 100µl 
of the deposit was used.  For virus isolation, Urine deposit was decontaminated 
before inoculation with 100µg/ml of gentamycin and 10µg/ml of amphotericin B.  
100µl of the deposit was used for inoculation. Only the deposits were stored at -
80oC and supernatants were discarded. 
 
Respiratory specimens 
 In case of purulent respiratory specimens 100 µl of the specimen was used as 
such for DNA extraction.   In case of washes, the specimens were was centrifuged at 
3000rpm for 15 minutes.  100 µl of deposits were used for DNA extraction. Both the 
supernatants and deposits were stored at -80oC. 
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Reagents 
 
1. Dextran solution (6%): 
Dextran          -    6 gms 
Sterile water   -    100 ml 
The solution was autoclaved. 
 
  
2. Ammonium Chloride solution (0. 8%): 
Ammoniuum Chloride       -    0. 8 gms 
Sterile water                       -    100 ml 
Required volumes of the solution was prepared fresh before every use and   
sterilized by filtration. 
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 3. Phosphate Buffered Saline ( PBS ) : 
NaCl                      -       8 gms 
Na2HPO4              -        1.21 gms 
KH2PO4                -        0.34 gms 
Distilled water       -       1000 ml 
pH                          -        7.3 
The solution was autoclaved and stored. 
 
4. Phosphate Buffered Saline – Tween (PBST) : 
NaCl                      -       8 gms 
Na2HPO4              -        1.21 gms 
KH2PO4                -        0.34 gms 
Distilled water       -       1000 ml 
Tween                    -       0.5 ml 
pH                          -        7.3 
 
 
5. Non-idet P-40 (0. 5%) : 
0.5 ml of Non-idet P-40 made upto 100ml with sterile PBS. 
 
6.  Evans Blue (0. 5%) : 
        0.5 g of evans blue stain dissolved in 100ml of water. 
 
 
TOTAL LEUCOCYTE COUNTS BY MANUAL METHODS 
  
 Twenty microlitres of blood and 380 µl of Turk’s fluid (2% glacial acetic 
acid with two drops of 1 % methyl violet) was mixed and incubated at room 
temperature for five minutes. Ten microlitre of the sample was loaded in Neubauer 
chamber and the cells were allowed to settle for five minutes. The four corner 
(WBC) squares were counted. The total count was given by the following formula: 
iii 
 No. of cells counted in 4 squares x 50 cells/ mm3. The number of cells was 
converted to cells/ ml for further calculation. 
 
 
DETERMINATION OF CELL COUNTS BY HAEMOCYTOMETER 
 
 The surface of the chamber and the cover slip was cleaned with 70% alcohol. 
The cell suspension was mixed well with pasteur pipette and the suspension was 
dispensed on the chamber. The suspension was drawn under the cover slip into the 
counting chamber by capillary action. Similarly, the second counting chamber was 
filled. The cells were allowed to settle for a few minutes before counting .The excess 
of fluid was blotted off. The slide was then viewed under an inverted phase contrast 
microscope with 200x magnification. The slide was positioned to view the large 
central area of the grid; Subdivisions within the large central area were bordered by 
three parallel lines and each subdivision was divided into sixteen smaller squares by 
single lines. Care was taken for even distribution of the cells within the area. If cells 
were not evenly distributed, the slide was washed and reloaded after vortexing the 
cell suspension. The cell suspensions were diluted suitably to ensure proper 
distribution and ease of counting. The dilution factor was taken into account during 
the final calculation. The number of cells in each of the four corner squares was 
counted in each counting chamber. The number of cells/ ml was obtained by the 
following calculations: 
           Cells/ml = average count per square x dilution factor x 104 
 NOTE: 104 is the volume correction factor for the chamber. Each   square is 
1x 1 mm and depth is 0.1 mm. 
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 APPENDIX – II 
 
 
EXTRACTION OF DNA USING COMMERCIAL KITS 
 
 DNA from all the clinical specimens were extracted using one of the three 
commercial kits  
a) QIAamp DNA mini kit (QIAGEN, Germany),  
b) Biogene DNA extraction kit (BIOGENE Inc., CA, USA) or  
c) AccupPrep Genomic DNA extraction kit (Bioneer corporation, Rockville, 
USA) 
 Predominantly QIAamp DNA mini kit was used for peripheral blood 
specimens and standard strain and Biogene DNA extraction kit was use for 
specimens other than blood till January 2005.  AccuPrep Genomic DNA extraction 
kit was used for all the specimens and standard strain after January 2005. In case of 
blood, the buffy coat fraction was used for extraction of DNA unless otherwise 
specified.  
 
Procedure for the extraction of DNA using QIAamp DNA mini Kit (QIAGEN, 
Germany)   
 
 Two hundred microlitres of AL buffer (Lysis buffer) and 20 µl of proteinase 
K were added to 200 µl of clinical specimen, cyclomixed and incubated at 56°C for 
10 minutes. Two hundred µl of absolute ethanol was added to the lysate and 
cyclomixed well. The contents were transferred into the spin column provided in the 
kit. The spin column was microfuged at 8,000 rpm for 1 minute. The collection tube 
of the spin column was discarded and the spin column transferred onto a fresh 
collection tube. To this 500 µl of AW1 buffer (Washing buffer 1) was added and 
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 microfuged at 8,000 rpm for 1 minute. The collection tube was discarded and the 
washing step was repeated with AW2 wash buffer (Wash buffer 2) at 14,000 rpm for 
3 minutes. The spin column was transferred to a fresh collection tube and 
microfuged at 14,000 rpm for 1 minute to remove the residual washing solution. The 
collection tube was discarded and the spin column was transferred onto a fresh 1.5 
ml microfuge tube.  200 µl of AE buffer (elution buffer) was added at the center of 
the collection tube and incubated at room temperature for 1 minute. The spin column 
was centrifuged at 10,000 rpm for 1 minute and the eluted DNA was stored at -20°C 
till use.  
 
Procedure for the extraction of DNA using BIOGENE DNA extraction kit 
(BIOGENE Incorp., CA, USA) 
 
 Two hundred microlitres of digestion buffer and 3 µl of proteinase K were 
added to 100 µl of clinical specimen, cyclomixed and incubated at 56°C for 30 
minutes. Two hundred µl of absolute ethanol was added to the lysate and 
cyclomixed well. The contents were transferred into the spin column provided in the 
kit. The spin column was microfuged at 8,000 rpm for 1 minute. The collection tube 
of the spin column was discarded and the spin column transferred onto a fresh 
collection tube. To this 500 µl of working wash solution was added (100 µl 
concentrated wash solution and 400 µl of absolute ethanol) and microfuged at 8,000 
rpm for 1 minute. The collection tube was discarded and the washing step was 
repeated once. The spin column was transferred to a fresh collection tube and 
microfuged at 12,000 rpm for 1 minute to remove the residual washing solution. The 
collection tube was discarded and the spin column was transferred onto a fresh 1.5 
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 ml microfuge tube.  100 µl of elution buffer was added at the center of the collection 
tube and incubated at 56°C for 2 minutes. The spin column was centrifuged at 
10,000 rpm for 1 minute and the eluted DNA was stored at -20°C till use.  
 
Procedure for the extraction of DNA using AccupPrep Genomic DNA extraction 
kit (Bioneer corporation, Rockville, USA) 
 
 Two hundred microlitres of Binding buffer (Lysis buffer) and 20 µl of 
proteinase K were added to 200 µl of clinical specimen, cyclomixed and incubated 
at 60°C for 10 minutes. Hundred µl of isopropanol was added to the lysate and 
mixed well with micropipette, vortexing was avoided. The contents were transferred 
into the spin column provided in the kit. The spin column was microfuged at 8,000 
rpm for 2 minute. The collection tube of the spin column was discarded and the spin 
column transferred onto a fresh collection tube. To this 500 µl of Wash buffer 1 was 
added and microfuged at 8,000 rpm for 3 minutes. The collection tube was discarded 
and the washing step was repeated with Wash buffer 2 at 8,000 rpm for 3 minutes. 
The spin column was transferred to a fresh collection tube and microfuged at 12,000 
rpm for 5 minutes to remove the residual washing solution. The collection tube was 
discarded and the spin column was transferred onto a fresh 1.5 ml microfuge tube.  
200 µl of elution buffer was added at the center of the collection tube and incubated 
at room temperature for 1 minute. The spin column was centrifuged at 10,000 rpm 
for 3 minutes and the eluted DNA was stored at -20°C till use.  
 
Quantitation of DNA by spectrophotometry 
 One microlitre of the extracted DNA was diluted to one millilitre in Milli Q 
water and was spectrophotometrically (Beckman DU 640, USA) read at 260nm. One 
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 OD corresponds to 50µg/ml of DNA.  The concentration of DNA was found from 
the corresponding OD value. 
 
POLYMERASE CHAIN REACTION (PCR) 
 All the PCR reagents were obtained from Bangalore genei Pvt Ltd., 
Bangalore, India. 
 
Primer dilution 
 The lyophilized primer was reconstituted in 100µl of sterile Milli Q water. 
One microlitre of this primer was diluted to one millilitre in Milli Q water and was 
spectrophotometrically read at 260nm. One optical density (OD) corresponds to 
33µg/ml of primer.  The concentration of primer was found from the corresponding 
OD value. Based on the molecular weight and concentration of the primer it was 
diluted to the required concentration as mentioned in the detailed procedure for each 
of the PCRs in the methodology section. 
 
Specificity of PCR 
 The specificity of the PCR was determined with the DNA extracted from 
HSV-1 (ATCC 733-VR), HSV-2 (SP753167), VZV (Oka vaccine strain), Epstein-
Barr virus (EBV) culture filtrate of B 958 marmoset cell line (obtained from 
National Eye Institute, Bethesda, USA), Adenovirus serotypes 7a (ATCC 848-VR), 
and 10 human leucocyte DNA. Briefly, the DNA extracted from the above 
organisms was submitted to amplification along with the controls. Absence of 
amplification with the DNA of above mentioned organisms with amplification in the 
positive control alone indicated absolute specificity of the PCR. 
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 Sensitivity of PCR 
 The sensitivity of the PCR was determined by subjecting serial log dilutions 
of neat DNA to amplification with specific PCR.  The concentration of the neat 
DNA was ascertained spectrophotometrically (Beckman DU 640, USA) at 260nm. 
The highest dilution that gave a visible band was used to calculate the sensitivity of 
the PCR. 
For eg. Neat DNA = 1 µg 
Final dilution that gave a visible band = 10 -6 
Sensitivity of the PCR = 1 µg x 10-6 = 1 pg of HCMV DNA. 
 
Titration of MgCl2  
 The magnesium chloride was titrated using the following concentrations for 
all the PCRs: 1.5mM, 2.0mM, 2.5mM, 3mM, 3.5mM and 4mM concentrations.  The 
optimal magnesium ion concentration was decided based on the intensity of the 
specific band.  
 
Precautions for PCR 
 The DNA extraction and PCR preparation, PCR amplification, and detection 
of amplified products were physically separated into different rooms to prevent 
contamination.  To prevent amplicon carry over, dedicated pipettes, filter guarded 
tips for adding DNA and single use aliquots of all the reagents were used.  
Appropriate negative buffer and water controls and positive controls were included 
along with every PCR reaction. 
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 RESTRICTION FRAGMENT LENGTH POLYMORPHISM (RFLP): 
Details of concentration of restriction enzymes, composition of buffer, 
temperature of incubation for RFLP of amplified products of PCR for gB, gH, 
gO, gL and gN gene of HCMV 
 
In all the cases 10 µl of unpurified amplicon was subjected to RFLP in 25µl reaction 
mixture and enzyme inactivation was carried out by snap cooling. All the restriction 
enzymes were obtained from Fermentas Inc., USA. 
Genetic  
loci 
Restriction 
enzyme 
Concentration 
(units) 
Temperature 
& Time  
of 
 incubation 
Buffer composition 
(used in 1X concentration) 
 
gB 
Hinf I 10u 37oC for 2 hrs 10mM Tris-HCl (pH 8.5) 
10mM MgCl2, 100mM KCl and 
0.1mg/ml BSA 
Rsa I 10u 37oC for 2 hrs 33mM Tris-acetate (pH 7.9) 10mM 
Mg-acetate, 66mM K-acetate and 
0.1mg/ml BSA 
 
gH 
Hha I 15u 37oC for 2 hrs 33mM Tris-acetate (pH 7.9) 10mM 
Mg-acetate, 66mM K-acetate and 
0.1mg/ml BSA 
Hpa II 10u 37oC for 2 hrs 33mM Tris-acetate (pH 7.9) 10mM 
Mg-acetate, 66mM K-acetate and 
0.1mg/ml BSA 
Stu I 10u 37oC for 2 hrs 10mM Tris-HCl (pH 7.5) 
10mM MgCl2 and 0.1mg/ml BSA 
 
gO 
Hpa II 20u 37oC for 2 hrs 33mM Tris-acetate (pH 7.9) 10mM 
Mg-acetate, 66mM K-acetate and 
0.1mg/ml BSA 
Hae III 20u 37oC for 2 hrs 10mM Tris-HCl (pH 8.5) 
10mM MgCl2, 100mM KCl and 
0.1mg/ml BSA 
 
gL 
Rsa I 20u 37oC for 3 hrs 33mM Tris-acetate (pH 7.9) 10mM 
Mg-acetate, 66mM K-acetate and 
0.1mg/ml BSA 
Taq I 20u 65oC for 3 hrs 10mM Tris-HCl (pH 8.0) 
5mM MgCl2, 100mM NaCl and 
0.1mg/ml BSA 
 
gN 
Sal I 10u 37oC for 3 hrs 50mM Tris- HCl(pH 7.5), 100mM 
KCl, 10mM 2-mercaptoethanol, 
0.1mM EDTA, 0.2mg/ml BSA and 
50% (v/v) glycerol 
Sac I 10u 37oC for 3 hrs 10mM Bis-Tris Propane-HCl (pH 6.5) 
10mM MgCl2 and 0.1 mg/ml BSA 
Sca I 10u 37oC for 3 hrs 10mM Bis-Tris Propane-HCl (pH 6.5) 
10mM MgCl2, 100mM KCl and 0.1 
mg/ml BSA 
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 Expected RFLP patterns of different genotypes for the five glycoprotein genes of 
HCMV 
 
gB 
 
 
gB  genotype 
 
Hinf I 
 
Rsa I 
 
 
gB1 
 
gB2 
 
gB3 
 
gB4 
 
 
202,67,36 bp, 
 
202, 100 bp 
 
202, 97 bp 
 
202,67, 36 bp 
 
239, 66 bp 
 
239, 63 bp 
 
195,63,41 bp 
 
195,66,44 bp 
 
gH 
 
 
gH  
genotype 
 
HpaII StuI Hha I 
 
gH1  
 
gH2  
 
 
162, 51 bp 
 
Undigested 
(210bp) 
 
Undigested  
(213 bp) 
 
158, 52 bp 
 
81, 75, 29, 20,  
8 bp 
 
92, 81, 29, 8 bp 
 
gL 
 
 
gL genotype 
 
RsaI TaqI 
 
gL 1 
gL 2 
gL 3 
gL 4 
 
287, 117, 96, 50 bp 
337, 117, 96 bp 
287, 117, 96, 50 bp 
337, 117, 95 bp 
 
386, 156, 8 bp 
386, 156, 8 bp 
542, 8 bp 
542, 8 bp 
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gO 
 
 
gO 
genotype 
HpaII HaeIII 
 
gO1  
 
 
gO2 
 
gO3 
 
gO4  
 
345, 25 bp 
 
 
202, 141, 26 bp 
 
229, 130, 11 bp 
 
202, 116, 26, 14, 12 bp 
 
Undigested (370 bp)/ 
270,100 bp (for Toledo) 
 
302, 68 bp 
 
222, 100, 34, 14 bp 
 
354, 16 bp 
 
 
 
gN 
 
gN 
genotypes 
Sac I 
(bp) 
ScaI 
(bp) 
Sal I 
(bp) 
 
 
gN1 
 
gN2 
 
gN3a 
 
gN3b 
 
gN4a 
 
gN4b 
 
gN4c 
 
 
297,123  
 
229,123,65 
 
420 
 
420 
 
291,123 
 
414 
 
411 
 
420 
 
417 
 
420 
 
221,172,27 
 
221,166,27 
 
414/387,27 
 
239,172/239, 
145,27 
 
420 
 
296,121 
 
420 
 
420 
 
341,73 
 
341,73 
 
338,73 
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 VISUALISATION OF PCR/ RFLP PRODUCTS 
 
Agarose gel electrophoresis 
Reagents 
1. Tris Boric acid EDTA buffer (TBE) 10x: The buffer was prepared by dissolving 
54.1gm of Tris base, 3.65gm of EDTA and 27.8gm of Boric acid in Milli Q 
water in the respective order. The pH was checked to be 8.0 and finally the 
volume was made upto 500ml.  Working concentration (1x) was made by 
diluting the above prepared 10x buffer ten times in Milli Q water. 
 
2. Bromophenol blue: Equal volumes of 0.1% bromophenol blue dissolved in 1x 
TBE buffer and 40% sucrose solution prepared in Milli Q water were mixed. 
  
3. Ethidium Bromide: Two milligram of ethidium Bromide was dissolved in one 
millilitre of Milli Q water.  This stock dye was added to the agarose gel at a final 
concentration of 0.5µg/ml. 
Procedure 
 The gel trough was cleaned with ethanol and the ends were sealed with 
cellophane tape with the combs placed in the respective positions to form wells. 
Agarose gels were prepared in 2% to 4% concentrations in 1x TBE buffer as 
required depending on the molecular weight of the amplified products.  The agarose 
gel was incorporated with 0.5µg/ml of Ethidium Bromide (Sambrook et al., 1989). 
The amplified products were loaded onto the gel after mixing them with a tracking 
dye, bromophenol blue. First the negative controls, samples, positive control and 
finally the molecular weight marker (φX 174 DNA/Hinf I digest or 100bp ladder) 
were loaded. The molecular weight marker loaded contains one microlitre of the 
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 molecular weight marker, 9µl of the 1x TBE buffer and 1µl of the dye. 
Electrophoresis was carried out at 100 volts. The gel was visualized and documented 
in CN-2000W Vilber Lourmat photo documentation and imaging systems  
(Cedex, France). 
 
Polyacrylamide gel electrophoresis (PAGE) (Sambrook et al., 1989) 
Reagents 
1. 30% Acrylamide 
  Acrylamide  -  29.2 gm 
  Bis acrylamide - 0.8 gm 
 These were dissolved in 30ml of Milli Q water and the volume was finally 
made upto 100ml with Milli Q water.  This was filtered and stored in refrigerator. 
 
2. Tris – Cl (pH-8.8) 
 Eighteen grams of Tris was dissolved in 40ml of Milli Q water.  The pH was 
adjusted to 8.8 with 1N HCl.  The volume was finally made upto 100ml with Milli Q 
water.  
 
3. Ammonium persulphate (APS)  
  Ammonium persulphate - 0.1 gm 
  Milli Q water   - 1.0 ml 
 This was freshly prepared and can be used for one day at 25ºC. 
 
4.  N,N,N’,N’tetramethylethylenediamine ( TEMED ) 
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 Procedure 
 The glass plates (16x19 cms) were assembled with spacers. This was then 
transferred to casting slots of the casting stand. 2 % agarose was poured onto the 
casting slot to make it leak proof. A 20% polyacrylamide gel consisting of 26.5 ml 
of 30% acrylamide, 10 ml of Tris [pH 8.8], 200 µl of 10% APS and 20µl of N1  N1 
N1 N1 - tetramethylene diamine was prepared and poured in between the plates and 
the comb was inserted. The gel was allowed to polymerize for 30 minutes. After 
complete polymerization the wells were washed with milli Q water to remove 
unpolymerized acrylamide. The plate was removed from the casting slot and 
attached firmly to the electrophoresis tank. Working buffer (1X TBE) was added to 
the upper and lower tanks. The wells were loaded with digested products along with 
the molecular weight marker and electrophoresis was carried out at 100 volts. After 
3/4 of the run was over the plates were removed and the gel was transferred into the 
fixative for silver staining. 
 
Silver nitrate staining technique 
 The polyacrylamide gel was placed in 100ml of the following reagents and 
rocked for the stipulated time mentioned.  Fixation was done in two changes of 10% 
methanol and 0.5% acetic acid for five minutes each.  The gel was stained with 0.1% 
silver nitrate for 20 minutes and then washed in three changes of water.  The gel was 
differentiated in 1.5% sodium hydroxide containing 0.1% formalin till bands of 
satisfactory intensity were visualized.  The differentiated bands were fixed in 0.75% 
sodium carbonate for ten minutes.  The gel was finally stored in water till it was 
documented in the CN- 2000W Vilber Lourmat photo documentation and imaging 
systems (Cedex, France). The gel picture was also captured by a digital camera. 
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 NOTE: For the silver staining technique, all the reagents were freshly prepared only 
in Milli Q water.  Care was taken to avoid contact of the gel with bare hands till the 
completion of the staining technique. 
 
DNA SEQUENCING 
 The DNA sequences were either determined by custom sequencing at 
Bangalore Genei Pvt Ltd or carried out by an “in- house” DNA sequencing 
procedure. In case of the custom sequencing amplicons purified by QIAquick Gel 
extraction kit was provided along with 10 picomoles of primers for every 
sequencing. The in-house procedure for DNA sequencing is as follows: 
 
‘In-house’ DNA sequencing 
  Different procedures were followed depending on the type of template. In 
case of the mixed templates the amplicons were subjected to exonuclease-Shrimp 
Alkaline phosphatase (Exo-SAP) treatment. In case of sequencing of pure sequences 
crude amplicons were as such subjected to DNA sequencing. In case of background 
in sequencing of pure sequences, the products were treated with Exo-SAP and 
subjected to DNA sequencing.  
 
Exo-SAP treatment of amplicons 
 Reaction mixture containing 10u of  Exonuclease I (Fermentas Inc., USA), 
1u of Shrimp alkaline phosphatase (SAP), 1X buffer (67mM glycine-KOH (pH 9.5), 
6.7mM MgCl2, 1mM DTT) was prepared. Five ml of the crude PCR product was 
added to the mixture and incubated at 37oC for 15 minutes followed by heat 
inactivation at 85oC for 15 minutes. 
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Cycle Sequencing 
 Both the sequences of the amplified products were sequenced in cases of 
mixed templates and isolates. For pure sequences of the amplified products from 
other clinical strains any one of the sequence was determined. As a rule upstream 
primer was used for DNA sequencing. Downstream primers were used if the DNA 
sequencing with upstream primers did not give a proper result.  
 For cycle sequencing a 10µl reaction was set with 2 picomoles of respective 
primer, 5x sequencing buffer (400mM Tris-Cl, 10mM MgCl2 [pH 9.0]) and Ready 
Reaction mix (RR mix) containing dye labeled terminators (ddNTPs), dNTPs, and 
AmpliTaq DNA polymerase FS. The concentration of the template subjected to 
sequencing differed based on the quality and size. In cases of crude amplicons of 
less than 500bp, 1 µl were used, in case of amplicons more than 500bp and  
Exo-SAP treated amplicons 2µl and 3µl of templates were used respectively. The 
reactions were carried out in a thermal cycler (Perkin Elmer model no. 2700, USA).  
The thermal profile for cycle sequencing consisted of a single cycle of initial 
denaturation at 96°C for one minute followed by 25 cycles of denaturation at 96°C 
for ten seconds, annealing at 50°C for five seconds and extension at 60°C for four 
minutes.  
 
Purification of Extension Products & Analysis of sequences: 
 The products  were purified to remove the unincorporated dye terminators 
before subjecting the samples to capillary electrophoresis. Two µl of 125mM EDTA 
and 10 µl of 3M sodium acetate (pH4.8) were mixed to the cycle sequenced 
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 prodcuts  followed by the addition of 50µl of absolute ethanol  and incubated at 
room temperture for 15 minutes follwed by centrifugation at 8000rpm for 20 
minutes to precipitate the amplified product and remove the unutilized ddNTPs, 
primer (short length molecules) etc. The pellet was washed twice with 75% ethanol 
followed by air drying. The purified samples were suspended in 20µl of template 
suppressor reagent (TSR), denatured at 90oC for 3 minutes and subjected for 
capillary electrophoresis in ABI PRISM 310/3100 genetic analyser. The sequences 
were then analyzed in Sequence Navigator software (version 1.0.1; ABI Prism 310) 
or Seq scape manager (version 2.1; ABI Prism 3100 AVANT). 
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